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vGLOSSARY OF TERMS USED IN THESE GUIDELINES
Abstinence
Refraining from alcohol or drug use. The term “abstinence” should not be confused with the term “abstinence 
syndrome”, which refers to a withdrawal syndrome.
Alcohol 
In chemical terminology, alcohols are a large group of organic compounds derived from hydrocarbons 
and containing one or more hydroxyl (-OH) groups. Ethanol (C2H5OH, ethyl alcohol) is one of this class of 
compounds, and is the main psychoactive ingredient in alcoholic beverages. By extension the term “alcohol” 
is also used to refer to alcoholic beverages. Alcohol is a sedative/hypnotic with effects similar to those of 
barbiturates.
Antagonist 
A substance that counteracts the effects of another agent. Pharmacologically, an antagonist interacts with 
a receptor to inhibit the action of agents (agonists) that produce specific physiological or behavioural effects 
mediated by that receptor.
Amphetamines / amfetamines
One of a class of sympathomimetic amines with powerful stimulant actions on the central nervous system. 
The class includes amphetamine, dexamphetamine, and methamphetamine. Pharmacologically related drugs 
include methylphenidate, phenmetrazine and amphepramone (diethylpropion). 
Barbiturate 
One of a group of central nervous system depressants that chemically are substituted derivatives of barbituric 
acid; examples are amobarbital, pento-barbital, phenobarbital, and secobarbital. They are used as anti epileptics, 
anaesthetics, sedatives, hypnotics and, less commonly, as anxiolytics or anti-anxiety drugs (see sedative/
hypnotic). Acute and chronic use induces effects similar to those of alcohol.
Benzodiazepine 
One of a group of structurally related drugs used mainly as sedatives/hypnotics, muscle relaxants, and anti-
epileptics, and once referred to by the now-deprecated term “minor tranquillisers”. These agents are believed 
to produce therapeutic effects by potentiating the action of gamma-aminobutyric acid (GABA), a major inhibitory 
neurotransmitter.
Bloodborne diseases
Diseases such as HIV and Hepatitis B and C, which are spread by blood-to-blood contact (e.g. needle-sharing).
Cannabis 
A generic term used to denote the several psychoactive preparations of the marijuana (hemp) plant, Cannabis 
sativa. They include marijuana leaf (in street jargon: grass, pot, dope, weed or reefers), bhang, ganja or hashish 
(derived from the resin of the flowering heads of the plant), and hashish oil.
Cocaine 
An alkaloid obtained from coca leaves or synthesized from ecgonine or its derivatives. Cocaine hydrochloride 
was commonly used as a local anaesthetic in dentistry, ophthalmology, and in ear, nose and throat surgery 
because its strong vasoconstrictor action helps to reduce local bleeding. Cocaine is a powerful central nervous 
system stimulant used non-medically to produce euphoria or wakefulness. Repeated use produces dependence. 
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Dependence
A cluster of physiological, behavioural and cognitive phenomena in which the use of a substance or a class of 
substances takes on a much higher priority for a given individual than other behaviours that once had greater 
value. A central descriptive characteristic of the dependence syndrome is the desire (often strong, sometimes 
overpowering) to take psychoactive drugs (which may or may not have been medically prescribed), alcohol, 
or tobacco.
Detoxification
Also referred to as a managed withdrawal or supported withdrawal, detoxification refers to the process of an 
individual being withdrawn from the effects of a psychoactive substance. When referring to a clinical procedure, 
detoxification refers to a withdrawal process that is carried out in a safe and effective manner, minimizing the 
withdrawal symptoms, and supporting the person physically and mentally through the process. 
Drug-related problem 
Any of the range of adverse accompaniments of drug use, particularly illicit drug use. “Related” does not 
necessarily imply causality.
Fetal alcohol syndrome (FAS) 
A pattern of retarded growth and development, both neuropsychological and physical, with typical facial 
dysmorphic features, found in some children exposed to alcohol during pregnancy. A spectrum of physical 
and neurodevelopmental abnormalities, which includes FAS, has been attributed to the effects of alcohol on 
the fetus. The level of maternal consumption that produces Fetal Alcohol Spectrum Disorders (FASD) has not 
been established and is influenced by genetic and other maternal and fetal characteristics.
Harmful substance use
A pattern of psychoactive substance use that causes damage to health (ICD-10, code F11.1). The damage may 
be physical (e.g. in the cases of hepatitis from the self-administration of injected psychoactive substances) or 
mental. 
Hazardous substance use
A pattern of substance use that increases the risk of harmful consequences for the user and fetus. 
Intoxication 
A condition that follows the administration or consumption of a psychoactive substance and results in 
disturbances in the level of consciousness, cognition, perception, judgement, affect, or behaviour, or other 
psychophysiological functions and responses. 
Neonatal Abstinence Syndrome / Neonatal Withdrawal Syndrome
When a neonate shows signs of withdrawal from exposure to psychotropic substances in utero, this is referred 
to as neonatal abstinence or neonatal withdrawal. 
Opioid maintenance treatment
Also referred to as opioid agonist maintenance treatment, or opioid substitution treatment. Examples of opioid 
maintenance therapies are methadone and buprenorphine maintenance treatment. Maintenance treatment 
can last from several months to more than 20 years, and is often accompanied by other treatment (e.g. 
psychosocial treatment). 
Psychosocial intervention
Any non-pharmacological intervention carried out in a therapeutic context at an individual, family or group level. 
Psychosocial interventions range from structured, professionally administered psychological interventions (e.g. 
cognitive behaviour therapy or insight oriented psychotherapy) to non-professional psychological and social 
interventions (e.g. self-help groups and non-pharmacological interventions from traditional healers, as well as 
accommodation, financial support, legal support, information and outreach). 
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Substance use disorders
The concept of “substance use disorders” includes both the dependence syndrome and the harmful use of 
psychoactive substances such as alcohol, cannabis, amphetamine-type stimulants (ATS), cocaine, opioids and 
benzodiazepines.
Volatile substances 
Substances that vaporize at ambient temperatures. Volatile substances that are inhaled for psychoactive effects 
(also called inhalants) include the organic solvents present in many domestic and industrial products (such as 
glue, aerosol, paints, industrial solvents, lacquer thinners, gasoline and cleaning fluids) and the aliphatic nitrites 
such as amyl nitrite. 
Withdrawal syndrome (abstinence syndrome, withdrawal reaction, withdrawal state)
A group of symptoms of variable clustering and degree of severity that occur on cessation or reduction of use 
of a psychoactive substance that has been taken repeatedly, usually for a prolonged period or in high doses 
(ICD-10 code F1x.3). The onset and course of withdrawal syndrome are time-limited and relate to the type of 
substance and dose being taken immediately before cessation or reduction of use. Typically, the features of 
withdrawal syndrome are the opposite of acute intoxication.
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AAP American Academy of Pediatrics
AUDIT alcohol use disorders identification test
ASSIST alcohol, smoking and substance involvement screening test
ALT alanine aminotransferase
AST aspartate aminotransferase
ATS amphetamine-type stimulants
CBT cognitive behavioural therapy
CDT carbohydrate-deficient transferrin
CI confidence interval
CM contingency management
CND Commission on Narcotic Drugs
CNS central nervous system
CSAP Center for Substance Abuse Prevention 
EUFASD European Fetal Alcohol Spectrum Disorders Alliance
FAS fetal alcohol syndrome
FASD fetal alcohol spectrum disorders
FIGO International Federation of Gynecology and Obstetrics
GABA gamma-aminobutyric acid
GDG guidelines development group
GGT gamma-glutamyl transpeptidase
DSM Diagnostic and Statistical Manual of Mental Disorders
HCW health-care workers
HIV human immunodeficiency virus
ICD International Classification of Diseases
IUGR intrauterine growth retardation
ITT intention-to-treat
IV intravenous
MCV mean corpuscular volume
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xEXECUTIVE SUMMARY 
Use of alcohol, illicit drugs and other psychoactive substances during pregnancy can lead to multiple health and 
social problems for both mother and child. Use of alcohol during pregnancy can lead to fetal alcohol syndrome 
and other harms such as spontaneous abortion, stillbirth, low birthweight, prematurity and birth defects. 
Dependence on alcohol and other drugs can also severely impair an individual’s functioning as a parent, spouse 
or partner, and instigate and trigger gender-based and domestic violence, thus significantly affecting the physical, 
mental and emotional development of children. 
Pregnancy may be an opportunity for women, their partners and other people living in their household to change 
their patterns of alcohol and other substance use. Health workers providing care for women with substance 
use disorders during pregnancy need to understand the complexity of the woman’s social, mental and physical 
problems in order to provide appropriate advice and support throughout pregnancy and the postpartum period. 
Why these guidelines were developed
These guidelines have been developed to enable professionals to assist women who are pregnant, or have 
recently had a child, and who use alcohol or drugs or who have a substance use disorder, to achieve healthy 
outcomes for themselves and their fetus or infant. They have been developed in response to requests from 
organizations, institutions and individuals for technical guidance on the identification and management of alcohol 
and other substance use and substance use disorders in pregnant women. They were developed in tandem 
with the WHO recommendations for the prevention and management of tobacco use and second-hand smoke 
exposure in pregnancy. There are currently no global guidelines providing evidence-based recommendations 
for identifying and managing substance use and substance use disorders in pregnancy. While several high-
income countries have developed national guidelines covering these issues, low- and middle-income countries 
currently lack such guidance. 
Who should use these guidelines
These guidelines have been primarily written for health-care providers managing women from conception to 
birth, and during the postnatal period, and their infants. 
Objectives and scope of these guidelines
These guidelines aim to provide evidence-based technical advice to health-care providers on identifying 
and managing substance use and substance use disorders in pregnant women, which enables health-care 
practitioners to apply the scientific principles of a public health approach in their own countries. An equally 
important objective is to enable pregnant women to make healthy decisions about alcohol and other substance 
use in the context of pregnancy and breastfeeding.
After a broad search of the needs of this population and challenges faced by health-care providers working with 
pregnant women with substance use disorders, it was decided that the guidelines should focus on six areas: 
1. Screening and brief intervention
2. Psychosocial interventions
3. Detoxification
4. Dependence management
5. Infant feeding
6. Management of infant withdrawal
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How these guidelines were developed
The development of these guidelines began in mid 2012 as a collaborative effort between the WHO 
departments of Mental Health and Substance Abuse and the Tobacco Free Initiative with production of the 
guidelines proposal, a virtual meeting of the Guidelines Development Group (GDG), and subsequent approval 
of the guidelines proposal by the WHO Guidelines Review Committee. The GDG has conferred through 
teleconferences and virtual meetings, as well as at two face-to-face meetings. At the first meeting, held 
at the WHO offices in Washington DC, USA, (29 January to 1 February 2013), where the evidence for the 
harms of different patterns of alcohol and drug use in pregnancy was reviewed, and the scope and areas of 
evidence retrieval were established. At the second and final meeting, held at the WHO headquarters in Geneva 
(11–13 September 2013) the evidence retrieved was presented using evidence profiles and GRADE tables (see 
annex), and final recommendations were formulated. The GDG used the evaluation of the evidence of effect, 
plus further evidence on harms, benefits, values, preferences, resource use and feasibility, to set the strength 
of the recommendations (see decision tables and evidence profiles in annex). 
The strength of the recommendation was set as either:
‘strong’: meaning that the Guideline Development Group was confident that the quality of 
the evidence of effect, combined with certainty about the values, preferences, benefits and 
feasibility, made this a recommendation that should be done in most circumstances and settings;
or
‘conditional’: meaning there was less certainty about the quality of the evidence and values, 
preferences, benefits and feasibility of this recommendation. Thus, there may be circumstances 
or settings in which the recommendation should not apply.
Recommendations
Governing principles
It was noted by the GDG that certain principles apply to all the recommendations described below. These 
overarching principles are proposed to provide guidance in the process of planning, implementing and evaluating 
the most suitable and relevant recommendations according to the national contexts and available resources. 
I. Prioritizing prevention. Preventing, reducing and ceasing the use of alcohol and drugs during pregnancy 
and in the postpartum period are essential components in optimizing the health and well-being of women 
and their children. 
II. Ensuring access to prevention and treatment services. All pregnant women and their families affected 
by substance use disorders should have access to affordable prevention and treatment services and 
interventions delivered with a special attention to confidentiality, national legislation and international human 
rights standards; women should not be excluded from accessing health care because of their substance 
use. 
III. Respecting patient autonomy. The autonomy of pregnant and breastfeeding women should always be 
respected, and women with substance use disorders need to be fully informed about the risks and benefits, 
for herself and for her fetus or infant, of available treatment options, when making decisions about her 
health care. 
IV. Providing comprehensive care. Services for pregnant and breastfeeding women with substance use 
disorders should have a level of comprehensiveness that matches the complexity and multifaceted nature 
of substance use disorders and their antecedents. 
V. Safeguarding against discrimination and stigmatization. Prevention and treatment interventions should 
be provided to pregnant and breastfeeding women in a way that will prevent stigmatization, discrimination 
and marginalization, and promote family, community and social support, as well as social inclusion by 
fostering strong links with available childcare, employment, education, housing and other relevant services. 
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IDENTIFICATION AND MANAGEMENT OF SUBSTANCE USE AND SUBSTANCE USE DISORDERS IN PREGNANCY
No. Recommendation
Strength of 
recommendation
Quality of 
evidence
Screening and brief interventions for hazardous and harmful substance use during pregnancy
 Health-care providers should ask all pregnant women about their 
use of alcohol and other substances (past and present) as early 
as possible in the pregnancy and at every antenatal visit.
Strong Low
 Health-care providers should offer a brief intervention to all 
pregnant women using alcohol or drugs.
Strong Low
Psychosocial interventions for substance use disorders1 in pregnancy
 Health-care providers managing pregnant or postpartum women 
with alcohol or other substance use disorders should offer 
comprehensive assessment2, and individualized care.3
Conditional Very low
Detoxification or quitting programmes for substance dependence in pregnancy
 Health-care providers should at the earliest opportunity advise 
pregnant women dependent on alcohol or drugs to cease their 
alcohol or drug use and offer, or refer to, detoxification services 
under medical supervision where necessary and applicable.4
Strong Very low
 Pregnant women dependent on opioids should be encouraged 
to use opioid maintenance treatment5 whenever available rather 
than to attempt opioid detoxification.
Strong Very low
 Pregnant women with benzodiazepine dependence should 
undergo a gradual6 dose reduction, using long-acting 
benzodiazepines.
Strong Very low
 Pregnant women who develop withdrawal symptoms following 
the cessation of alcohol consumption should be managed with 
the short-term use of a long-acting benzodiazepine.7
Strong Very low
 In withdrawal management for pregnant women with stimulant 
dependence, psychopharmacological medications may be useful 
to assist with symptoms of psychiatric disorders but are not 
routinely required. 
Strong Very low
Pharmacological treatment (maintenance and relapse prevention) for substance dependence in pregnancy
 Pharmacotherapy is not recommended for routine treatment of 
dependence on amphetamine-type stimulants, cannabis, cocaine, 
or volatile agents in pregnant patients. 
Conditional Very low
 Given that the safety and efficacy of medications for the 
treatment of alcohol dependence has not been established 
in pregnancy, an individual risk-benefit analysis should be 
conducted for each woman.
Conditional Very low
 Pregnant patients with opioid dependence should be advised to 
continue or commence opioid maintenance therapy with either 
methadone or buprenorphine.
Strong Very low
Breastfeeding with maternal alcohol and/or substance dependence
 A. Mothers with substance use disorders should be encouraged 
to breastfeed unless the risks clearly outweigh the benefits.
B. Breastfeeding women using alcohol or drugs should be 
advised and supported to cease alcohol or drug use; however, 
substance use is not necessarily a contraindication to 
breastfeeding. 
Conditional Low
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No. Recommendation
Strength of 
recommendation
Quality of 
evidence
 Skin-to-skin contact is important regardless of feeding choice and 
needs to be actively encouraged for the mother with substance 
use disorder who is able to respond to her baby’s needs.
Strong Low
 Mothers who are stable on opioid maintenance treatment with 
either methadone or buprenorphine should be encouraged to 
breastfeed unless the risks clearly outweigh the benefits.
Strong Low
Management of infants exposed to alcohol and other psychoactive substances
 Health-care facilities providing obstetric care should have a 
protocol in place for identifying, assessing, monitoring and 
intervening, using non-pharmacological and pharmacological 
methods, for neonates prenatally exposed to opioids. 
Strong Very low
 An opioid should be used as initial treatment for an infant with 
neonatal opioid withdrawal syndrome if required.
Strong Very low
 If an infant has signs of a neonatal withdrawal syndrome due 
to withdrawal from sedatives or alcohol, or the substance the 
infant was exposed to is unknown, then phenobarbital may be a 
preferable initial treatment option.
Conditional Very low
 All infants born to women with alcohol use disorders should be 
assessed for signs of fetal alcohol syndrome.8
Conditional Very low
1 The concept of “substance use disorders” includes dependence syndrome and harmful use of psychoactive substances such as alcohol, cannabis, amphetamine-
type stimulants (ATS), cocaine, benzodiazepines etc.
2 A comprehensive assessment of women using alcohol or drugs in pregnancy and the postpartum period include assessment of patterns of substance use, medical 
or psychiatric co-morbidity, family context and social problems.
3 Individual care planning involves selecting appropriate psychosocial and pharmacological interventions based on a comprehensive assessment.
4 Pregnant women dependent on alcohol or drugs who agree to undergo detoxification should be offered the supported withdrawal from substance use in an 
inpatient or hospital facility, if medically indicated; equal attention should be paid to the health of mother and fetus and treatment adjusted accordingly.
5 Methadone maintenance treatment or buprenorphine maintenance treatment.
6 For as short a time as medically feasible.
7 Management of alcohol withdrawal usually includes administration of thiamine.
8 Signs of Fetal Alcohol Syndrome (FAS) include growth impairment, dysmorphic facial features (short palpebral fissures, smooth or flattened philtrum, thin upper lip) 
and central nervous system abnormalities.

1INTRODUCTION
Use of alcohol, illicit drugs and other psychoactive substances during pregnancy is common and can lead to 
multiple health and social problems for both mother and child.
 
Use of alcohol during pregnancy can lead to fetal alcohol syndrome and other harms such as spontaneous 
abortion, stillbirth, low birthweight, prematurity and birth defects. Use of alcohol and other drugs can also 
severely impair an individual’s functioning as a parent, spouse or partner, and trigger gender-based and domestic 
violence, thus significantly affecting the physical, mental and emotional development of children. Injecting drug 
use is also associated with an increased risk of transmission of HIV and viral hepatitis to pregnant women and 
their infants. 
Alcohol and other substance use by expectant mothers and other people living in their households is not only 
detrimental to maternal and child health – the topics of UN Millennium Development Goals 2, 4, 5 and 6 – but 
can also undermine the social and health gains achieved in many low- and middle-income countries.
 
Pregnancy may be an opportunity for women, their partners and other people living in their household to change 
their patterns of alcohol and other substance use. Health workers providing care for women with substance 
use disorders during pregnancy need to understand the complexity of the woman’s social, mental and physical 
problems and to provide the right advice and support throughout pregnancy and the postpartum period. 
WHY THESE GUIDELINES WERE DEVELOPED 
These guidelines have been developed to enable professionals to assist pregnant women who use alcohol or 
drugs or with substance use disorders to achieve healthy outcomes. There are currently no global guidelines 
providing evidence-based recommendations for identifying and managing substance use and substance use 
disorders in pregnancy. While several high-income countries have developed national guidelines covering these 
issues, low- and middle-income countries currently lack such guidance. 
The project was initiated in response to requests from organizations, institutions and individuals for technical 
guidance on the identification and management of alcohol and other substance use disorders in pregnant 
women. These recommendations have been developed in tandem with the WHO recommendations for the 
prevention and management of tobacco use and second-hand smoke exposure in pregnancy. 
These guidelines are also a response to Resolution 63.13 of the World Health Assembly (outlining and endorsing 
a Global Strategy to Reduce the Harmful Use of Alcohol), and the Political Declaration and Plan of Action on 
International Cooperation Towards an Integrated and Balanced Strategy to Counter the World Drug Problem 
(agreed at the High Level Segment of the 52nd Session of the Commission of Narcotic Drugs; CND). 
Development of these guidelines is part of a range of activities carried out by the WHO Department of Mental 
Health and Substance Abuse (MSD). These include the development and dissemination of the ASSIST tool 
for screening for substance use in health-care settings; the ASSIST-linked brief intervention manual; the WHO 
mhGAP intervention package for management of priority mental health and behavioural disorders; the WHO 
guidelines for the psychosocially assisted pharmacological treatment of opioid dependence; the UNODC/WHO 
discussion paper on the principles of drug dependence treatment; and the UNODC/WHO programme on drug 
dependence treatment and care.
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
EXISTING RELEVANT GUIDELINES ON RELATED 
PROBLEMS AND DISORDERS
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Manual for use in primary care
http://whqlibdoc.who.int/publications/2010/9789241599382_eng.pdf
Brief Intervention. The ASSIST-linked brief intervention for hazardous or harmful substance use. Manual for use in 
primary care. 
http://whqlibdoc.who.int/publications/2010/9789241599399_eng.pdf
AUDIT: Alcohol Use Disorders Identification Test: Guidelines for use in primary care*
http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf
Brief Intervention for Hazardous and Harmful Drinking: Manual for use in primary care*
http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6b.pdf
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence
http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf
mhGAP – Intervention Guide
http://www.who.int/mental_health/publications/mhGAP_intervention_guide/en/
Contains recommendations on the management of alcohol and drug use disorders in non-psychiatric settings which 
are applicable to antenatal services.
Working with Individuals, Families and Communities to Improve Maternal and Newborn Health
http://whqlibdoc.who.int/hq/2010/WHO_MPS_09.04_eng.pdf
Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for essential practice
http://www.who.int/maternal_child_adolescent/documents/924159084x/en/index.html
PMTCT Strategic Vision 2010–2015 
http://whqlibdoc.who.int/publications/2010/9789241599030_eng.pdf
Contains recommendations on the prevention of mother-to-child transmission of HIV in women who inject drugs. 
Guidelines on HIV and Infant Feeding 2010
http://www.who.int/maternal_child_adolescent/documents/9789241599535/en/index.html
Contains recommendations on postnatal care in HIV-positive women relevant to intravenous drug users.
Acceptable Medical Reasons for Use of Breast-milk Substitutes 
http://whqlibdoc.who.int/hq/2009/WHO_FCH_CAH_09.01_eng.pdf
Contains recommendations on circumstances when breastfeeding is not advised.
* Although these guidelines were published in 2001, prior to establishment of current WHO guideline methodology requiring systematic review of the evidence, 
the effectiveness of brief interventions for alcohol use disorders has been confirmed in recent WHO guidelines approved by the WHO Guideline Review 
Committee, including the mhGAP Intervention Guide in the above table. 
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WHO SHOULD USE THESE GUIDELINES
These guidelines have been primarily written for health-care providers managing women from conception to 
birth and the postnatal period, and their infants.
OBJECTIVES AND SCOPE OF THE DOCUMENT
These guidelines aim to provide evidence-based technical advice to health-care providers on identifying and 
managing substance use in pregnant women, which enables users to apply the scientific principles of a 
public health approach in their own countries. An equally important objective is to enable pregnant women 
to make healthy decisions about alcohol and other substance use in the context of pregnancy, breastfeeding 
and the postnatal period.
After a broad search of the needs of this population and challenges faced by health-care providers working with 
pregnant women with substance use disorders, it was agreed by the Guideline Development Group (GDG) 
that these guidelines should focus on six areas: 
1. Screening and brief intervention
2. Psychosocial interventions
3. Detoxification
4. Dependence management
5. Infant feeding
6. Management of infant withdrawal
INDIVIDUALS AND PARTNERS INVOLVED IN 
DEVELOPMENT OF THE GUIDELINES
WHO steering group
An internal steering group was drawn from the WHO departments of Mental Health and Substance Abuse, 
Reproductive Health and Research, Gender Equity and Human Rights, and the Tobacco Free Initiative. The full 
list of names is provided in Annex 4.
Guideline Development Group 
The Guideline Development Group was made up of people with content expertise, relevant experience in 
primary health care in low- and middle-income countries and expertise in evidence-based guideline methodology. 
The Guideline Development Group selection also ensured gender balance and regional diversity. Members 
have been drawn from all WHO regions. 
Consultants with expertise in evidence search and GRADE methodology supported the Guideline Development 
Group. The full list of the Guideline Development Group members and consultants along with their expertise, 
affiliations and geographical base is provided in Annex 4. 
External review group
External reviewers were drawn from end-users, agencies and partners working in the subject area of the 
guidelines. Their names, affiliations, area of interest and geographical base are given in Annex 4.
External reviewers were asked to evaluate and comment at different stages of development of the guideline. 
Some members of the external review group attended the initial scoping meeting and the final recommendation 
decision meeting as ‘special invitees’ where they acted as observers providing comment but had no involvement 
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in decision-making. They reviewed the scoping questions, outcomes of interest, evidence profiles, and the 
final guideline document. Reviewer response was compiled and comments used to refine the scope of the 
guidelines, the outcomes of interest, and the final recommendations. 
Management of conflicts of interest
All Guideline Development Group members, external reviewers and consultants completed the WHO declaration 
of interest forms. Several Guideline Development Group members declared academic and financial interests. 
These were then reviewed by the secretariat for potential conflicts of interest (see summary in Annex 5). 
Hendree Jones had received funding from Reckitt Benckiser, a manufacturer of buprenorphine. She received 
small honoraria for presenting at conferences, and received free buprenorphine for use in her clinical trials. 
Gabriele Fischer received a small amount of consultancy funding from Reckitt Benckiser, a manufacturer of 
buprenorphine, Mundipharma, a manufacturer of morphine, and Lannacher, a manufacturer of psychiatric 
medication. Anju Dhawan had received funding for a clinical trial from Rusan Pharmaceuticals, a manufacturer 
of both methadone and buprenorphine. As these members are well-recognized researchers and clinicians in 
this field and, taking into consideration the level of funding, it was agreed that they should not be excluded 
from the GDG but that these potential competing interests should be managed by excluding them from active 
discussion and decision-making on the pharmaceuticals produced by companies from which they had received 
funds. Both meetings began with an open declaration of interests. It was made clear that those Guideline 
Development Group members with pharmaceutical industry funding could not participate in discussions on 
questions related to the medications associated with such companies.
HOW THE GUIDELINES WERE DEVELOPED
The development of these guidelines began in mid 2012 as a collaborative effort between the WHO 
departments of Mental Health and Substance Abuse and the Tobacco Free Initiative with production of the 
guidelines proposal, a virtual meeting of the Guidelines Development Group (GDG), and subsequent approval 
of the guidelines proposal by the WHO Guidelines Review Committee. The GDG has conferred through 
teleconferences and virtual meetings, as well as at two face-to-face meetings. At the first meeting, held 
at the WHO offices in Washington DC, USA (29 January to 1 February 2013), where the evidence for the 
harms of different patterns of alcohol and drug use in pregnancy was reviewed, and the scope and areas of 
evidence retrieval were established. At the second and final meeting, held at the WHO headquarters in Geneva 
(11–13 September 2013), the evidence retrieved was presented using evidence profiles and GRADE tables 
(see annex), and final recommendations were formulated. These were then reviewed by the external review 
group and finalized by the GDG using online discussions and a final teleconference. 
 
EVIDENCE SEARCH AND RETRIEVAL
The six focus areas agreed upon by the GDG were used to generate appropriate EVIDENCE questions to 
govern systematic searches for evidence. In April 2013, the GDG were asked to select and rate outcomes 
on a scale from 1 to 9, where 9 is most important (critical) and 1 is least important. Means were calculated 
for each outcome and the top seven outcomes used for the evidence review, except where the GDG agreed 
that more than seven outcomes were necessary (see evidence profiles and GRADE tables in Annex 1).
Four investigators (two consultants, two WHO interns) managed the evidence retrieval. The database search 
was conducted by Tomas Allen, WHO information specialist, who searched multiple databases: PubMed, 
EmBase, CENTRAL, Psychinfo, CINAHL (see Annex 2 for details of MeSH terms, etc). Essentially, the search 
strategy was to identify all randomized controlled trials (RCTs) and systematic reviews conducted in pregnant 
women using alcohol or drugs, and then to allocate these to the different areas of evidence retrieval. The 
search identified approximately 6000 articles, which were screened on the basis of title and abstract, then on 
the full paper (see Figure 1, and Tables 1 & 2, below). Where a recent Cochrane review or other high-quality 
systematic review was identified, this was used as the evidence base and results presented in GRADE tables. 
Where a Cochrane review or equivalent was not available, RCTs were identified and a systematic review 
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TABLE 1. NUMBER OF RECORDS BY DATABASE SEARCHED
Database Number of records
PubMed 1479
EmBase 3614
CENTRAL 84
PsychInfo 512
CINAHL 754
TOTAL 6443
Deduplicated 5632
TABLE 2. NUMBER OF ARTICLES AND DISTINCT RCTs BY EVIDENCE RETRIEVAL AREA 
Intervention Articles RCTs
Screening and brief intervention 17 10
Psychosocial interventions 30 15
Detoxification 0 0
Dependence management 36 4
Lactation 0 0
Management of the infant 5 4
Unclassified 5 n/a
Total 93 33
FIGURE 1: SCREENING OF RECORDS FROM THE LITERATURE SEARCH TO ELIGIBLE ARTICLES
FULL TEXT 
OBTAINED
172
ELIGIBLE 
ARTICLES
93
SCREENED
5632
conducted using Cochrane methods, including meta-analysis, where appropriate, to generate results that were 
then evaluated using GRADE. 
To supplement gaps in the RCT literature, the other studies identified in the systematic literature search were 
also allocated to each area of evidence retrieval used to provide supplementary information in the GRADE 
profiles. There were 598 such articles that were not RCTs but still considered relevant to the key issues covered 
by the guidelines.
A values and preferences survey was conducted over three weeks in August 2013. Respondents – many of 
them health-care workers or pregnant (or recently pregnant) women – were asked to rate their preference for 
each draft recommendation and to provide comments on how it might affect them. At the final face-to-face 
guideline development meeting, held in September 2013, an analysis of the responses was presented during 
discussion of each recommendation. These results were used by the GDG to weigh values and preferences 
when setting the strength of each recommendation. The form can be accessed at: https://sryyz.enketo.
formhub.org/webform
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EVIDENCE TO RECOMMENDATIONS
The GRADE system for assessing quality of evidence and using evidence to inform decisions was applied by 
the GDG when drafting the final recommendations. For each of the six areas of scoping focus, an evidence 
profile was provided summarizing the evidence retrieved, including evidence on values, preferences, 
benefits, harms and feasibility. Wherever possible, the evidence retrieved was evaluated using GRADE 
and GRADE tables were provided. Evidence of effectiveness was rated as high, moderate, low or very 
low depending on the certainty of effect measured in the studies evaluated. For many of the EVIDENCE 
questions the evidence was either lacking or very limited, leading to a rating of very low quality evidence. 
The GDG recognized that extensive research needs to be done to provide a solid evidence base for 
management of pregnant women with substance use and substance use disorders. A decision table was 
used by the Guideline Development Group to assess and agree on the quality of evidence and certainty 
about harms and benefits, values and preferences, feasibility and resource implications (see annex for 
details of each decision, presented in Evidence Profiles 1–6).
The strength of the recommendation was set as either:
‘strong’: meaning that the Guideline Development Group was confident that the quality of 
the evidence of effect, combined with certainty about the values, preferences, benefits and 
feasibility, made this a recommendation that should be done in most circumstances and settings;
or
‘conditional’: meaning there was less certainty about the quality of the evidence and values, 
preferences, benefits and feasibility of this recommendation. Thus, there may be circumstances 
or settings in which it should not apply.
Decisions were usually made by consensus but where there was disagreement, the GDG members voted and 
a two-thirds majority was required for a decision to be carried. Where a two-thirds majority was not achieved 
initially, it was agreed that the recommendation should be reworded and a vote taken again. This was necessary 
in only one instance – for recommendation 8, concerning management of stimulant withdrawal. 
RECOMMENDATIONS
Following an extensive review of the evidence in each of the six scoping areas, the GDG agreed on the 
following recommendations for the identification and management of substance use and substance use 
disorders during pregnancy. Each recommendation is followed by remarks clarifying contextual issues 
and relevant aspects of management. During development of the recommendations, the GDG identified 
considerable research gaps and agreed on a list of research priorities and questions, which are listed after 
the recommendations.
Overarching principles
It was noted by the Guideline Development Group that certain principles apply to all the recommendations 
described below. These overarching principles are proposed to provide guidance in the process of planning, 
implementing and evaluating the most suitable and relevant recommendations according to the national 
contexts and available resources. 
I. Prioritizing prevention. Preventing, reducing and ceasing the use of alcohol and drugs during pregnancy 
and in the postpartum period are essential components in optimizing the health and well-being of women 
and their children. 
This effort requires a multifaceted approach with multidisciplinary actions, including the right to accurate 
information about the risks of alcohol and drug use in pregnancy, a health-care system that implements 
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prevention strategies and supports healthy choices about substance use among women of childbearing age, 
and health promotion efforts encouraging a healthy home and social environment, supporting pregnant women 
and their partners in making healthy choices about their substance use and protecting from pressures to drink 
alcohol or use drugs.
II. Ensuring access to prevention and treatment services. All pregnant women and their families affected 
by substance use disorders should have access to affordable prevention and treatment services and 
interventions delivered with a special attention to confidentiality, national legislation and international human 
rights standards; women should not be excluded from accessing health care because of their substance 
use. 
Health-care services should be able to identify and manage substance use and substance use disorders in 
pregnancy. Substance use disorders should be identified by the health-care system at the earliest opportunity 
and quality, affordable and accessible treatment offered. Specialized services for women with substance use 
disorders should be recognized as an important component of the health system and need to be available 
proportional to the clinical need. Health-care services for women with substance use disorders should take into 
consideration the childcare needs of women when considering the accessibility of their services. Confidentiality, 
a fundamental right of every health-care user, is also affected by the organization of services. 
III. Respecting patient autonomy. The autonomy of pregnant and breastfeeding women should always be 
respected; women with substance use disorders need to be fully informed about the risks and benefits, 
for herself and for her fetus or infant, of available treatment options, when making decisions about her 
health care. 
Patient autonomy and patient-centred care are crucial components of health-care services for pregnant women. 
Treatment decisions should be based on accepted principles of medical-care ethics, respecting a women’s 
autonomy in decisions related to her care and the health of her fetus, and her right to privacy and confidentiality 
when discussing treatment options. It is essential to provide clear, accurate and consistent information to 
pregnant and breastfeeding women about the risks of alcohol and drug use, and all women with substance 
use disorders should have access to information about effective contraception.
IV. Providing comprehensive care. Services for pregnant and breastfeeding women with substance use 
disorders should have a level of comprehensiveness that matches the complexity and multifaceted nature 
of substance use disorders and their antecedents. 
Comprehensive services for pregnant and breastfeeding women include a range of gender-sensitive prevention 
and treatment interventions that can respond to multiple needs, including childcare needs, comorbid mental and 
concurrent medical conditions, bloodborne viruses and other infectious diseases, poor diet and psychosocial 
problems such as relationships with a partner/other people living in the same household, homelessness, poverty 
and violence. Comprehensive services that offer a continuity of care are generally much easier for vulnerable 
groups to access. 
V. Safeguarding against discrimination and stigmatization. Prevention and treatment interventions should 
be provided to pregnant and breastfeeding women in ways that prevent stigmatization, discrimination, 
marginalization, and promote family, community and social support as well as social inclusion by fostering 
strong links with available childcare, employment, education, housing and other relevant services. 
Health-care providers should seek to establish a clinician-patient relationship without discrimination or 
stigmatization. All important information about the risks of substance use and the benefits of treatment should 
be communicated in a non-judgemental, respectful, non-stigmatizing and empathic manner, sensitive to age, 
culture and language differences. All important information has to be provided verbally, as well as in writing, at 
reading and comprehension levels that are congruent with the patient’s level of literacy. Health-care providers 
should respond to disclosure of private and distressing information (e.g. gender-based violence or self-harm) 
with sensitivity. 
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Screening and brief interventions for hazardous and harmful substance use during 
pregnancy (Evidence Profile 1: see Annex 1, page 22) 
Much of the evidence underlying the effectiveness of screening and brief interventions during pregnancy comes 
from a period when reporting standards and measures of bias were not in standard use, hence the evidence 
quality is graded as low or very low. However, the evidence retrieved indicated that being asked about alcohol 
and other substance use in a detailed and comprehensive manner may increase a woman’s awareness of the 
risks associated with alcohol and drug use and may function to modify her behaviour. 
A brief motivational intervention has been found to reduce the number of drinks and the number of heavy 
drinking days during the postpartum period. Pregnant women with higher levels of alcohol use may reduce 
their alcohol use following a brief intervention that includes their partner.
Pregnant adolescent girls with a substance use disorder have been shown to reduce their substance use after 
a single-session, standardized brief intervention. Full details of studies evaluated, harms and benefits, feasibility 
and resource use are provided in Annex 1, page 22.
 
RECOMMENDATION 
Health-care providers should ask all pregnant women about their use of alcohol and other substances (past and 
present) as early as possible in the pregnancy and at every antenatal visit.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Asking	at	every	visit	is	important	as	some	women	are	more	likely	to	report	sensitive	information	only	after	a	trusting	
relationship has been solidly established.
•	 Pregnant	women	should	be	advised	of	the	potential	health	risks	to	themselves	and	to	their	babies	posed	by	alcohol	
and drug use. 
•	 Validated	screening	instruments	for	alcohol	and	other	substance	use	and	use	disorders	are	available	(see	Annex	3).
•	 Health-care	providers	should	be	prepared	to	intervene	or	refer	all	pregnant	women	who	are	identified	as	using	
alcohol and/or drugs (past and present).
•	 It	was	decided	that	despite	the	low	quality	of	evidence	of	effect,	the	benefit	–	potential	reduction	of	alcohol	and	
substance use – outweighed any potential harms of a brief psychosocial intervention, which were considered 
minimal. Therefore the balance of benefits versus harms was clearly positive despite uncertainty about the degree 
of benefit. In addition, the burden of implementation was minimal.
RECOMMENDATION 
Health-care providers should offer a brief intervention to all pregnant women using alcohol or drugs.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Brief	intervention	is	a	structured	therapy	of	short	duration	(typically	5–30	minutes)	offered	with	the	aim	of	assisting	
an individual to cease or reduce the use of a psychoactive substance. It is designed in particular for general 
practitioners and other primary health-care workers. 
•	 Health-care	providers	should	be	given	appropriate	training	and	resource	materials.
•	 The	brief	intervention	should	be	individualized,	and	include	feedback	and	advice	on	ceasing	or	reducing	alcohol	
and other substance use during pregnancy. There may need to be follow-up with the patient, with the possibility of 
referral to treatment for those patients who are unable to reduce or eliminate such use. 
•	 The	approach/attitude	of	health-care	providers	is	an	important	contributor	to	the	effectiveness	of	brief	interventions.
•	 As	for	recommendation	1,	it	was	decided	that,	despite	the	low	quality	of	evidence	of	effectiveness,	this	should	be	
a strong recommendation because the potential benefit – reduction of alcohol and/other substance use – likely 
outweighs any potential harms of a brief psychosocial intervention which were considered minimal. Therefore the 
balance of benefits versus harms was clearly positive, although there was uncertainty about the degree of benefit. 
In addition the burden of implementation was minimal.
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Psychosocial interventions for substance use disorders in pregnancy (Evidence Profile 2: 
see Annex 1, page 44)
The concept of “substance use disorders” includes dependence syndrome and harmful use of psychoactive 
substances such as alcohol, cannabis, amphetamine-type stimulants (ATS), cocaine, opioids and benzodiazepines.
The evidence review sought trials evaluating the effectiveness of psychosocial interventions, including trials of 
cognitive behavioural therapy (CBT), motivational interviewing (MI), contingency management (CM), and home 
visits. All the trials were conducted in services specializing in the management of substance use in pregnancy. 
“Treatment-as-usual” in this context is best considered a form of unstructured psychosocial intervention rather 
than the absence of psychosocial support.
 o Findings suggest that CBT may be superior to treatment-as-usual in terms of treatment retention, reductions 
in risky sex and needle use, and occurrence of preterm birth. 
 o Findings support the superiority of contingency management (CM) to treatment-as-usual in terms of 
retention in treatment, percentage of negative urines, and weeks of continuous cocaine abstinence. 
 o Findings do not support the superiority of MI to treatment-as-usual or educational control, with similar 
results for maternal retention in treatment and maternal substance abuse. 
 o A review of randomized trials suggests that increased home visits following delivery are not effective in 
reducing maternal substance use, or alcohol use, nor in improving adherence to substance abuse treatment. 
RECOMMENDATION 
Health-care providers managing pregnant or postpartum women with alcohol or other substance use disorders 
should offer comprehensive assessment and individualized care.
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 A	comprehensive	assessment	of	women	using	alcohol	or	drugs	in	pregnancy	and	the	postpartum	period	includes	
an assessment of patterns of substance use, medical or psychiatric comorbidity, family context, as well as social 
problems.
•	 Individualized	care	involves	selecting	appropriate	psychosocial	interventions	of	different	intensity	based	on	the	
particular needs of the pregnant women and the resources available. Psychosocial interventions include a number 
of psychological treatments and social supports, ranging from lesser to higher intensity. The psychosocial treatment 
and support referred to in this section is a more intensive set of interventions typically delivered by people with 
specific training in the management of substance use disorders, and usually includes repeated contact with the 
patient. The kinds of specific psychological techniques considered in this category include cognitive behavioural 
therapy, contingency management and motivational enhancement. The kinds of social support referred to in this 
section include assistance with accommodation, vocational training, parenting training, life-skills training, legal 
advice, home-visiting and outreach.
•	 Despite	the	benefits	of	psychosocial	treatment	outweighing	the	harms,	this	recommendation	was	considered	to	be	
conditional given the absence of strong evidence and the potential resource implications. 
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Detoxification or quitting programmes for alcohol and other substance dependence in 
pregnancy (Evidence Profile 3: see Annex 1, page 93)
A withdrawal syndrome requiring pharmacological treatment in pregnancy can be said to occur for three 
substances: benzodiazepines, alcohol, and opioids. The withdrawal syndrome associated with the cessation 
of other substances (such as psychostimulants) has not been considered to justify the use of psychotropic 
medication. For those pregnant women for whom medication-assisted withdrawal is successful, there does not 
appear to be any evidence of significant fetal distress during detoxification, no increased risk of fetal demise 
or premature delivery. 
For opioid dependence, in addition to recommending cessation of opioid use, there is the option of prescribing 
long-acting opioids such as methadone and buprenorphine to maintain stable opioid levels (see also Evidence 
Profile 4 in Annex 1). Although this treatment approach includes a risk of neonatal opioid withdrawal symptoms, 
opioids are essentially non-toxic at stable levels. Cessation of opioids, on the other hand carries a higher risk 
of relapse to unstable patterns of short-acting opioid use (such as heroin). The decision, therefore, is between 
opioid maintenance treatment approach with a known risk of neonatal withdrawal but a low risk of relapse, 
and opioid detoxification, which, if successful, carries no risk of neonatal withdrawal, but, if unsuccessful, 
has a high risk of adverse neonatal outcomes, including neonatal opioid withdrawal and intrauterine growth 
retardation (IUGR) and also adverse maternal outcomes such as overdose.
For dependence on other substances, there was considered to be no feasible maintenance treatment option. 
RECOMMENDATION 
Health-care providers should, at the earliest opportunity, advise pregnant women dependent on alcohol or drugs 
to cease their alcohol or drug use and offer, or refer to, detoxification services under medical supervision where 
necessary and applicable. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Pregnant	women	dependent	on	alcohol	or	drugs	who	agree	to	undergo	detoxification	should	be	offered	the	
supported withdrawal from substance use in an inpatient or hospital facility, if medically indicated. 
•	 Detoxification	can	be	undertaken	at	any	stage	in	pregnancy,	but	at	no	stage	should	antagonists	(such	as	naloxone,	
or naltrexone – in the case of opioid withdrawal) be used to accelerate the detoxification process. 
•	 Equal	attention	should	be	paid	to	the	health	of	mother	and	fetus	during	detoxification	and	treatment	adjusted	
accordingly.
•	 The	exceptions	to	this	recommendation	are	opioid	and	benzodiazepine	dependence,	which	are	covered	by	
recommendations 5 and 6 separately. 
•	 It	was	decided	that	this	recommendation	should	be	strong,	despite	the	very	low	quality	of	evidence	of	the	
effectiveness of the health-care intervention because there is clear evidence of harm to the fetus of ongoing 
maternal substance use, and the benefit to both mother and fetus of ceasing alcohol and/or substance use under 
medical supervision strongly outweighs any potential harms. 
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RECOMMENDATION 
Pregnant women dependent on opioids should be encouraged to use opioid maintenance treatment whenever 
available rather than to attempt opioid detoxification. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Opioid	maintenance	treatment	in	this	context	refers	to	either	methadone	maintenance	treatment	or	buprenorphine	
maintenance treatment.
•	 Pregnant	patients	with	opioid	dependence	who	wish	to	undergo	detoxification	should	be	advised	that	relapse	to	
opioid use is more likely following medication-assisted withdrawal than while undertaking opioid maintenance 
treatment.
•	 Such	medication-assisted	withdrawal	from	opioids	should	be	attempted	only	in	an	inpatient	unit,	using	a	gradual	
reduction in methadone or buprenorphine doses. Inpatient care should also be considered for the initiation and 
optimization of maintenance treatment.
•	 Psychosocial	treatment	should	be	an	integral	component	of	such	treatment.	
•	 Pregnant	women	who	fail	to	complete	medication-assisted	withdrawal	should	be	offered	opioid	agonist	
pharmacotherapy.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	low	quality	of	evidence	of	effectiveness	from	
randomized controlled trials, as the rate of relapse to opioid use following detoxification has been shown to be high 
and the risks of harm to both mother and fetus from failed detoxification are catastrophic compared to the very low 
risks of harm from opioid maintenance treatment. 
RECOMMENDATION 
Pregnant women with benzodiazepine dependence should undergo a gradual dose reduction, using long-acting 
benzodiazepines.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Long-acting	benzodiazepines	should	only	be	used	for	as	short	a	time	as	is	medically	feasible	in	managing	
benzodiazepine withdrawal.
•	 Psychosocial	interventions	should	be	offered	throughout	the	period	of	benzodiazepine	withdrawal.
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	benzodiazepine	
dependence.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	very	low	quality	of	evidence	of	effectiveness	
because ongoing benzodiazepine use in pregnancy is associated with significant risk of harm. At the same time, 
abrupt cessation of benzodiazepines can result in a severe withdrawal syndrome including seizures and psychosis. 
This leaves gradual reduction as the only practicable alternative. Significant clinical experience indicates that 
this approach is feasible and safe. Hence the GDG was in agreement that the benefits of gradual dose reduction 
outweigh the harms of both ongoing use and abrupt cessation.
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RECOMMENDATION 
Pregnant women who develop withdrawal symptoms following the cessation of alcohol consumption should be 
managed with the short-term use of a long-acting benzodiazepine.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Management	of	alcohol	withdrawal	usually	also	includes	administration	of	thiamine.
•	 Alcohol	withdrawal	management	may	be	facilitated	by	the	use	of	an	alcohol-withdrawal	scale	such	as	the	CIWA-Ar.	
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	alcohol	dependence.
•	 Alcohol	withdrawal	can	be	a	severe	and	even	life-threatening	condition,	provoking	seizures	and	delirium.	Evidence	
from non-pregnant populations has demonstrated the effectiveness of long-acting benzodiazepines for preventing 
seizures and delirium in alcohol withdrawal. Given the severity of alcohol withdrawal, and the lack of significant 
harm from short-term benzodiazepine use, and the evidence supporting the use of benzodiazepines in the 
management of alcohol withdrawal in the general population, the GDG decided that this recommendation should be 
strong despite the low quality of evidence in pregnant women.
RECOMMENDATION 
In withdrawal management for pregnant women with stimulant dependence, psychopharmacological medications 
may be useful to assist with symptoms of psychiatric disorders but are not routinely required. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Except	for	the	management	of	acute	intoxication,	withdrawal	management	in	amphetamine-type	stimulants	(ATS)	
dependence or cocaine dependence does not include psychopharmacological medications as a primary approach 
to treatment in pregnant patients. There is no evidence that medication-assisted withdrawal would benefit pregnant 
women with these respective disorders. 
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	stimulant	dependence.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	very	low	quality	of	evidence	because	the	
harms to mother and fetus of ongoing use of psychostimulants use have been shown to be high. The risks of 
providing short-term appropriate non-teratogenic medications for short-term management of psychologically 
distressing symptoms in pregnancy are very low. Therefore, the potential benefits of this approach strongly 
outweigh the harms of providing psychopharmacological treatment of symptoms, if required, during psychostimulant 
withdrawal.
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Pharmacological treatment (maintenance and relapse prevention) for alcohol and other 
substance dependence in pregnancy (Evidence Profile 4: see Annex 1, page 100)
Systematic reviews of psychopharmacological treatments, methadone versus buprenorphine and methadone 
compared to slow-release morphine for pregnant women with substance use disorders were performed and 
the evidence of effect evaluated (see GRADE tables and summary of findings tables in Annex 1 for full details). 
Findings in brief:
 o Pharmacotherapy has been shown to be successful in the treatment of opioid dependence and 
benzodiazepine dependence. Methadone and buprenorphine have similar efficacy in the management 
of opioid dependnece. Methadone appears to result in better maternal retention in treatment, and 
buprenorphine is associated with some better neonatal outcomes, such as higher birthweight.
 o Combining psychosocial interventions with pharmacotherapy has been shown to be superior to 
pharmacotherapy alone. 
 o No evidence was found on the use of medications for relapse prevention for alcohol dependence in 
pregnancy (acamprosate, disulfiram, nalmefene, naltrexone).
 o No RCT evidence was found on the use of naltrexone in relapse prevention from opioid dependence in 
pregnancy. 
 o No evidence was found on the use of benzodiazepine maintenance for benzodiazepine dependence in 
pregnancy.
RECOMMENDATION 
Pharmacotherapy is not recommended for routine treatment of dependence on amphetamine-type stimulants, 
cannabis, cocaine or volatile agents in pregnant patients. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 For	pregnant	patients	who	use	cannabis,	amphetamine-type	stimulants,	cocaine,	and	volatile	agents,	the	focus	of	
treatment should be on psychosocial interventions.
•	 The	recommendation	was	considered	conditional	given	the	complete	lack	of	research	on	this	issue.	
RECOMMENDATION 
Given that the safety and efficacy of medications for the treatment of alcohol dependence has not been established in 
pregnancy, an individual risk benefit analysis should be conducted for each woman. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Pregnant	patients	with	alcohol	dependence	should	be	offered	psychosocial	interventions.
•	 The	recommendation	was	considered	conditional	given	the	complete	lack	of	research	on	this	issue.
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RECOMMENDATION 
Pregnant patients with opioid dependence should be advised to continue or commence opioid maintenance therapy 
with either methadone or buprenorphine. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Pregnant	patients	with	opioid	dependence	should	be	encouraged	to	commence	opioid	agonist	pharmacotherapy,	
which should be combined with psychosocial interventions.
•	 Opioid-dependent	pregnant	women	who	are	already	taking	opioid	maintenance	therapy	with	methadone	should	
not be advised to switch to buprenorphine due to the risk of opioid withdrawal. Pregnant opioid-dependent women 
taking buprenorphine should not be advised to switch to methadone unless they are not responding well to their 
current treatment.
•	 In	opioid-dependent	pregnant	women,	the	buprenorphine	mono	formulation	should	be	used	in	preference	to	the	
buprenorphine/naloxone formulation. 
•	 Regardless	of	the	choice	of	medication,	psychosocial	interventions	should	be	an	integral	component	of	treatment.
•	 Opioid-dependent	pregnant	patients	who	wish	to	receive	opioid	antagonist	pharmacotherapy	should	be	discouraged	
from such a choice. 
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	low	quality	of	evidence	as	the	rate	of	relapse	
to opioid use following detoxification is high and the risks of harm from failed detoxification are catastrophic 
compared to the small risks of harm from opioid maintenance treatment.
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Breastfeeding and maternal substance use (Evidence Profile 5: see Annex 1, page 122) 
Enhanced maternal-infant attachment through breastfeeding is especially important, particularly for women 
feeling guilty about their prenatal substance use and those who lack self-confidence in parenting skills. 
Breastfeeding and/or breast milk may reduce the incidence and/or severity of neonatal withdrawal syndrome 
in opioid-exposed infants. 
Evidence of decreased stress response and increased vagal tone, indicating better autonomic regulation, in 
lactating compared to non-lactating women is salient for drug-dependent women. Stress can be a major factor 
in the development of psychiatric symptoms, and has been linked to relapse to substance use. Alcohol use, 
binge drinking, tobacco and marijuana use rates rebound substantially in the postpartum period compared 
with use during pregnancy. Depression correlates with substance use, and new mothers with postpartum 
depression may be at high risk for substance use or return to substance use. Maternal psychopathology is 
more common in substance-dependent women than in the general population, and is not infrequently related 
to poor judgment, enhancing the physical risk to the breastfed infant. Maternal somnolence, lack of adequate 
sleep-wake cycling, or decreased reaction times due to alcohol or drug use may increase the risk of infant injury. 
RECOMMENDATION 
A. Mothers with substance use disorders should be encouraged to breastfeed unless the risks clearly outweigh the 
benefits.
B. Breastfeeding women using alcohol or drugs should be advised and supported to cease alcohol or drug use; 
however, substance use is not necessarily a contraindication to breastfeeding.
Strength of recommendation: Conditional      Quality of evidence: Low
Remarks:
•	 A	risk	assessment	should	take	into	account	the	risks	of	exposure	to	alcohol	and	drugs	in	breast	milk,	HIV	status,	the	
specific pattern of substance use in each case, the availability of safe and affordable breast milk substitutes, as well 
as access to clean water, sterilizing equipment, and the age of the infant/child. Heavy daily alcohol consumption, 
such as in alcohol dependence, would constitute high risk to the infant, for example, and in the presence of safe 
breast milk alternatives, it would be preferable not to breastfeed. 
•	 The	message	to	breastfeeding	women	who	have	used	alcohol	and	drugs	to	cease	using	alcohol	and	drugs	while	
breastfeeding should be given in such a way that it does not undermine the potential benefits of breastfeeding. 
•	 It	is	possible	to	reduce	the	risk	of	exposure	through	breastfeeding	by	altering	the	timing	of	breastfeeding,	or	by	
the use of temporary alternatives, such as stored (frozen) breast milk or breast milk substitutes where they are 
available and can be safely used. Women who use alcohol intermittently should be discouraged from breastfeeding 
for 2 hours after consuming one standard drink (10 g of pure alcohol), and 4–8 hours after consuming more than one 
drink in a single occasion. Breastfeeding advice for women with HIV should also take into consideration the risk of 
HIV transmission (refer to the WHO guidelines on breastfeeding and HIV). 
•	 Mothers	of	infants	with	a	neonatal	withdrawal	syndrome	should	be	offered	appropriate	breastfeeding	information	
and support.
•	 This	recommendation	was	considered	conditional	because	the	different	values	and	preferences	of	women	and	the	
lack of strong evidence of harms of low levels of substance use in pregnancy.
RECOMMENDATION 
Skin-to-skin contact is important regardless of feeding choice and needs to be actively encouraged for a mother with 
substance use disorder who is able to respond to her baby’s needs. 
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 It	was	decided	that	the	recommendation	should	be	strong	despite	the	very	low	quality	evidence	as	the	risk	of	harm	
is minimal, it consumes no resources, the values and preferences were in favour of the recommendation, and there 
was considered to be certainty about the balance between benefits and harms.
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RECOMMENDATION 
Mothers who are stable on opioid maintenance treatment with either methadone or buprenorphine should be 
encouraged to breastfeed unless the risks clearly outweigh the benefits.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Women	prescribed	opioids	such	as	methadone	and	buprenorphine	and	wishing	to	stop	breastfeeding	should	wean	
their children off breast milk gradually to reduce the risk of developing withdrawal symptoms.
•	 It	was	decided	that	the	recommendation	should	be	strong,	as,	despite	the	low	quality	of	evidence	of	effect,	it	was	
considered highly likely that the benefit of avoiding withdrawal symptoms in the infant strongly outweighed any 
potential harms. The values and preferences expressed by end-users surveyed were strongly in favour of the 
recommendation and there was certainty about the balance between benefits and resources being consumed.
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Management of infants exposed to alcohol and other psychoactive substances (Evidence 
Profile 6: see Annex 1, page 135) 
Note: The term “neonatal withdrawal syndrome” is used here to remain consistent with WHO nomenclature, 
but the term “neonatal abstinence syndrome (NAS)” is commonly used with the same meaning.
The small study size and risk of bias in the studies evaluated mean that the evidence of treatment effectiveness 
is very uncertain. Protocols for the management of neonatal withdrawal syndrome have changed considerably 
over the last 40+ years. Initial treatment guidelines were weight-based, and tables for treatment with 
phenobarbital and paregoric were published. Current treatment involves use of an opioid such as morphine 
sulfate or tincture of opium, or a sedative, typically phenobarbital, with infrequent use of a benzodiazepine. 
Systems for scoring withdrawal are usually used to guide treatment initiation, maintenance and weaning. 
Because there is neither a uniform assessment method for measuring neonatal withdrawal nor an established 
treatment protocol, and health-care practices worldwide are variable, it is difficult to state with any precision 
how neonatal withdrawal is treated across the globe. 
RECOMMENDATION 
Health-care facilities providing obstetric care should have a protocol in place for identifying, assessing, monitoring 
and intervening, using non-pharmacological and pharmacological methods, for neonates prenatally exposed to 
opioids.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Evidence	of	a	dose-response	relationship	between	opioid	maintenance	treatment	and	neonatal	withdrawal	
syndrome has been inconsistent, which implies that all infants should be assessed. 
•	 Infants	exposed	to	opioids	during	pregnancy	should	remain	in	the	hospital	at	least	4–7	days	following	birth	and	
be monitored for neonatal withdrawal symptoms using a validated assessment instrument, which should be first 
administered 2 hours after birth and then every 4 hours thereafter.
•	 Non-pharmacological	interventions	including	low	lights,	quiet	environments,	swaddling	and	skin-to-skin	contact	
should be used with all neonates prenatally exposed to alcohol and drugs.
•	 It	was	decided	that	the	recommendation	should	be	strong	despite	the	low	quality	of	evidence	of	effect,	as	the	GDG	
agreed that the benefits of such an approach strongly outweighed any potential harms. The values and preferences 
of end-users were in favour of the recommendation, and there was certainty that while resources would be 
consumed, the benefits strongly outweighed costs. There was a high value placed on identifying preventable 
suffering in affected neonates.
RECOMMENDATION 
An opioid should be used as initial treatment for an infant with neonatal opioid withdrawal syndrome if required.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Prolonged	treatment	of	neonatal	opioid	withdrawal	syndrome	with	opioids	is	generally	not	necessary	and	aiming	for	
shorter treatment is preferable. 
•	 Phenobarbital	can	be	considered	as	an	additional	therapy	if	there	has	been	concurrent	use	of	other	drugs	in	
pregnancy, particularly benzodiazepines, and if symptoms of neonatal opioid withdrawal are not adequately 
suppressed by an opioid alone. If opioids are unavailable, phenobarbital can be used as an alternative therapy.
•	 Infants	with	signs	of	a	neonatal	withdrawal	syndrome	in	the	absence	of	known	maternal	opioid	use	should	be	fully	
assessed for possible benzodiazepine, sedative or alcohol exposure.
•	 The	strong	recommendation	to	use	opioids	rather	than	phenobarbital	despite	the	very	low	quality	of	evidence	of	
effectiveness was based on vast clinical experience with opioids in the management of both adult and neonatal 
opioid withdrawal. There has only been very limited clinical experience with phenobarbital use. In addition, the 
values and preferences of end-users were in favour of the recommendation, and the GDG agreed that there was 
certainty about the balance between benefits and resources being consumed.
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RECOMMENDATION 
If an infant has signs of a neonatal withdrawal syndrome due to withdrawal from sedatives or alcohol or the 
substance the infant was exposed to is unknown, then phenobarbital may be a preferable initial treatment option.
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Infants	with	signs	of	a	neonatal	withdrawal	syndrome	in	the	absence	of	known	maternal	opioid	use	should	be	fully	
assessed for possible benzodiazepine, sedative, or alcohol exposure.
•	 This	recommendation	was	considered	conditional	because	of	the	lack	of	high-quality	evidence	and	the	lack	of	
certainty of the balance between benefits and harms.
RECOMMENDATION 
All infants born to women with alcohol use disorders should be assessed for signs of fetal alcohol syndrome. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Signs	of	fetal	alcohol	syndrome	(FAS)	include	growth	impairment,	dysmorphic	facial	features	(short	palpebral	
fissures, smooth or flattened philtrum, thin upper lip) and central nervous system abnormalities, including 
microcephaly. 
•	 When	assessing	such	infants	the	following	information	should	be	recorded:	
– birthweight and length
– head circumference
– dysmorphic facial features
– gestation
– prenatal exposure to alcohol
– follow-up of infants with signs of FAS should be provided
•	 This	recommendation	was	considered	conditional	because	of	the	lack	of	high-quality	evidence,	and	questions	about	
the feasibility of implementation in all settings.
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RESEARCH PRIORITIES AND GAPS
The extensive search for evidence of effective interventions for managing alcohol and other substance 
disorders in pregnancy yielded useful baseline information but also highlighted considerable gaps in 
knowledge. The GDG identified priority areas and questions that need to be researched in order to increase 
certainty about what works most effectively when managing pregnant women with these disorders. 
General Remarks
The GDG calls upon the research community to:
 o Improve descriptions of current clinical practices – including routine clinical outcome data; 
 o Agree on standardized outcomes;
 o Perform observational studies on risks and benefits of pharmacotherapies in pregnancy; 
 o conduct a global cohort study with standardized patient-centred outcome measurements and data 
repository;
 o Conduct qualitative research on ethical issues;
 o Encourage more research in low-income countries; 
 o Evaluate the benefits of comprehensive-care models (e.g. psychosocial, spiritual support, programmes for 
very young children affected by maternal substance use in utero); and
 o Provide better prevalence data on prescription opioid use.
Exposure to different drugs and medications in utero
The GDG calls upon the research community to conduct further research on the impact of substance use upon:
 o maternal outcomes,
 o fetal outcomes,
 o neonatal outcomes,
 o long-term outcomes for the exposed children.
A number of critical questions on the optimal use of specific interventions in pregnancy remain unanswered.
Screening
 o What is the best way for health-care workers to screen pregnant women for alcohol and other substance 
use and substance use disorders without being judgemental? 
 o Which instruments are most effective? 
 o What sort of training yields effective screening?
 o What is the effectiveness and cost-effectiveness of screening in routine clinical practice? 
 o What are the optimal screening methods – for different substances/different settings, e.g. in low-income 
countries? A systematic review of screening instruments currently used is needed.
 o What are the optimal ways of organizing screening and brief interventions in different settings?
 o What factors modify the disclosure level?
Brief interventions
Brief interventions should be clinically trialled, using standardized outcomes and trial designs to determine:
 o Who should be targeted?
 o Does this vary according to levels of substance use and type of substance use?
 o What elements of the brief intervention are effective? 
 o What level of brief intervention is most effective?
 o What categories of health-care workers can provide brief interventions effectively? 
 o How late can a brief intervention be given effectively?
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Psychosocial interventions
 o Better reporting and agreement on standardized designs and outcomes is needed.
 o Stronger RCT evidence of effect is needed, comparing interventions with different levels of intensity and 
models of care with different levels of comprehensiveness, and including cost-effectiveness analyses.
Detoxification
 o What type of benzodiazepine reduction regimes work best for which types of patients?
 o What medications are the safest and most effective for mother and fetus being withdrawn from alcohol?
 o Is fetal monitoring useful in determining the relative safety of detoxification during pregnancy?
 o What are the best assessment tools to measure withdrawal in pregnant women?
 o What are the best ways to manage withdrawal from cocaine, cannabis, ATS, alcohol or volatile solvents 
in pregnant women?
 o How can fetal stress and potential intrauterine withdrawal be monitored when mothers are detoxified from 
opioids and other drugs?
Pharmacological treatment
 o A case registry of pregnancies exposed to different substances, including psychotropic medication used for 
the treatment of substance use disorders in pregnancy, could help explore the potential risks and benefits 
of pharmacotherapy in substance use disorders in pregnancy.
 o Further studies could explore the optimal method of treatment with methadone and buprenorphine in 
pregnancy (including further dose/response studies).
 o Data on the safety of pharmacotherapy for alcohol dependence in pregnancy is lacking.
Breastfeeding
 o Effects of breastfeeding and substance use on the neonate still need to be better understood. 
 o How best to promote the initiation and continuation of breastfeeding in appropriate situations, such as in 
mothers receiving opioid maintenance treatment?
 o To what degree are different drugs and medications excreted in human milk?
 o What is the safety of breastfeeding while the mother is using different drugs and psychoactive medications?
 o What is the effect of breastfeeding on neonatal withdrawal for mothers receiving methadone or 
buprenorphine treatment
Birth and labour 
 o What is the optimal treatment during labour, including pain management?
Management of infants exposed to alcohol or drugs in utero 
 o What is the sensitivity and specificity of screening for FAS in the neonatal period and what are the risks 
and benefits of early identification and intervention, including in low resource settings?
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PLANS FOR DISSEMINATING, ADAPTING AND 
IMPLEMENTING THESE RECOMMENDATIONS 
These recommendations will be used to provide guidance on the identification and management of 
substance use and substance use disorders in pregnancy through a range of derivative publications including 
training materials and a manual describing how best to put these recommendations into practice. This 
will be widely disseminated through the WHO regional and country WHO offices, collaborating centres, 
professional organizations and partner agencies. 
Local adaptation/implementation of these recommendations 
These recommendations will be adapted for the field by developing suitable training materials in consultation 
with regional, national and local stakeholders. Adaptation will include translation into appropriate languages and 
ensuring that the interventions are acceptable in local sociocultural contexts suitable for local health systems.
EVALUATING THE IMPACT OF THESE 
RECOMMENDATIONS
The impact of these recommendations will be measured in the following ways:
 o use of maternal and child health indicators to assess improvement in maternal and child health outcomes 
in this population;
 o measurement of inclusion of alcohol and drugs into the routine screening protocols in different countries/
guidelines;
 o WHO survey of resources for the prevention and treatment of substance use disorders;
 o assessment of any increase in specialized services for pregnant women with substance use disorders; and
 o assessment of number of references to the WHO guidelines in the medical literature. 
REVIEW BY DATE
It is not expected that these recommendations will need to be reviewed until 2016. However, developments 
in the field will be continually monitored and should there be significant changes in practice and/or the 
evidence base that affect any of the recommendations, review may be undertaken earlier. 
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ANNEX 1: EVIDENCE PROFILES
Evidence Profile 1: Screening and brief interventions
Evidence question:
In pregnant or postpartum women using alcohol or drugs, does screening for alcohol or drug use, followed by 
a brief intervention (or referral to treatment for those with possible dependence), result in better maternal, fetal 
or neonatal outcomes (see separate outcome list) than treatment-as-usual (generally the absence of screening, 
or brief interventions and the occasional referral to treatment)?
Study selection criteria for the systematic review:
Study design: RCTs
Population: Pregnant or postpartum women using alcohol or drugs (some studies included women who 
had alcohol or drug use only in the past; studies with up to one third of participants in this category were still 
eligible for inclusion).
Intervention: Systematic screening of all patients followed by a brief intervention. The Cochrane Review 
definition of brief intervention in the general population review was used (anything beyond simple advice or 
information up to 4 sessions), accepting any referral of more severe patients for treatment. 
Control: Brief advice or information or no intervention.
Outcomes: The outcomes ranked as important were:
Outcome Ranking
Maternal: Identification of substance use 8.89
Maternal: Provision of intervention for substance use 8.22
Maternal: Referral to relevant treatment of substance use 8.22
Maternal: Ongoing substance use during pregnancy 7.33
Infant: Birth defects 6.00
Infant: Gestational age at delivery 6.00
Infant: Birthweight 5.89
Infant: Spontaneous abortion 5.44
Infant: Head circumference at birth 5.44
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EVIDENCE TO RECOMMENDATIONS TABLE
Screening and brief interventions for alcohol and other substance use in pregnancy in general health-care settings
Summary of the Evidence: For GRADING of evidence see summary of findings and GRADE tables below
RCT evidence – 10 studies were included in the review. Most studies were underpowered and there were differences 
in study design and outcome measures used which limited the capacity for meta-analysis. As a result, the level of 
evidence for most outcomes was low or very low. Nonetheless, there was a small but consistent effect in favour of 
screening and brief interventions for both alcohol and, to a lesser extent, drugs. 
Other evidence:
•	 Simply	asking	about	alcohol	and	other	substance	use	may	result	in	a	change	in	behaviour	(Goler	et	al.,	2008;	Klesges	
et al., 2001; Nilsen, 2009).
•	 Being	asked	about	alcohol	or	other	substance	use	in	a	detailed	and	comprehensive	manner	may	increase	a	
woman’s awareness of actual levels of consumption and may function to modify her behavior (Delrahim-Howlett, 
2011). 
•	 A	brief	motivational	intervention	has	been	shown	to	reduce	the	risk	of	an	alcohol-exposed	pregnancy	(Floyd,	2007).	
A brief alcohol intervention has been found to reduce the number of drinks and the number of heavy drinking days 
during the postpartum period (Fleming et al., 2008). Pregnant women with higher levels of alcohol use may reduce 
their alcohol use following a brief intervention that includes their partner (e.g., Chang, 2005). 
•	 Pregnant	adolescent	girls	with	a	substance	use	disorder	have	been	shown	to	reduce	their	substance	use	after	a	
single-session, standardized brief intervention (Whicher et al., 2012).
Benefits and harms
Benefits •	 Discussion	of	alcohol	and	illicit	substance	use	during	pregnancy	is	a	teachable	moment	(Chang	
et al., 2000)
•	 Depending	on	the	substance	of	use,	brief	interventions	have	been	associated	with	these	
positive outcomes: 
– reduction in harmful consumption
– reduction in risk to fetus
– increase in birthweight
– increase in the detection of harmful use and referral to treatment
– improved general health of pregnant women
– improved maternal psychological well-being
– less risk of fetotoxicity
– improved perinatal outcomes (e.g. reduction in preterm births, increased overall 
birthweights, reduction in number of low-birthweight infants)
– reductions in congenital defects or anomalies
Harms •	 Unpleasant	symptoms	associated	with	reduction	or	cessation	of	alcohol	or	substance	use	
•	 Potential	legal	or	social	consequences	for	disclosing	use
•	 Social	consequences	–	problematic	interaction	with	partners/peers	associated	with	reduction	
or cessation of alcohol or substance use
•	 Cessation	may	interfere	with	activities	of	daily	living
•	 Referral	for	cessation	intervention	may	induce	time	and	economic	burdens	
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EVIDENCE TO RECOMMENDATIONS TABLE
Values and preferences
In favour: 
Pregnant women
Health-care 
workers (HCW)
•	 Value	opportunity	for	greater	personal	contact	and	support
•	 Value	opportunity	for	development	of	coping	strategies
•	 Value	positive	responses	from	partners,	family	and,	co-workers
•	 Value	opportunity	to	identify	problem	early
•	 Value	opportunity	to	intervene
•	 Value	opportunity	to	improve	fetal	outcomes
Against: 
Pregnant women
Health-care 
workers (HCW)
•	 Resent	stigmatization	for	drinking	alcohol	or	using	illicit	substances	during	pregnancy
•	 Resentment	of	questioning	private	life/behaviour
•	 Resentment	of	consequences	of	referral	–	perceived	time,	logistical	and	financial	burden	
imposed 
•	 Fear	of	possible	negative	responses	from	health-care	providers,	partners,	family,	friends	and	
others in the woman’s community
•	 HCW	may	resent	extra	time	taken	to	screen.	Estimates	of	screening	time	vary	widely	given	
the relatively large number of screening instruments that are available [Although a little bit 
dated, CSAP Special Report 13: Maternal substance use assessment methods reference 
manual: a review of screening and clinical assessment instruments for examining maternal 
use of alcohol, tobacco, and other drugs Rockville, MD: US Department of Health and Human 
Services, Public Health Service, Substance Abuse and Mental Health Services Administration 
(Center for Substance Abuse Prevention, 1993) contains an excellent review in regard to all 
such instruments], which vary in length from 4 questions to more than 100, and which can be 
administered by the clinician or require paper-and-pencil administration 
•	 HCW	may	resent	difficulties	of	interaction	when	identifying	a	substance	user
•	 HCW	may	resent	extra	time	and	difficulty	imposed	by	need	to	refer
•	 HCW	may	be	unwilling	to	provide	intervention	
•	 HCW	may	believe	they	are	not	competent	to	screen:	Gassman	(2003)	found	that	the	biggest	
barrier to the implementation of screening and brief intervention among obstetricians was self-
rated competence to deliver the intervention. 
Costs and feasibility
Costs and 
resource use
•	 Additional	cost	in	terms	of	staff	time	should	be	minimal	if	integrated	into	routine	care.	However,	
there are no good estimates of cost for either the screening or the brief intervention, given 
the fact that a brief intervention may be no more than guidance provided in the office or a 
structured and standardized administration of a behavioural intervention by a counsellor
•	 Appropriate	staff	training	requires	resource	use
•	 Appropriate	intensive	treatment	needs	to	be	made	available	for	referral	when	substance	use/
alcohol use identified. Long-term, sustainable support is required
•	 Brief	interventions	have	been	assessed	as	highly	cost-effective	(Windsor,	1985;	Ershoff,	1989;	
Dornelas, 2006: Parker, 2007)
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EVIDENCE TO RECOMMENDATIONS TABLE
Feasibility 
(including 
economic 
consequences)
•	 Self-report	screening	has	been	shown	to	be	accurate.	Yonkers	et	al.	(2011)	found	a	high	degree	
of agreement between urine toxicology and self-report results for marijuana and cocaine 
testing in 168 pregnant women. Moreover, self-report was found to lead to more positive 
reporting of use when a larger window was available for such reporting than was available 
for toxicology screening, leading to the conclusion that self-report may be a better indicator of 
use. 
•	 Some	time	is	needed	for	the	care	provider	to	either	complete	and/or	review	the	screening	
results. Diekman et al. (2000) have reported than only 23% of obstetricians in the USA used a 
standardized screening tool for the detection of substance use, yet research (e.g. Bailey & 
Sokol, 2008; Svikis & Reid-Quinones, 2003) has shown that such tools substantially increase the 
rate of detection of such use. Oser et al. (2011) found that less than 50% of USA obstetricians 
were using a standardized screening instrument, and of those using such an instrument, most 
were using the CAGE, which was not specifically developed for use with a pregnant population.
•	 Effective	interventions	are	labour	intensive.	Providing	reading	material	is	not	sufficient	as	
a brief intervention. Face-to-face counselling about abstaining from alcohol (and other 
substances) is needed (Calabro, 1996).
•	 Other	research	has	shown	that	non-mental-health	specialists	can	be	trained	to	perform	brief	
interventions in general health-care settings. 
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Draft recommendations: 
 o Screening for use of alcohol and other substance use among all pregnant women is recommended in all 
health-care settings (e.g., primary care, obstetrical care).
 o Pregnant women reporting hazardous or harmful alcohol or other substance use should receive a brief 
intervention.
 o Pregnant women found to be dependent on alcohol or other substances should be referred to specialist 
services, where such services exist.
Final recommendations: 
RECOMMENDATION 
Health-care providers should ask all pregnant women about their use of alcohol and other substances (past and 
present) as early as possible in the pregnancy and at every antenatal visit.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Asking	at	every	visit	is	important	as	some	women	are	more	likely	to	report	sensitive	information	only	after	a	trusting	
relationship has been solidly established.
•	 Pregnant	women	should	be	advised	of	the	potential	health	risks	to	themselves	and	to	their	babies	posed	by	alcohol	
and drug use. 
•	 Validated	screening	instruments	for	alcohol	and	other	substance	use	and	use	disorders	are	available	(see	Annex	3).
•	 Health-care	providers	should	be	prepared	to	intervene	or	refer	all	pregnant	women	who	are	identified	as	using	
alcohol and/or drugs (past and present).
•	 It	was	decided	that	despite	the	low	quality	of	evidence	of	effect,	the	benefit	–	potential	reduction	of	alcohol	and	
substance use – outweighed any potential harms of a brief psychosocial intervention, which were considered 
minimal. Therefore the balance of benefits versus harms was clearly positive despite uncertainty about the degree 
of benefit. In addition, the burden of implementation was minimal.
RECOMMENDATION 
Health-care providers should offer a brief intervention to all pregnant women using alcohol or drugs.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Brief	intervention	is	a	structured	therapy	of	short	duration	(typically	5-30	minutes)	offered	with	the	aim	of	assisting	
an individual to cease or reduce the use of a psychoactive substance. It is designed in particular for general 
practitioners and other primary health-care workers. 
•	 Health-care	providers	should	be	given	appropriate	training	and	resource	materials.
•	 The	brief	intervention	should	be	individualized,	and	include	feedback	and	advice	on	ceasing	or	reducing	alcohol	
and other substance use during pregnancy. There may need to be follow-up with the patient, with the possibility of 
referral to treatment for those patients who are unable to reduce or eliminate such use. 
•	 The	approach/attitude	of	health-care	providers	is	an	important	contributor	to	the	effectiveness	of	brief	interventions.
•	 As	for	recommendation	1,	it	was	decided	that	despite	the	low	quality	of	evidence	of	effectiveness,	this	should	be	
a strong recommendation because the potential benefit – reduction of alcohol and/other substance use – likely 
outweighs any potential harms of a brief psychosocial intervention which were considered minimal. Therefore the 
balance of benefits versus harms was clearly positive, although there was uncertainty about the degree of benefit. 
In addition the burden of implementation was minimal.
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Factors in considering the strength of the recommendations (recommendations 1 & 2): 
Research gaps
More evidence is needed from low-income countries. Topics in need of further research include training on 
sceening and brief interventions, how to screen (which instrument), cost-effectiveness, whether to screen for 
alcohol or drugs together, whether to ask about tobacco at the same time, and whether or not to combine with 
other issues (such as depression). There is a need for more real-world effectiveness studies, and a systematic 
review of screening instruments.
Factor Decision
Is there high- or moderate-quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation. 
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty 
that the costs of the resources being consumed outweigh any benefit gained?
Yes
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SCREENING AND BRIEF INTERVENTION VERSUS USUAL CARE FOR HARMFUL SUBSTANCE USE IN PREGNANCY
Patient or population: Patients with harmful substance use in pregnancy
Settings: Ante-natal and post-natal general health-care settings
Intervention: Screening and brief intervention versus usual care
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Control
Screening and brief 
intervention versus 
usual care
Abstinence from 
drug use in the last 4 
weeks – ITT analysis 
Follow-up: mean 38.6 
days
Study population OR 0.55 
(0.12 to 2.55)
30
(1 study)
⊕⊕
LOW1,2,3
733 per 1000 602 per 1000
(248 to 875)
Moderate
733 per 1000 602 per 1000
(248 to 875)
Total number of 
drinks in the past 28 
days 
Follow-up: mean 6 
months
The mean total 
number of drinks in 
the past 28 days in 
the control groups 
was
27.1 standard drinks
The mean total 
number of drinks 
in the past 28 days 
in the intervention 
groups was
7.3 lower
(12.61 to 1.99 lower)
235
(1 study)
⊕⊕
LOW1,4
Number of heavy 
drinking days in the 
past 28 days 
Follow-up: mean 6 
months
The mean number of 
heavy drinking days 
in the past 28 days 
in the control groups 
was
2.6 days
The mean number of 
heavy drinking days 
in the past 28 days 
in the intervention 
groups was
0.9 lower
(1.59 to 0.21 lower)
235
(1 study)
⊕⊕
LOW1,4
Number of standard 
drinks per week
Follow-up: mean 33 
days
The mean number of 
standard drinks per 
week in the control 
groups was
0.13 standard drink
The mean number 
of standard drinks 
per week in the 
intervention groups 
was
0.19 higher
(0.31 lower to 0.69 
higher)
50
(1 study)
⊕⊕
LOW1,3
Estimated peak BAC 
Follow-up: 1–2 
months
The mean estimated 
peak bac in the 
control groups was
0.004 g/dl
The mean estimated 
peak bac in the 
intervention groups 
was
0 higher
(0.01 lower to 0.01 
higher)
50
(2 studies)
⊕⊕
LOW1,3
Audit score 
Follow-up: mean 58 
days
The mean audit 
score in the control 
groups was
2.22 AUDIT score
The mean audit 
score in the 
intervention groups 
was
1.69 lower
(2.88 to 0.5 lower)
179
(1 study)
⊕⊕
LOW1,4,6
Motivation to 
change
Follow-up: mean 38.6 
days
The mean motivation 
to change in the 
control groups was
77.4 Visual analogue 
scale
The mean motivation 
to change in the 
intervention groups 
was
11.4 higher
(0.08 to 22.72 higher)
30
(1 study)
⊕⊕
LOW1,2
Summary of findings and GRADE tables
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Control
Screening and brief 
intervention versus 
usual care
Spontaneous 
abortion
Study population OR 0.84 
(0.34 to 2.06)
753
(3 studies)
⊕
VERY	LOW1,2,3,4
28 per 1000 24 per 1000
(10 to 57)
Moderate
29 per 1000 24 per 1000
(10 to 58)
Head circumference
Follow-up: mean 33 
days
The mean head 
circumference in the 
control groups was
34.1 cm
The mean head 
circumference in the 
intervention groups 
was
0.27 lower
(1.1 lower to 0.56 
higher)
50
(1 study)
⊕⊕
LOW1,3
Depression 
postpartum
Follow-up: mean 6 
months
The mean depression 
postpartum in the 
control groups was
8.06 Edinburgh 
postpartum 
depression scale
The mean depression 
postpartum in the 
intervention groups 
was
1.22 lower
(2.71 lower to 0.27 
higher)
205
(1 study)
⊕
VERY	LOW1,4,6,7
Birthweight –  
all participants
The mean 
birthweight – all 
participants in the 
control groups was
3240 grams
The mean 
birthweight – all 
participants in the 
intervention groups 
was
57.8 higher
(77.26 lower to 192.86 
higher)
555
(3 studies)
⊕
VERY	
LOW1,2,3,4,6,8,9
Attending substance 
abuse treatment
Follow-up: mean 38.6 
days
Study population OR 0.31 
(0.01 to 8.28)
30
(1 study)
⊕
VERY	LOW1,2,3
67 per 1000 22 per 1000
(1 to 372)
Moderate
67 per 1000 22 per 1000
(1 to 373)
Birthweight – 
drinking more than 
1 drink per occasion 
or per day (post-hoc 
analysis)
The mean 
birthweight – 
drinking more than 
1 drink per occasion 
or per day (post-
hoc analysis) in the 
control groups was
3134 grams
The mean 
birthweight – 
drinking more than 
1 drink per occasion 
or per day (post-
hoc analysis) in the 
intervention groups 
was
199.63 higher
(57.06 to 342.19 
higher)
168
(2 studies)
⊕⊕
LOW1,4,6,10
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 The control group received a screening session
2 Up to a third of the participants were not heavy drinkers
3 Wide confidence interval
4 Cluster Randomized trial not analysed as such
5 High dropout rate
6 Outcome assessment was not blinded
7 Post-hoc analysis, selective outcome reporting 
8 No explanation was provided
9 Suggestion on funnel plot of publication bias
10 Post-hoc analysis 29
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Characteristics of included studies
Chang 1999
Methods STUDY	TYPE:	RCT
COUNTRY:	USA
SETTING: Bigham and Women's Hospital - General Ante-natal clinic
DURATION OF RECRUITMENT: One year
DURATION OF TRIAL: 22 months
FOLLOW-UP: Postpartum follow up interview
Participants INCLUSION CRITERIA:
pregnant women presenting for ante-natal care
screen positive on an alcohol survey for hazardous or harmful use
EXCLUSION CRITERIA:
(1) gestational age greater than 28 weeks (44%),
(2) no alcohol consumption in the immediate 6 months before study participation (19%),
(3) miscarriage in the time between survey completion and telephone interview (14%),
(4) intention to receive prenatal care elsewhere (7%),
(5) non-English-speaking (3%),
(6) intended abortion or false pregnancy (3%),
(7) current substance abuse treatment (1%) and (8) other (9%).
Screened: 1165
Agreed to participate: 886
Screen positive: 532
Met inclusion/excusion criteria: 250
Number of participants randomized: 250
123 randomized to intervention group, and 127 to control group.
Number followed up: 247
Number included in the analysis: 250
Interventions INTERVENTION:
Screening and comprehensive Assessment and Brief Intervention
The BI was structured as follows:
(1) review the subject’s general health and course of pregnancy to date, (2) review the subject’s life-style changes made since 
pregnancy, including work schedule, exercise, diet, cigarette smoking and alcohol consumption, (3) request that the subject 
articulate her drinking goals while pregnant and their reason, (4) have the subject identify circumstances when she might be 
tempted to drink, (5) identify alternatives to drinking when she is tempted to drink, and (6) summarize the session by empha- 
sizing four key points (drinking goal, motivation, risk situations for drinking and alternatives to alcohol) and noting them in the 
take-home manual, “How to prevent alcohol-related problems”, given to the subject. This manual was based on materials 
provided by the WHO Amethyst Project (Babor et al., 1987; Babor & Grant, 1992; WHO Brief Intervention Study Group, 1996). All 
subjects receiving the BI were informed of the recommendation of the US Surgeon General, with prenatal abstinence being the 
most prudent drinking goal.
Time: 45 minutes
CONTROL:
Screening and comprehensive assessment
The comprehensive assessment was administered by a research assistant over the course of 2 hours and consisted of: (1) the 
alcohol and drug abuse modules from the Structured Clinical Interview for DSM-III-R to generate standard diagnoses (SCID, 
Spitzer et al., 1990);
(2) the Addiction Severity Index (ASI, McLellan et al., 1980); (3) the Alcohol Use Disorders
Identification	Test	(AUDIT,	Bohn,	Babor	&	Kranzler,	1995);	(4)	the	Short	Michigan	Alcoholism	Screening	Test	(SMAST,	Selzer,	
Vinokur & van Rooijen, 1975);
(5) the Timeline Follow- back interview for the quantity and frequency of alcohol consumption for the 90 days immediately before 
study assessment (Sobell & Sobell, 1992);
(6) the Alcohol Craving Scale, a visual analog scale to measure the desire to drink at the moment and in the past week (Wewers, 
Rachfal & Ahijevych, 1990);
(7) the Global Assessment of Functioning (GAF, Endicott et al., 1976); and (8) the Situational Confidence Questionnaire, a 
measure of the subject’s confidence in managing drinking situations (Annis, 1981). Subjects were asked to report any alcohol 
consumed, even a sip, when completing the Timeline Follow-back interview (Allen & Columbus, 1995). In this study, alcohol 
consumption was quantified by drinks per drinking day, since few pregnant women drink daily (Jacobson et al., 1991). Drinking 
episodes, defined with each episode beginning with a drinking day and ending with 7 consecutive days of abstinence, were also 
calculated. Additional details about the alcohol assessment are available elsewhere (Chang et al., 1998).
COMPLIANCE:
CO-INTERVENTIONS:
Outcomes MATERNAL OUTCOMES:
Alcohol consumption ante-partum
Drinks per drinking day
INFANT OUTCOMES:
Birthweight
APGAR score
Notes ETHICS: Approved by the human subjects committee of the Brigham and Women's Hospital
INFORMED CONSENT: Obtained
FUNDING: This study was supported by ROI AA 9670 from the National Institute on Alcohol Abuse and Alcoholism (Dr Chang)
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Characteristics of included studies
Chang 2005
Methods STUDY	TYPE:
Randomized controlled trial
COUNTRY:
United States
SETTING:
1 of 3 obstetric practices (clinic, faculty, or private group affiliate) of the Brigham and Women’s Hospital in Boston, MA
DURATION OF RECRUITMENT:
February 2000 and September 2002
DURATION OF TRIAL:
FOLLOW-UP:
Postu-partum follow-up interview
Participants INCLUSION CRITERIA:
1) positive T-ACE, with a total score of 2 or more
2) being at risk for prenatal alcohol use, which was defined as any alcohol consumption in the 3 months before study enrollment 
(while pregnant), or consumption of at least one drink per day in the 6 months before study enrollment, or drinking during a 
previous pregnancy
3) gestation less than 28 weeks and intention to carry pregnancy to term
4) agreement to study terms, which included randomization to treatment by computer assignment, postpartum follow-up 
interview, selection of a partner who would participate in a diagnostic interview, the brief intervention if so randomized, and 
postpartum interview
EXCLUSION CRITERIA:
1) current treatment for alcohol or drug abuse, or substance abuse–related medical illness
2) current physical dependence on alcohol requiring medically supervised detoxification
3) current use of opiates, cocaine, or other illicit substances
4) inability to complete study questionnaires
5) intention to terminate pregnancy before term gestation
Number of screened participants: 2927
Number of screened positive: 802
Number of participants successfully contacted: 399
Meet inclusion criteria and agree to participate, and randomized: 304
Brief intervention group: 152
Total lost to follow-up in brief intervention group: 10
Control group: 152
Total lost to follow-up in control group: 6
Randomized to intervention group, and to control group.
Number included in the analysis: 152 for both groups
Median age of participants: 31.4
Interventions INTERVENTION: Single-session brief intervention given to the woman and her partner
CONTROL: Screening and diagnostic interview only
Outcomes MATERNAL OUTCOMES: Alcohol consumption
Notes
Fleming 2008
Methods STUDY	TYPE:	Cluster	randomized	controlled	trial
COUNTRY:	USA
SETTING: 34 obstetrical practices from 15 counties in Wisconsin.
DURATION OF RECRUITMENT: Obstetricians were recruited in 2001. Actual duration was not stated. Postpartum women were 
recruited between 2002 and 2004.
DURATION OF TRIAL: Reported as between 2002 and 2005
FOLLOW-UP: Mothers attended two 15-minute face-to-face visits
1 month apart for a brief intervention and a reinforcement session, followed by a phone call 2 weeks after each face-to-face 
meeting.
There were a total of 4 contacts to the participants spread over an 8-week period.
Follow-up procedures included a telephone interview at 6 months by one of the researchers not assigned to participant’s clinic.
Participants INCLUSION CRITERIA:
For physicians:
Trained in obstetrics and gynecology, practice medicine at least 50% time, amenable to having a research team identify and 
work with their patients, willingness to have their office staff complete research protocols.
For postpartum women: 18 years or older, seeing their obstetrician or advanced practice nurse for a postpartum visit, 20 or more 
standard drinks in the previous 28 days or 4 or more drinks on 4 or more occasions in the last 28 days or 20 or more drinking days 
in the last 28 days.
EXCLUSION CRITERIA: Not stated
Number of participants randomized: 235 (the unit of randomization was the individual patient).
122 postpartum women randomized to intervention group and 113 to control group.
There were no significant statistical differences in baseline data between the two groups.
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Characteristics of included studies
Interventions All postpartum patients 18 years or older were asked to complete a health screening survey (HSS). Computer-generated 
allocation method was used to assign participants to the experimental and control groups in each physician’s office.
INTERVENTION: brief intervention GROUP
Participants in the experimental group received health booklet (on general health issues) plus face-to-face 30-minute session 
and were followed up at 6 months.
CONTROL: usual care GROUP
Those assigned to the control group received a health booklet (on general health issues) and were followed up at 6 months.
COMPLIANCE:
Participants took the workbook home between visits and filled out a number of homework assignments, and were asked to fill 
out drinking diary cards between visits, and follow-up phone calls were made to reinforced the drinking limits set at each visit, 
challenges they faced in cutting down on drinking and offering continued support.
CO-INTERVENTIONS:
Participants were paid a total of $150 if they completed the required procedures.
Outcomes Outcomes	were	clearly	defined	as	PRIMARY	or	SECONDARY.
MATERNAL OUTCOMES:
Primary:
Alcohol use as measured by total number of drinks, number of drinking days, and number of heavy drinking days (4 or more 
drinks in a day), in the previous 28 days.
Secondary :
Other outcomes of interest such as depression, accidents, injuries, driving while intoxicated, and health care utilization.
INFANT OUTCOMES:
Not stated
Notes ETHICS:
Research protocol approved by the University of Wisconsin Health Sciences Human Subjects Committee and 11 additional 
human subject committees specific to the different health-care systems.
INFORMED CONSENT:
All participants gave written informed consent.
FUNDING
NIH NIAAA grant number R01 AA12522.
Handmaker 1999a
Methods STUDY	TYPE:	Randomized	controlled	trial
COUNTRY:	USA
SETTING: University of New Mexico (UNM) Medical Center obstetric clinics
DURATION OF RECRUITMENT: Not stated.
DURATION OF TRIAL: Not stated.
FOLLOW-UP: Pregnant women were interviewed two months later using the Follow-up Drinker Profile (FDP)
Participants INCLUSION CRITERIA: Not stated
EXCLUSION CRITERIA: Not stated
Number of participants randomized: 42
20 randomized to intervention group and 22 to control group.
It was not stated if there were any significant statistical differences in baseline data between the two groups.
Interventions All participants were initially assessed using the Brief Drinker Profile (BDP), supplemented by calendar for timeline 
reconstruction of drinking during the previous 2 months.
Subsequently, the interviewer privately opened a prepared envelope to determine the randomized group assignment.
INTERVENTION: motivational interviewing GROUP
Pregnant women in the treatment group completed SOCRATES, a measure of motivation for change.
The motivational interview lasted for 1 hour, starting with ascertaining participant’s knowledge of the effects of alcohol on 
pregnancy, feedback on severity of participant’s drinking, and showing chart of fetal development by gestational week. They 
were followed-up 2 months later.
CONTROL GROUP
Those assigned to the control group were sent letters informing them about the potential risks of drinking during pregnancy and 
referring them to their healthcare provide and were followed up at 2 months.
COMPLIANCE:
Not stated
CO-INTERVENTIONS:
To corroborate self-report, participants’ significant others were interviewed (with the participant’s permission) at intake and 
follow-up, using a Collateral Information Form.
All participants were paid $20.00 for completing baseline assessment, were entered into a lottery drawing for a $50 cash prize 
upon completing follow-up sessions, and those in the intervention group were paid $ 10 upon completing SOCRATES again after 
the interview.
Outcomes Outcomes	were	not	clearly	defined	as	PRIMARY	or	SECONDARY.
MATERNAL OUTCOMES:
Alcohol consumption as measured by total standard ethanol content (SEC), estimated peak blood alcohol concentration (BACs) 
and total days abstinent during the most recent 2 months of pregnancy.
INFANT OUTCOMES:
Not stated.
Notes ETHICS:
Not stated
INFORMED CONSENT:
All participants gave informed consent – it was not stated if it was verbal or written.
FUNDING:
Partly supported by a grant from the New Mexico Developmental Disabilities Planning Council and by grants T32-AA07460 and 
K05-AA00133	from	the	National	Institute	on	Alcohol	Abuse	and	Alcoholism.
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Magnusson 2005
Methods STUDY	TYPE:
Randomized controlled trial
COUNTRY:
Sweden
SETTING:
Two antenatal care clinics of central Stockholm
DURATION OF RECRUITMENT:
September 1, 2001, and May 30, 2002
DURATION OF TRIAL:
FOLLOW-UP:
Screening interview after standard admission in the clinics. Following evaluation, blood was obtained for analysis of biomarkers 
for the intervention group.
Participants INCLUSION CRITERIA:
EXCLUSION CRITERIA:
1106 admissions between September 1, 2001, and May 30, 2002
Among these, 303 were randomly selected by offering participation to all admissions to the respective clinic on randomly 
alternating weekdays to avoid bias caused by the possibility that subjects with hazardous alcohol use avoid scheduling visits 
immediately after weekends.
Number of participants randomized: 303
Intervention group: 147 participants
Control group: 156 participants
Number included in the analysis:
Interventions INTERVENTION:
The women in the intervention group were evaluated by the research midwife in addition to and independently of regular 
antenatal care. Following evaluation, blood was obtained for analysis of biomarkers.
Screening methods used:
1) TLFB: the period assessed by TLFB varied depending on the week of pregnancy at the time of the clinic visit (median [range] = 
12 [8-24] weeks). An interviewer administered the TLFB with the standard elements of this technique
2) AUDIT: applied to behavior during the 12-month period preceding pregnancy.
3) Biomarkers: Following the interview, together with ordinary routine laboratory tests, a venous blood sample was drawn 
and analysed for the following biomarkers (with upper reference interval limit indicated for each): MCV (76-96 f/L), GGT (< 0.80 
pkat/L), AST (< 0.60. pkat/L), ALT (< 0.60 pkat/L) and CDT (< 1.5%).
CONTROL: CONTROL GROUP
The women in the control group returned to continued regular care only.
COMPLIANCE:
CO-INTERVENTIONS:
Outcomes MATERNAL OUTCOMES:
TLFB and AUDIT scores, biomarker levels
INFANT OUTCOMES: none
Notes ETHICS:
The project followed the Declaration of Helsinki and was approved by Stockholm South Human Subjects Ethics committee 
(199/00).
INFORMED CONSENT:
Subjects gave their informed consent
FUNDING:
Funding for this study was obtained from the County of Stockholm Research and Development Fund, from the Swedish 
Government Social Ministry and from the Swedish Alcohol Monopoly Research Foundation. Funding agencies had no influence 
over collection, analysis, interpretation or publication of data.
Marais 2011
Methods STUDY	TYPE:
Cluster randomized trial
COUNTRY:
South Africa
SETTING:
8 clinics in a chosen sub-district
DURATION OF RECRUITMENT:
March to September 2007
DURATION OF TRIAL:
The recruitment plus follow-up interviews stretched over a period of 9 months
FOLLOW-UP:
Initial assessment interview lasted one hour.
2 follow-up interviews (a month and a half apart)
A last follow-up interview before the birth
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Participants INCLUSION CRITERIA:
1) All pregnant women attending any one of the eight clinics in the area
2) less than 20 weeks pregnant
3) more than 15 years of age
Women who reported no drinking were not excluded
EXCLUSION CRITERIA:
Number of elligible participants: 711
Excluded: 517
Sample size: 194
All clinics in the area, 8, were cluster randomized
Intervention group: 98 women from 4 randomized clinics
Control group: 96 women from 4 randomized clinics
Randomized to intervention group, and to control group.
Number included in the analysis in the intervention group: 97
Number included in the analysis in the control group: 82
Interventions INTERVENTION:
1) Initial assessment interview – lasting an hour – included the consent form, the personal questionnaire, the Alcohol Use 
Disorders Identification Test (AUDIT), explaining the meaning of AUDIT results, BI with setting drinking goals, and making notes 
in a take-home alcohol booklet.
2) In two follow-up interviews (a month and a half apart), BIs consisted of feedback on drinking behaviour, negotiations, goal 
setting, and reinforcement. A questionnaire on changes in drinking behaviour and bonding was completed. These interviews 
lasted 20 minutes on average.
3) The last follow-up interview before the birth comprised a BI and feedback on drinking behaviour, completing a questionnaire 
on changes in drinking behaviour, and completing a second AUDIT.
Interviews were conducted by two trained fieldworkers. Incentives in the form of a food parcel were given to all participants in 
the trial
CONTROL: CONTROL GROUP
Involvement with respondents was kept to the minimum that was allowed ethically:
1) The initial assessment interview included the consent form, the personal questionnaire, the AUDIT, written material, i.e. the 
take-home alcohol booklet, and appointment for the follow-up interview.
2) The last follow-up interview just before the birth consisted of a second AUDIT and a questionnaire on changes in drinking 
behaviour.
COMPLIANCE:
CO-INTERVENTIONS:
Outcomes MATERNAL OUTCOMES:
AUDIT score at post-intervention was used to measure the intervention effect
INFANT OUTCOMES:
none
Notes ETHICS:
The protocol for the study was ethically approved by a university ethics committee
INFORMED CONSENT:
All participants were given the consent form at the first interview
FUNDING:
The study was funded by the Western Cape Department of Social Development
O'Connor 2007
Methods STUDY	TYPE:
Cluster randomized controlled trial
COUNTRY:
United States
SETTING:
community-based setting; 12 centers of the Public Health Foundation Enterprises Management Solutions Special Supplemental 
Nutrition Program for Women, Infants, and Children; PHFE-WIC
DURATION OF RECRUITMENT:
June 2001 to March 2004
DURATION OF TRIAL:
FOLLOW-UP:
Women were screened at every monthly prenatal visit and, if they were still drinking, were provided brief intervention or 
assessment only. Women were followed to the third trimester
Participants INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Screened: 4980
Agree to participate: 4084
Use of alcohol postconception: 972
Currently drinking alcohol: 369
Number of participants randomized: 345
Intervention group: 162
Control group: 183
Number included in the analysis:
Intervention group: 117
Control group at follow-up:138
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Interventions INTERVENTION:
Within the 6 centers in the brief inter- vention condition, participants received the same comprehensive assessment of alcohol 
use plus a standardized workbook-driven brief intervention, designed specifically to help women reduce alcohol consumption 
during pregnancy. Women were screened at every monthly prenatal visit and, if they were still drinking, were provided brief 
intervention or assessment only.
The brief intervention represented a logical extension of the individual nutrition education that women enrolled in WIC already 
receive. A brief intervention workbook was designed by study investigators to help nutritionists standardize and administer the 
intervention. The workbook consisted of traditional brief intervention techniques, including education and feedback, cognitive- 
behavioral procedures, goal setting, and contracting.
CONTROL: CONTROL GROUP
Within the 6 centers in the assessment- only condition, current drinkers received a comprehensive assessment of alcohol use 
and were advised to stop drinking during pregnancy
COMPLIANCE:
CO-INTERVENTIONS:
Outcomes MATERNAL OUTCOMES:
of 369 currently drinking, 24 were referred to an alcohol treatment programme (prior to randomization)
1) Maximum drink per drinking occasion
2)	TWEAK	mean
3) Marijuana use
4) Cocaine use
INFANT OUTCOMES:
1) Gestational age at delivery
2) Birthweight
3) Birth length
Notes ETHICS
Protocols and consent forms were approved by the University of California, Los Angeles, institutional review board, and a 
Certificate of Confidentiality was obtained from the National Institute on Alcohol Abuse and Alcoholism
INFORMED CONSENT:
Women participating in this study were provided with a clear description of the study protocol and signed an informed consent 
form
FUNDING
Ondersma 2005
Methods STUDY	TYPE:
Randomized controlled trial
COUNTRY:
USA
SETTING:
Large urban obstetric hospital in Detroit
DURATION OF RECRUITMENT:
between September 9, 2003, and February 26, 2004
DURATION OF TRIAL:
Not stated
FOLLOW-UP:
A research assistant, blind to experimental condition, contacted the participants again by telephone at an average follow-up 
duration of 38.6 days (range 25–77).
At baseline, participants completed a screener made up of multiple items and substance use was evaluated using ASSIST. 
Motivation to change was evaluated using eight visual analogue scale items.
At follow-up, the 14-day edition of the Treatment Services Review was used to evaluate drug and alcohol use, receipt of 
services such as substance -abuse treatment, employment, and family relations during the prior 14 days.
Participants INCLUSION CRITERIA:
All participants were postpartum women who had given birth at a large urban obstetric hospital and who endorsed any illicit 
drug use in the month before becoming pregnant.
Participation was further limited to those who had slept since giving birth, those who could understand spoken English, were 
between 18 and 45 years, and had not been administered narcotic pain medication in the past 3 hours.
EXCLUSION CRITERIA:
Not stated
Number of participants randomized: 30.
15 randomized to intervention group, and 15 to control group.
Participants had high rates of cannabis and cocaine use.
There were no significant differences between intervention and control groups on any baseline substance-use variables.
Interventions After completing assessment battery, participants were randomly assigned by the software into intervention and control 
conditions.
INTERVENTION: assessment plus intervention conditions GROUP
Participants viewed personalized feedback, the pros and cons of drug use, and optional goal-setting in counterbalanced 
order. Three visual analogue-scale items from the motivation to change measure were presented after each counterbalanced 
component.
CONTROL: Assessment only GROUP
Participants were only assessed for drug use.
COMPLIANCE:
Not applicable.
CO-INTERVENTIONS:
Not stated
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Outcomes Outcomes	were	not	clearly	defined	as	PRIMARY	or	SECONDARY.
MATERNAL OUTCOMES:
To evaluate the magnitude of intervention effects on drug use, service involvement, and motivation at follow-up.
INFANT OUTCOMES:
None
Notes ETHICS
Wayne State University Institutional Review Board.
INFORMED CONSENT:
All participants provided verbal informed consent for the screening and written informed consent for the full study.
FUNDING
Grants DA00516 and DA14621 from the National Institute on Drug Abuse.
Tzilos 2011
Methods STUDY	TYPE:
Randomized controlled trial
COUNTRY:
USA
SETTING:
Inner city prenatal care clinic at Michigan (exact city not stated).
DURATION OF RECRUITMENT:
Not stated.
DURATION OF TRIAL:
Not stated.
FOLLOW-UP:
Women were followed-up one month after the intervention, with average follow-up time of 33 days (SD: 7.9, range: 25 – 72 days). 
Follow-up was conducted over the telephone for approximately 10 – 15 minutes, and included TLFB assessment of drinking in 
the past month.
Participants INCLUSION CRITERIA:
Being pregnant, between ages 18 and 45 (with at least 1 month expected gestation remaining), able to understand spoken 
English,
and either (1) meeting T-ACE criteria for problem alcohol use, (2) exceeding the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA) ‘‘normal’’ sensible drinking limits before pregnancy (more than seven standard drinks a week or more than 
two drinks at a time), or (3) reporting drinking at least one time per month during pregnancy.
EXCLUSION CRITERIA:
Inability to provide informed consent (e.g., due to psychosis, intoxication, or other clear cognitive impairment), inability to 
communicate in English, and not having access to a phone (for follow-up).
Number of participants randomized: 50
27 randomized to intervention group, and 23 to control group.
Mean age of 26 years (SD 5.2), and a mean gestational age of 25 weeks (SD 8). Differences in characteristics and baseline data 
between the two groups were not statistically significant.
Interventions All participants rated their satisfaction with the software after completing the intervention section (or assessment section for 
the control group); ratings were based on a 1–5 Likert scale, where 1 = low and 5 = high.
INTERVENTION: Computer-delivered single-session brief intervention
Participants self-administered and solely computer-delivered, with assistance available from the investigator as needed and it 
lasted for 15–20 minutes.
The software tailored content based on the current drinking status of each participant. For women who reported they already 
quit, the narrator presented a section that focused on relapse prevention (‘‘My plan to remain abstinent’’) while asking the 
participant to provide the reasons/benefits to them of having made this change.
The remaining women were asked about their current interest in quitting.
Those reporting a goal of immediate abstinence moved more quickly to a section consistent with phase 2 of MI (primarily goal 
setting), whereas those who did not wish to quit received elements consistent with phase 1 of MI (e.g. pros and cons, normed 
feedback).
CONTROL: CONTROL GROUP
Participants were administered series of questions about TV shows, videos of popular entertainers/shows, followed by requests 
for ratings of subjective preference. Duration was equivalent to that of intervention group.
COMPLIANCE:
Assessing compliance - not applicable
CO-INTERVENTIONS:
All eligible participants received gift cards (equivalent to $30) for their participation at the baseline visit. Women who completed 
the follow-up session received an additional gift card (equivalent to $5) by mail.
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Outcomes Outcomes	were	clearly	defined	as	PRIMARY	or	SECONDARY.
PRIMARY	OUTCOMES	:	(1)	the	feasibility	of	the	computer-delivered	approach	through	evaluation	of	the	rate	of	identification	of	
at-risk drinking and of the proportion of participants able to complete the computer-delivered
session and (2) acceptability of computer-delivered SBIRT via participant report of ease of use, helpfulness, and overall 
satisfaction.
SECONDARY	OUTCOMES:	to	conduct	preliminary	effect	size	estimation	of	intervention-related	changes	in	(1)	alcohol	
consumption (frequency, quantity, and binge use) 30 days after the single-session intervention and (2) birth outcome variables 
(i.e., gestational age, birthweight, and head circumference).
MATERNAL OUTCOMES:
Feasibility of the computer-delivered approach as measured by rate of identification of at-risk drinking and the proportion of 
women completing the session.
Acceptability of the computer-delivered SBIRT as measured by reported ease of use, helpfulness and overall satisfaction.
Alcohol consumption as measured by frequency, quantity, and binge use post-intervention.
INFANT OUTCOMES:
Gestational age, birthweight, and head circumference as measured by information from the medical records.
Notes ETHICS
Wayne State University Institutional Review Board as well as the Detroit Medical Center Research Review Committee.
INFORMED CONSENT:
Participants provided signed informed consent.
FUNDING
The	research	was	supported	by	NIAAA	training	grant	AA16256	(to	G.	K.T;	mentor,	S.J.O.).
Whaley 2003
Methods STUDY	TYPE:
Cluster randomized trial
COUNTRY:
USA
SETTING:
Public Health Foundation Enterprises WIC center sites
DURATION OF RECRUITMENT:
DURATION OF TRIAL: 25 months: from May 2000 to May 2002
FOLLOW-UP:
Participants Of the 53 PHFE-WIC sites in Los Angeles and Orange counties, 12 were randomly selected to administer a self-report alcohol 
screening tool to all pregnant women.
The remaining 41 WIC sites continued to administer the WIC standard care. From these 41 sites, 12 control sites (matched to the 
intervention group on caseload size, size of the Hispanic population, maternal age, and maternal education) were selected for 
this analysis.
INCLUSION CRITERIA:
Pregnant women visiting the 24 WIC sites over the course of the study were included in the sample for each month of their 
pregnancy.
EXCLUSION CRITERIA:
Number of participants randomized:
randomized to intervention group, and to control group.
Number included in the analysis:
Interventions INTERVENTION:
The alcohol screening tool incorporates 2 methods found in previous research to most accurately assess alcohol intake 
because of their ease of use and sensitivity. Quantitiy-frequency measures inquire about typical consumption patterns and 
include the amount of drinking on an average day (quantity) and the average number of days on which alcohol was consumed 
(frequency). The Time-line Followback method was also used on the alcohol screening tool, because it provides a more detailed 
picture of a person's drinking over designated time periods and has been evaluated extensively with clinical and nonclinical 
population.
CONTROL:
The 12 control clinics continued to administer the WIC standard of care.
COMPLIANCE:
CO-INTERVENTIONS:
Outcomes MATERNAL OUTCOMES: ongoing substance use during pregnancy
INFANT OUTCOMES: none
Notes ETHICS
INFORMED CONSENT: The tool was part of a research protocol, and consent forms were not obtained from approximately 30% 
of the prenatal participants.
FUNDING The research was supported by NIAAA grant ROI-AA12480 to M. O'Connor and S. Whaley.
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Evidence Profile 2: Psychosocial interventions for harmful use and 
dependence on alcohol and other substances in pregnancy
Evidence question:
For pregnant and postpartum women with harmful alcohol or drug use, do some psychosocial interventions 
result in better maternal, fetal and infant outcomes than other psychosocial interventions or usual care? 
Study selection criteria for the systematic review:
Study design: RCTs
Population: Pregnant or postpartum women with harmful use of alcohol or drugs.
Interventions: Psychological or social interventions longer in duration and intensity than brief interventions. 
Control: Other psychosocial interventions or usual care (usual obstetric care or usual specialist care).
Outcomes: The key outcomes selected were:
PSYCHOSOCIAL INTERVENTIONS compared with USUAL CARE or OTHER INTERVENTIONS Ranking (0–9)
Maternal: Substance use 8.22
Maternal: Retention in substance use treatment 7.89
Infant: Birthweight 6.78
Custody of infant 6.56
Infant: Gestational age at delivery 6.44
Infant: Birth defects 6.00
Infant: Neonatal death 5.89
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Psychosocial interventions for harmful use and dependence on alcohol and other substances in pregnancy
Summary of evidence: see also summary of findings and GRADE tables below 
Summary of RCT evidence: 
With the exception of home visits, all RCTs compared a specific form of psychosocial intervention to treatment-as-
usual in the specialist drug and alcohol treatment service, not usual obstetric care. As such, they are comparing one 
form of psychosocial intervention with another, since all specialist treatment is considered to include a component of 
psychosocial care. 
 
Motivational Interviewing (MI)
Two randomized clinical trials have compared motivational interviewing (MI) to treatment-as-usual or educational 
control. Findings do not support the superiority of MI to treatment-as-usual or educational control, with similar results 
for maternal retention in treatment and maternal substance abuse. Data are absent regarding neonatal outcomes. 
Both samples were identified as needing substance-abuse treatment.
Cognitive Behavioural Therapy (CBT)
Two randomized clinical trials compared cognitive behavioural therapy (CBT) to treatment-as-usual. Findings suggest 
that CBT may be superior to treatment-as-usual in terms of treatment retention, reductions in sex and needle risk, 
and occurrence of preterm birth. One sample was in methadone treatment and the other sample was using alcohol or 
another illicit substance exclusive of opiates. 
Contingency Management (CM)
Five randomized clinical trials compared contingency management (CM) to treatment-as-usual. Findings support the 
superiority of CM to treatment-as-usual in terms of retention in treatment, percentage of negative urines, and weeks of 
continuous cocaine abstinence. Three of the samples met requirements for methadone maintenance, one sample met 
requirements for opioid or cocaine dependence, and one met criteria for cocaine dependence. 
Other
Standard management home visits have been shown to be not effective. A review of randomized trials (Turnbull & 
Osborn, 2012) suggests that home visits following delivery are not effective in reducing maternal retention in treatment, 
substance use or alcohol use. Findings from 4 other studies (Butz et al., 1998; Grant et al., 1996; Quinlivan et al., 2000; 
Schuler et al., 2000) omitted by Turnbull and Osborn (2013) are consistent with their conclusion. 
Educational and counselling interventions may encourage women to cease alcohol use or reduce the amount of 
alcohol consumed during pregnancy (Stade, 2009).
Benefits and harms
Benefits •	 Pregnancy	presents	a	unique	opportunity	to	help	support	women	to	reduce	and	ideally	cease	
alcohol and/or illicit substance use (Chang et al., 2000)
•	 Depending	on	the	substance	of	use,	psychosocial	interventions	are	considered	to	be	superior	
to usual care in terms of:
– reduction in harmful consumption
– reduction in risk to fetus
– increase in birthweight
– improved general health of pregnant women
– improved maternal psychological well-being
– less risk of fetotoxicity
– improved perinatal outcomes (e.g. reduction in preterm births, increased overall 
birthweights, reduction in number of low-birthweight infants)
– reductions in congenital defects or anomalies (Lui, Terplan, & Smith, 2008; Terplan & Lui, 
2007)
•	 There	is	a	high	incidence	of	mental	health	disorders	in	opioid-dependent	pregnant	women	and	
psychosocial interventions may be appropriate in many instances (Martin et al., 2009)
•	 Considerable	research	supports	a	variety	of	psychosocial	interventions	for	substance	use	and	
co-occurring mental disorders in non-pregnant populations (Drake, O’Neal, & Wallach, 2008)
•	 Retention	in	substance	abuse	treatment	is	an	important	factor	in	reducing	illicit	substance	use	
(Laken, 1997)
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Harms •	 Physical	and	mental	symptoms	associated	with	reduction	or	cessation	of	alcohol	or	substance	
use 
•	 Possible	development	of	depression	or	anxiety	as	a	result	of	cessation	or	reduction	of	alcohol	
or illicit substance use
•	 Possible	verbal	and/or	physical	abuse	by	the	partner	as	a	result	of	the	pregnant	woman’s	
behaviour change
•	 Possible	risk	of	switching	from	one	substance	to	another	substance
•	 Between	7%	and	15%	of	individuals	participating	in	psychosocial	interventions	to	treat	
substance use disorders may be worse off after treatment than before treatment. This decline 
in functioning may be due to a lack of bonding with the provider, lack of goal direction and 
monitoring, confrontation, criticism, and high emotional arousal and stigma (Moos, 2012)
•	 Stigmatization-risk	of	incarceration/loss	of	infant	in	punitive	systems
•	 Economic	and	time	burdens	imposed	by	need	to	attend	interventions
•	 Conflict	with	partner/family/employer	over	time/	commitment	to	intervention	
Values and preferences
In favour: 
Pregnant woman
Health-care 
worker
Community
•	 Personal	contact	and	support
•	 Development	of	coping	strategies
•	 Commitment	to	behaviour	change
•	 Opportunity	to	intervene
•	 Positive	means	of	intervening
•	 Effective	means	of	intervening
•	 Possible	reduction	of	crime	in	the	community
•	 Possible	reduction	of	STI	risk	in	the	community
•	 Possible	positive	responses	from	partners,	family	and,	co-workers
Against: 
Pregnant woman
Health-care 
workers
Community
•	 Stigmatization	of	pregnant	women	who	drink	alcohol	or	use	illicit	substances	during	pregnancy
•	 Stigmatization	of	women	who	are	in	need	of	counselling
•	 Negative	responses	from	partners,	family	and	co-workers
•	 Time	and	inconvenience	involved	in	referral	for	intervention
•	 Concern	about	effectiveness	of	intervention	
•	 Resentment	of	diversion	of	resources	to	intervention	
•	 Resentment	of	resources	used	for	intervention
•	 Disbelief	in	effectiveness
•	 Partners/family	may	see	changes	in	woman	undergoing	intervention	as	harmful
Costs and feasibility
Costs •	 Additional	costs	beyond	routine	care
•	 Trained	staff	and	a	sustainable	programme	are	required.	Training	for	management	of	substance	
use disorders on the part of obstetricians and their staff can increase their self-efficacy 
regarding the treatment of patients who use substances (Schumacher, 2000)
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Feasibility 
(including 
economic 
consequences)
•	 Inconvenient	for	women	
•	 Referral	to	addiction	medicine	specialist	would	be	necessary	to	manage	any	short-term	toxicity	
or withdrawal
•	 Requires	patient	monitoring	to	ensure	patient	remains	enrolled	in	and	engaged	in	the	
psychosocial intervention
•	 A	comprehensive	care	model	in	which	obstetrical	care	is	part	of	a	women-centered,	trauma-
informed program would be the best model of care – and also potentially the costliest 
•	 A	therapeutic	workplace	has	been	shown	to	be	superior	to	usual	care	in	reducing	opioid	and	
cocaine use in pregnant women with substance use disorders (Silverman et al., 2001) 
•	 Well-child	care	visits	may	not	be	sufficient	to	prevent	deterioration	in	competence	and	social	
isolation in postpartum women who use substances (Taylor, 1998)
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Draft recommendations: 
 o Pregnant women with dependent alcohol or other substance use (or harmful alcohol or other substance 
use not responding to brief interventions) should be offered intensive psychosocial support and treatment.
 o Postpartum women with substance dependence should be offered intensive psychosocial support and 
treatment including home visits, parenting support, psychotherapy and social assistance.
Final recommendations: 
RECOMMENDATION 
Health-care providers managing pregnant or postpartum women with alcohol or other substance use disorders 
should offer comprehensive assessment and individualized care.
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 A	comprehensive	assessment	of	women	using	alcohol	or	drugs	in	pregnancy	and	the	postpartum	period	includes	
an assessment of patterns of substance use, medical or psychiatric comorbidity, family context, as well as social 
problems.
•	 Individualized	care	involves	selecting	appropriate	psychosocial	interventions	of	different	intensity	based	on	the	
particular needs of the pregnant women and the resources available. Psychosocial interventions include a number 
of psychological treatments and social supports, ranging from lesser to higher intensity. The psychosocial treatment 
and support referred to in this section is a more intensive set of interventions typically delivered by people with 
specific training in the management of substance use disorders, and usually includes repeated contact with the 
patient. The kinds of specific psychological techniques considered in this category include cognitive behavioural 
therapy, contingency management and motivational enhancement. The kinds of social support referred to in this 
section include assistance with accommodation, vocational training, parenting training, life-skills training, legal 
advice, home visiting and outreach.
•	 Despite	the	benefits	of	psychosocial	treatment	outweighing	the	harms,	this	recommendation	was	considered	to	be	
conditional given the absence of strong evidence and the potential resource implications. 
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Factors in considering the strength of the recommendation (recommendations 3): 
Research recommendations
 o Better reporting and agreement on standardized designs and outcomes is needed.
 o Stronger RCT evidence of effect is needed, in particular comparing interventions with different levels of 
intensity and models of care with different levels of comprehensiveness, and including cost-effectiveness 
analyses.
Factor Decision
Is there high or moderate quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation. 
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty 
that the costs of the resources being consumed outweigh any benefit gained?
No
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FOREST PLOTS OF CASE MANAGEMENT COMPARISON
RISK OF BIAS IN EACH TRIAL INCLUDED IN THE CASE MANAGEMENT COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Jansson 2005
Walton-Moss 2006 was an incompletely reported trial and as a result a risk of bias assessment was not conducted.
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INTENSIFIED CASE MANAGEMENT COMPARED TO ROUTINE CASE MANAGEMENT FOR PREGNANT OR POSTPARTUM 
WOMEN WITH PROBLEMATIC SUBSTANCE USE
Patient or population: Pregnant or postpartum women with problematic substance use
Settings: Specialist treatment outpatient
Intervention: Intensified case management
Comparison: Routine case management
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Routine case 
management
Intensified case 
management
Maternal treatment 
retention (intention 
to treat analysis)
Follow-up: 0–4 
months
382 per 1000 409 per 1000
(210 to 791)
RR 1.07 
(0.55 to 2.07)
56
(1 study)
⊕
VERY	LOW1,2
Maternal urine 
positive for 
opiates other than 
methadone 
Follow-up: 0–4 
months
160 per 1000 267 per 1000
(78 to 912)
RR 1.67 
(0.49 to 5.7)
40
(1 study)
⊕
VERY	LOW1,2
Maternal urine 
positive for cocaine 
Follow-up: 0–4 
months
160 per 1000 29 per 1000
(2 to 502)
RR 0.18 
(0.01 to 3.14)
40
(1 study)
⊕
VERY	LOW1,2
Infant birthweight –
not measured
See comment See comment Not 
estimable
50
(1 study)
See comment
Infant gestational 
age – not measured
See comment See comment Not 
estimable
50
(2 studies)
See comment As above
Infant custody –
not measured
See comment See comment Not 
estimable
179
(1 study)
See comment As above
Infant head 
circumference –
not measured
See comment See comment Not 
estimable
30
(1 study)
See comment As above
Infant birth defects –
not measured
See comment See comment Not 
estimable
See comment As above
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of bias: rated as very serious. Randomization did not result in similar numbers in each group indicating a possible effect of chance or selection bias. Random 
generation and allocation concealment methods were not reported. Blinding was not possible for participants or providers and attrition was high.
2 Imprecision: The sample size is small and the confidence interval wide.
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RISK OF BIAS IN EACH TRIAL INCLUDED IN THE COGNITIVE BEHAVIOURAL THERAPY COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
O'Neill 1996
Yonkers 2012
FOREST PLOTS OF COGNITIVE BEHAVIOURAL THERAPY COMPARISON
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COGNITIVE BEHAVIOURAL THERAPY COMPARED TO CONTROL FOR PREGNANT OR POSTPARTUM WOMEN WITH 
PROBLEMATIC SUBSTANCE USE
Patient or population: Pregnant or postpartum women with problematic substance use
Settings: General treatment settings (antenatal) and specialist substance use programmes: Outpatient
Intervention: Cognitive behavioural therapy 
Comparison: Control
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Control
Cognitive 
Behavioural 
Therapy
Maternal 
treatment retention 
Participants 
retained after 6 
weeks of treatment 
or participants 
attending at least 
one session
Follow-up: 6–24 
weeks
919 per 1000 846 per 1000
(781 to 928)
RR 0.92 
(0.85 to 1.01)
275
(2 studies)
⊕⊕
LOW1,2
Maternal substance 
use 
% days used drugs 
or alcohol in past 
month measured at 
delivery
Follow-up: mean 12 
weeks3
The mean 
maternal 
substance use in 
the intervention 
groups was
1 higher
(5.05 lower to 7.05 
higher)
163
(1 study)
⊕⊕
LOW4
Mixed effects 
negative binomial 
regression test 
for group by time 
interaction found 
no significant dif-
ferences between 
groups at delivery 
and 3 mnths pp
Low birthweight 
< 2500g
Medical records
202 per 1000 146 per 1000
(73 to 289)
RR 0.72 
(0.36 to 1.43)
160
(1 study)
⊕⊕
LOW4,5
3 women had 
an unknown 
birthweight and 
were not included 
in the analysis
Preterm birth 
< 37 weeks 
From medical 
records
202 per 1000 101 per 1000
(47 to 221)
RR 0.5 
(0.23 to 1.09)
163
(1 study)
⊕⊕
LOW4,5
Infant birth defects –
not measured
See comment See comment Not 
estimable
— See comment
Infant custody –
not measured
See comment See comment Not 
estimable
— See comment
Infant head 
circumference –
not measured
See comment See comment Not 
estimable
— See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of bias: Rated as Serious: Lack of reporting of sequence generation and allocation concealment in O'Neill 1996 and the loss-to-follow up > 10% resulted in 
down-grading for risk of bias. A likely lack of blinding for providers and participants in both trials may have introduced performance bias.
2 Indirectness: Rated as Serious. The measurement for treatment retention used in the analysis is a proxy measure for both trials. In O'Neill 1996 completion and 
availability for 6 week follow-up is used but not all sessions would have been attended as appointments were missed at an average of mean 2.9 (SD 6.45) with a 
range of 0–11. In Yonkers 2012 the proxy measure is attending at least one of 6 session during the entire study period which continued to 3 months postpartum. 
3 Inclusion criteria was women of < 28 weeks pregnant. The mean duration of follow-up was calculated as from 28 weeks to delivery although women may have 
been in treatment for longer if enrolled before 28 weeks.
4 Risk of Bias: Rated as Serious. This well-conducted trial Yonkers 2012 was down-graded on the basis of a likely lack of blinding which may have introduced 
performance bias.
5 Imprecision: The event rate is very low < 300.
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RISK OF BIAS IN EACH TRIAL INCLUDED IN THE CONTINGENCY MANAGEMENT COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Carroll 1995
Jones 2001
Jones 2011
Schottenfeld 2011
Tuten 2012
FOREST PLOTS OF CONTINGENCY MANAGEMENT COMPARISON
67
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Usual Care
Contingency 
Management
Maternal % Urine 
positive for opioids1
Follow-up: 13–31 
weeks
See comment See comment Not 
estimable1
14
(1 study)
⊕
VERY	LOW2,3
The GRADE 
assessment 
is specific to 
this single trial. 
Results of other 
trials from which 
data could not 
be extracted are 
included in the 
footnotes.
Maternal % Urine 
negative for cocaine4
Follow-up: 24 weeks
The mean 
maternal % 
urine negative 
for cocaine in 
the intervention 
groups was
13.9 higher
(0.53 to 27.27 
higher)
71
(1 study)
⊕
VERY	LOW5,6
This trial also 
reported weeks 
of continuous 
cocaine 
abstinence 
& reported a 
statistically 
significant 
favourable effect 
of CM (F (1.141) = 
7.76; p < 0.01)
Maternal % Urine 
positive for cocaine7
Follow-up: 13–31 
weeks
See comment See comment Not 
estimable7
14
(1 study)
⊕
VERY	LOW2,3
The GRADE 
assessment 
is specific to 
this single trial. 
Results of other 
trials from which 
data could not 
be extracted are 
included in the 
footnotes.
Maternal retention 
in treatment8
Various proxy 
measures
Follow-up: 2–24 
weeks
See comment See comment Not 
estimable8
165
(3 studies)
⊕
VERY	LOW2,9,10,11
Treatment 
duration was 
varying across 
trials and different 
proxy measures 
were used for 
retention e.g. no 
of prenatal visits. 
The results were 
thus not pooled.
Birthweight
Grams
The mean 
birthweight ranged 
across control 
groups from 
2942–2996 g.
The mean 
birthweight in 
the intervention 
groups was
17.29 lower
(573.03 lower to 
538.45 higher)
103
(2 studies)
⊕
VERY	LOW12,13,14
CONTINGENCY MANAGEMENT COMPARED TO USUAL CARE FOR PREGNANT OR POSTPARTUM WOMEN WITH 
PROBLEMATIC SUBSTANCE USE
Patient or population: Pregnant or Postpartum women with problematic substance use
Settings: Residential, inpatient and outpatient
Intervention: Contingency Management 
Comparison: Usual Care
68
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Jones 2001 reported a significant effect of CM on the rate of opiate positive urine samples in day 8 - 14 (outpatient) (F (1.78) = 5.76; p =< 0.05) and this effect 
disappeared after vouchers were no longer provided after week 2. Jones 2011 reported that there was no statistically significant difference between heroin 
positive urines in the last 30 days between the groups. Tuten 2012 reported no statistically significant difference in the first opioid-positive assessment time point 
between the fixed combined with escalating voucher group compared with the control group (F(1,78.0) = 1.05; p = 0.31) and between the fixed and escalating groups 
((F(1,92.4) = 1.23; p = 0.27). 
2 Risk of Bias: Rated as Very serious. No reporting of randomization sequence, no blinding and high attrition.
3 Imprecision: Rated as Very Serious. This is a very small trial (N = 20) with 14 analysed. The risk of imprecision is very high.
4 Tuten 2012 reported no statistically significant differences in the the number of cocaine-negative urine tests between the combined fixed with escalating voucher 
group compared with the control group (F(1,54.3) = 0.01; p = 0.91) and between the fixed and escalating voucher groups ((F(1,88.7) = 0.09; p = 0.76).
5 Risk of bias: Rated as Very Serious. The high rate of attrition and lack of blinding resulted in down-grading this trial.
6 Imprecision: Rated as VERY SERIOUS. The 95% confidence interval is very wide.
7 Jones 2001 reported a statistically significant favourable effect of CM on the rate of cocaine-positive urine from day 8 to 14 (F(1,78) - 7.05); p =< 0.05). This effect 
disappeared after the vouchers were stopped at the end of week 2. Jones 2011 reported no statistically significant effect between groups for cocaine-positive 
urine. 
8 The results from the three trials favoured contingency management over usual care for maternal retention in treatment. Carroll 1995 (N = 14 analysed) found no of 
prenatal visits was statistically significantly higher (CM: Mean = 14.7; SD: 5.9)(Usual Care: Mean = 5.1; SD: 3.6). In Jones 2001 (N = 80 analysed) participants in 
CM attended statistically significant more treatment days (CM: Mean = 12.1; SD: 2.3)(Usual Care: Mean = 10.6; SD: 2.4). In Schottenfeld 2011 (N = 71 analysed) 
participants in CM attended statistically significantly more therapy sessions (CM: Mean: 25.3; SD: 13.7)(Usual Care: Mean = 19.9; SD: 12.8).
9 Risk of bias: Rated as Very Serious. Jones 2001 and Schottenfeld 2001 randomized adequately. However the lack of provider blinding across all three trials and the 
high attrition in two of the three trials, resulted in overall downgrading.
10 Indirectness: Rated as Serious. Treatment duration was varying across trials and different proxy measures were used for retention e.g. no of prenatal visits versus 
no of groups attended
11 Imprecision: Rated as Serious. This was difficult to rate as the measures were varying, but within each trial the 95% confidence intervals were large and so overall 
it was down-graded for imprecision.
12 Risk of Bias: Rated as Very Serious. The high rate of attrition in Jones 2011 and Carroll 1995 resulted in the risk of bias rated as very serious. In addition, lack of 
blinding may result in a high risk of performance bias.
13 Inconsistency: Rated as Serious. There was unexplained heterogeneity present
14 Imprecision: The confidence interval was wide and the overall sample size small.
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Usual Care
Contingency 
Management
Infant gestational 
age at delivery
Weeks
The mean infant 
gestational age 
at delivery in 
the intervention 
groups was
1.4 higher
(0.96 lower to 3.76 
higher)
14
(1 study)
14
(1 study)
⊕
VERY	LOW2,3
GA at delivery 
also reported in 
Jones 2011 (N = 
89) by Poisson 
regression: GA 
on delivery: CM 
(Mean 37.2; SE 
1.1); Usual Care 
(Mean: 38.5; SE 
1.6); P = 0.52
Infant custody –
not measured
See comment See comment Not 
estimable
— See comment None of the five 
included trials 
measured or 
reported this as 
an outcome.
Infant birth defects –
not measured
See comment See comment Not 
estimable
— See comment None of the five 
included trials 
measured or 
reported this as 
an outcome.
Infant head 
circumference –
not measured
See comment See comment Not 
estimable
— See comment None of the five 
included trials 
measured or 
reported this as 
an outcome.
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RISK OF BIAS IN EACH STUDY INCLUDED IN THE HOME VISITS COMPARISON
FOREST PLOTS OF HOME VISITS (FROM COCHRANE REVIEW SO NUMBERING NOT SEQUENTIAL)
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Bartu 2006
Black 1994
Butz 1998
Dakof 2003
Grant 1996
Quinlivan 2000
Schuler 2000
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
No home visits
Home visits during 
pregnancy and 
after birth
Maternal retention 
in treatment
Failure of retention 
in program at latest 
time measured
325 per 1000 299 per 1000
(224 to 400)
RR 0.92 
(0.69 to 1.23)
315
(3 studies)
⊕
VERY	LOW1,2,3
The GRADE 
assessment 
is specific to 
this single trial. 
Results of other 
trials from which 
data could not 
be extracted are 
included in the 
footnotes.
Maternal continued 
illicit drug use
569 per 1000 598 per 1000
(507 to 706)
RR 1.05 
(0.89 to 1.24)
384
(3 studies)
⊕⊕
LOW4,5,6
This trial also 
reported weeks 
of continuous 
cocaine 
abstinence 
& reported a 
statistically 
significant 
favourable effect 
of CM (F (1.141) = 
7.76; p < 0.01)
Maternal continued 
alcohol use
435 per 1000 513 per 1000
(417 to 635)
RR 1.18 
(0.96 to 1.46)
379
(3 studies)
⊕⊕
LOW4,6,7
The GRADE 
assessment 
is specific to 
this single trial. 
Results of other 
trials from which 
data could not 
be extracted are 
included in the 
footnotes.
Infant birthweight – not 
reported
See comment See comment Not 
estimable
See comment
Infant gestational 
age at delivery – not 
reported
See comment See comment Not 
estimable
See comment
Infant custody – not 
reported
See comment See comment Not 
estimable
See comment
Infant birth defects – 
not reported
See comment See comment Not 
estimable
See comment
Infant head 
circumference – not 
reported
See comment See comment Not 
estimable
See comment
HOME VISITS DURING PREGNANCY AND AFTER BIRTH COMPARED TO NO HOME VISITS FOR WOMEN WITH AN 
ALCOHOL OR DRUG PROBLEM
Patient or population: Women with an alcohol or drug problem
Settings: Community
Intervention: Home visits during pregnancy and after birth
Comparison: No home visits
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
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1 The meta-analysis included three RCTs (Black 1994, Bartu 2006, and Dakof 2003). Two were judged to be at low risk of selection bias (although allocation 
concealment was unclear in Bartu 2006) and Black 1994 was judged to be at unclear risk of selection bias. All trials were judged to be at high risk of performance 
bias as blinding was not possible for the intervention. All trials were judged for this outcome (failure of retention in program) to be at high or unclear risk of 
detection bias. Attrition bias was a high risk for Black 1994 at 28% loss-to-follow-up. 
2 Heterogeneity is present (I-squared = 49%). There are multiple sources of heterogeneity including differences in the type of home visitor, frequency and duration of 
the home visit and differences in content of visit. These subgroups are explored in additional analyses and may explain some of the heterogeneity; however, given 
the uncertainty and extent of the heterogeneity, the analysis was downgraded for inconsistency. 
3 The sample size is small, and the event rate is less than 300. 
4 This meta-analysis includes three RCTs (Bartu 2006, Butz 1998 and Schuler 2000). Two trials were judged to be at low risk of selection bias and one was of unclear 
risk. All three trials were judged to be at high risk of performance bias as the visits could not be blinded. Two of three trials ensured outcome assessment was 
blinded reducing the risk of detection bias. Two trials had very high loss-to-follow-up (> 40%) at 18 months and are therefore at high risk of attrition bias.
5 Heterogeneity is present (I-squared = 64%). As there is moderate heterogeneity, it may be more appropriate to use a random effects model. This provides a RR = 
1.04 (95% CI: 0.78, 1.38). This does not differ qualitatively from the fixed effects model. However, there are multiple sources of heterogeneity including differences 
in the type of home visitor, frequency and duration of the home visit and differences in content of visit. These sub-groups are explored in additional analyses and 
may explain some of the heterogeneity; however, given the uncertainty and extent of the heterogeneity, the analysis was downgraded for inconsistency. 
6 The event rate is less than 300. However, given the relatively large event rate and narrow confidence interval, the analysis was not downgraded for imprecision.
7 There was no statistical heterogeneity in the results. However, there are multiple potential causes of clinical heterogeneity including differences in the type 
of home visitor, frequency and duration of the home visit and differences in content of visit. These subgroups are explored in additional analyses but given the 
uncertainty regarding heterogeneity, the analysis was downgraded for inconsistency. 
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) t
o 
be
 a
t h
ig
h 
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 u
nc
le
ar
 ri
sk
 o
f d
et
ec
tio
n 
bi
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. 
At
tri
tio
n 
bi
as
 w
as
 a
 h
ig
h 
ris
k 
fo
r B
la
ck
 1
99
4 
at
 2
8%
 lo
ss
-to
-fo
llo
w
-u
p.
 
2  
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te
ro
ge
ne
ity
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 p
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se
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 (I
-s
qu
ar
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 =
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9%
). 
Th
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ar
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m
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 o
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 in
cl
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 o
f h
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m
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 d
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 c
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m
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ro
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ity
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er
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, t
he
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 d
ow
ng
ra
de
d 
fo
r i
nc
on
si
st
en
cy
. 
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m
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at
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 m
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 b
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 b
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t b
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 d
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 b
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ro
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 p
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 m
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ro
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t m
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 b
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 C
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 d
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 m
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 d
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 d
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 c
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m
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 d
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at
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 c
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at
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l c
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 c
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 d
ur
at
io
n 
of
 th
e 
ho
m
e 
vi
si
t a
nd
 d
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 c
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 re
ga
rd
in
g 
he
te
ro
ge
ne
ity
, t
he
 a
na
ly
si
s 
w
as
 d
ow
ng
ra
de
d 
fo
r i
nc
on
si
st
en
cy
. 
79
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
M
O
TI
VA
TI
O
N
A
L 
IN
TE
R
VI
E
W
IN
G
 d
ur
in
g 
pr
eg
na
nc
y 
an
d 
af
te
r 
bi
rt
h 
fo
r 
w
om
en
 w
it
h 
an
 a
lc
oh
ol
 o
r 
dr
ug
 p
ro
bl
em
TA
B
LE
 O
F 
CH
A
RA
CT
ER
IS
TI
CS
 O
F 
IN
CL
U
D
ED
 R
CT
s:
 2
 IN
 T
O
TA
L
Tr
ia
l I
D
Co
un
tr
y
N
G
es
ta
tio
na
l 
ag
e 
A
lc
oh
ol
 a
nd
 
dr
ug
 u
se
Se
tti
ng
 (d
ur
at
io
n)
St
ud
y 
du
ra
tio
n
Ra
nd
om
iz
ed
 g
ro
up
s
Pr
im
ar
y 
ou
tc
om
es
IN
TE
RV
EN
TI
O
N
 D
U
RI
N
G
 P
RE
G
N
A
N
CY
 O
N
LY
G
en
er
al
 tr
ea
tm
en
t s
et
tin
gs
N
o 
tr
ia
ls
 w
er
e 
id
en
tifi
ed
 fr
om
 th
es
e 
se
tti
ng
s.
Sp
ec
ia
lis
t t
re
at
m
en
t s
et
tin
gs
W
in
hu
se
n 
20
08
U
SA
20
0 
R
20
0 
A
 in
 IT
T
17
1 
A
 in
 
ev
al
ua
bl
e 
sa
m
pl
e 
< 
32
 w
ks
Id
en
tifi
ed
 
as
 n
ee
di
ng
 
su
bs
ta
nc
e 
ab
us
e 
tr
ea
tm
en
t v
ia
 
th
e 
Cl
in
ic
al
 
Tr
ia
ls
 N
et
w
or
k 
(C
TN
) s
ite
 
ac
co
rd
in
g 
to
 u
su
al
 
sc
re
en
in
g 
pr
oc
ed
ur
es
 
us
ed
 o
n 
si
te
.
O
ut
pa
tie
nt
. M
ul
tis
ite
 tr
ia
l i
n 
fo
ur
 C
TN
 s
ite
s:
 A
ll 
pr
ov
id
e 
co
m
pr
eh
en
si
ve
 tr
ea
tm
en
t 
pr
og
ra
m
m
es
 s
pe
ci
fic
al
ly
 fo
r 
pr
eg
na
nt
 w
om
en
 a
bu
si
ng
 
su
bs
ta
nc
es
1 
m
on
th
 a
ct
iv
e 
tr
ea
tm
en
t; 
3 
m
on
th
s 
fo
llo
w
-u
p
M
ot
iv
at
io
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m
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ue
s 
of
 M
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di
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si
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d 
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t t
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l e
nt
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ra
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w
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 p
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 p
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ce
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tm
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ra
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in
di
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w
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 c
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t b
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M
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M
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m
en
t u
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io
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at
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ea
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en
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 o
f h
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 o
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lo
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 C
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l d
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 d
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M
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r s
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t t
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m
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 c
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t w
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ar
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 c
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m
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e,
 a
t 
1 
w
k 
po
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 p
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m
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ta
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, p
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ce
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Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Mullins 2004
Winhusen 2008
RISK OF BIAS IN EACH TRIAL INCLUDED IN THE MOTIVATIONAL INTERVIEWING COMPARISON
FOREST PLOTS OF MOTIVATIONAL INTERVIEWING COMPARISON
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Any control 
(treatment-
as-usual or 
Educational 
Control)
Motivational 
Interviewing 
Maternal retention 
in treatment
Follow-up: 1–2 
months
716 per 1000 695 per 1000
(609 to 788)
RR 0.97 
(0.85 to 1.1)
271
(2 studies)
⊕⊕
LOW1,2
Maternal substance 
use
Mean proportion 
of negative urine 
screens
Follow-up: mean 
2 months
The mean 
maternal 
substance use in 
the intervention 
groups was
0.06 higher
(0.12 lower to 0.24 
higher)
71
(1 study)
⊕⊕
LOW3,4
Winhusen 2008  
(N = 200) 
measured 
proportion of 
positive urines 
in months 1 and 
3. There were 
no statistically 
significant 
differences 
between the MI 
and TAU groups.
Infant birthweight – 
not reported
See comment See comment Not 
estimable
See comment
Infant gestational 
age at delivery – not 
reported
See comment See comment Not 
estimable
See comment
Infant custody – not 
measured
See comment See comment Not 
estimable
See comment
Infant birth defects – 
not measured
See comment See comment Not 
estimable
See comment
Infant head 
circumference – not 
measured
See comment See comment Not 
estimable
See comment
MOTIVATIONAL INTERVIEWING COMPARED TO ANY CONTROL (TREATMENT-AS-USUAL OR EDUCATIONAL CONTROL) 
FOR PREGNANT OR POSTPARTUM WOMEN WITH PROBLEMATIC SUBSTANCE USE
Patient or population: Pregnant or postpartum women with problematic substance use
Settings: Outpatient in specialist substance use treatment programmes
Intervention: Motivational Interviewing 
Comparison: Any control (treatment-as-usual or educational control)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of Bias: Serious. Both trials were unblinded so the risk of performance bias is high. Attrition bias is also likely to be present due to the loss-to-follow-up.
2 Imprecision: Rated as Serious. The number of events is less than 300. 
3 Risk of Bias: Serious. The trial was unblinded so the risk of performance bias is high. Attrition bias is also likely to be present due to the differential loss-to-follow-
up between the groups.
4 Imprecision: Rated as Very Serious. The sample size is very small. 
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RISK OF BIAS IN EACH TRIAL INCLUDED IN THE THERAPEUTIC WORKPLACE COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Silverman 2001
FOREST PLOTS OF THERAPEUTIC WORKPLACE COMPARISON
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Control
Therapeutic 
Workplace versus 
Usual Care 
Treatment retention
Mean weeks of 
treatment
Follow-up: 24 weeks
The mean 
treatment 
retention in the 
intervention 
groups was
3.5 higher
(1.35 lower to 8.35 
higher)
40
(1 study)
⊕
VERY	LOW1,2
Maternal substance 
use
Urine-negative for 
opiates and cocaine
Follow-up: 24 weeks
See comment See comment 40
(1 study)
⊕
VERY	LOW1,3
There was a 
statistically 
significant 
difference 
favouring the 
Therapeutic 
Workplace group 
over Usual Care 
for urine-negative 
for opiates and 
cocaine
Birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Infant gestational 
age at delivery – not 
reported
See comment See comment Not 
estimable
— See comment
Infant custody – not 
measured
See comment See comment Not 
estimable
— See comment
Infant birth defects – 
not measured
See comment See comment Not 
estimable
— See comment
Infant head 
circumference – not 
measured
See comment See comment Not 
estimable
— See comment
THERAPEUTIC WORKPLACE VERSUS USUAL CARE FOR PREGNANT OR POSTPARTUM WOMEN WITH PROBLEMATIC 
SUBSTANCE USE
Patient or population: Pregnant women with problematic substance use
Settings: Specialist substance use treatment setting: Outpatient
Intervention: Therapeutic Workplace versus Usual Care
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of bias: Rated as Very Serious. There was no blinding which may introduce performance bias. Detection bias is less likely as the primary outcome was 
objectively measured: urine screens. The high rate of attrition across the study period and the differential between the groups resulted in a very serious risk of bias 
rating.
2 Imprecision: Rated as Very Serious. The confidence interval is very wide and the sample size is very small (N = 40).
3 Imprecision: Rated as Serious. The data is presented as a t test and 95% Confidence intervals (CI) are not reported so imprecision cannot be interpreted from the CI. 
The very small sample size of the participants (N = 40) indicates that imprecision is likely, despite this measurement being for 24 weeks of urine specimens per each 
participant.
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Evidence Profile 3: Detoxification or quitting programmes for alcohol and other 
substance dependence in pregnancy
Evidence question:
For pregnant women with alcohol or other substance dependence, do detoxification or quitting programmes 
result in better maternal, fetal or infant outcomes compared to treatment-as-usual, maintenance treatment (in 
the case of opioids), or other methods of detoxification? 
Study selection criteria for the systematic review:
Study design: RCTs
Population: Pregnant women with alcohol or other substance dependence.
Interventions: Detoxification, either inpatient or outpatient. 
Control: Non-detoxification, delayed detoxification, gradual detoxification, maintenance treatment (in the case 
of opioids), treatment-as-usual.
Outcomes: The following outcomes were selected by the guidelines group:
Ranking (0–9)
Maternal: Substance use 8.11
Maternal: Withdrawal 8.00
Maternal: Retention in substance use treatment 8.00
Infant: Neonatal Abstinence Syndrome 7.56
Infant: Gestational age at delivery 7.11
Infant: Birthweight 7.00
Infant: Spontaneous abortion 6.78
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EVIDENCE TO RECOMMENDATIONS TABLE
Detoxification or quitting programmes for alcohol and other substance dependence in pregnancy
There were no randomized clinical trials identified by the systematic literature search on this evidence profile, 
hence the GRADE profile is based on a narrative review of the literature. 
Summary of evidence
A withdrawal syndrome requiring pharmacological treatment in pregnancy can be said to occur for three substances: 
benzodiazepines, alcohol and opioids. The withdrawal syndrome associated with the cessation of other substances 
(such as psychostimulants) has not been considered severe enough to justify the routine use of psychotropic 
medication. For those pregnant women for whom medication-assisted withdrawal is successful, there does not appear 
to be any evidence of fetal distress during detoxification, no increased risk of fetal demise or premature delivery 
(Dashe et al., 1998). However, the nature and extent of withdrawal of the fetus from opioids or other substances is 
largely unknown, because there have been no methods developed to measure such withdrawal directly, and there is 
insufficient information available to distinguish the effects of fetal withdrawal from fetotoxicity. 
 
Benzodiazepines
Medication-assisted withdrawal for benzodiazepines typically consists of a gradual withdrawal regimen with the goal 
of having the women benzodiazepine-free at the time of delivery, or later in the postpartum period. Withdrawal from 
benzodiazepines has typically been managed by transfer to a long-acting benzodiazepine (e.g. diazepam) followed by 
a gradual dose reduction, with the goal of being benzodiazepine-free at birth, or earlier if possible, without provoking 
significant withdrawal symptoms for the pregnant women. There are no reliable data regarding the relative success 
or failure of such an approach in pregnant women, although the general belief is that relapse to use is common, 
particularly if the taper is too fast or too short.
Alcohol
Medication-assisted withdrawal for alcohol use in pregnant women typically uses a benzodiazepine, often diazepam, 
as primary pharmacotherapy. There are no reliable data related to outcome following detoxification during the 
different trimesters.
Opioids
Medication-assisted withdrawal from opioids typically involves tapered doses of methadone over a period of 3 to 14 
days. Withdrawal from opioids is typically managed by tapered doses of methadone. The safety profile of methadone 
is well known but both conflicting and incomplete. Methadone maintenance pharmacotherapy has been found 
superior	to	detoxification	in	terms	of	treatment	retention	and	heroin	use	(Mattick,	Breen,	Kimber,	&	Davoli,	2009).	
During pregnancy, methadone-maintenance pharmacotherapy has been found superior to detoxification for treatment 
retention, attending more obstetrical visits, and more often delivering at the program hospital (Jones et al., 2008).
Although there are considerable data regarding the failure of medication-assisted withdrawal for opioids, there are 
few data specific to trimester.
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EVIDENCE TO RECOMMENDATIONS TABLE
Benefits and harms
Benefits •	 Pregnancy	presents	a	unique	opportunity	to	support	women	to	reduce	and	ideally	cease	
alcohol and/or illicit substance use (Chang et al., 1992)
•	 Depending	on	the	substance	of	use,	medication-assisted	withdrawal	that results in continued 
non-use of substances following medication-assisted withdrawal is considered to be superior 
to usual care in terms of:
– reduction in harmful consumption
– reduction in risk to the fetus
– increase in birthweight
– improved general health of pregnant women
– improved maternal psychological well-being
– less risk of fetotoxicity
– improved perinatal outcomes (e.g. reduction in preterm births, increased overall 
birthweights, reduction in number of low-birthweight infants
– reductions in congenital defects or anomalies noting that: a meta-analysis by Enato et al. 
(2011) suggests that benzodiazepines are unrelated to an increased risk of major congenital 
abnormalities. However, research on the longer-term effects of benzodiazepines on the child 
exposed to benzodiazepines is largely lacking.
•	 Improved	general	health	of	pregnant	women
•	 Improved	maternal	psychological	well-being
•	 Shorter	hospitalizations,	lower	peak	neonatal	abstinence	syndrome	scores,	and	less	likelihood	
of withdrawal treatment for neonates of mothers who had successfully completed medication-
assisted withdrawal than for neonates of mothers who had been unsuccessful (Stewart, 2013) 
•	 Medication-assisted	withdrawal	has	been	associated	with	a	significantly	lower	mean	
NAS peak score, a significantly lower mean amount of morphine to treat NAS, significantly 
fewer days medicated for NAS, significantly fewer number of days in the hospital relative to 
methadone, and significantly lower mean amount of morphine to treat NAS and significantly 
fewer days medicated for NAS than buprenorphine (Lund et al., 2012) 
Harms •	 The	success	of	medication-assisted	withdrawal	during	pregnancy	is	generally	considered	to	
be poor, with estimates of failure as low as 41% (Dashe et al., 1998) and as high as 96% (e.g., 
Luty et al., 2003). Failure rate is difficult to estimate precisely, because some authors have 
defined failure as failure to complete detoxification, while others have defined failure as return 
to substance use. This failure is associated with a number of negative outcomes, including 
increased fetal exposure to illicit substances and other maternal risk behaviors, reduced 
compliance with obstetrical care, and poorer neonatal birth parameters (Jones et al., 2008; 
summarized	in	Kaltenbach	et	al.,	1998).	
•	 High	risk	of	relapse	to	opioids	following	opioid	detoxification	(see	above)	
•	 High	risk	of	relapse	to	benzodiazepines	following	detoxification
•	 Often	stressful	short-term	symptoms	associated	with	reduction	or	cessation	of	alcohol	or	
substance use 
•	 Little	development	of	coping	skills
•	 Increased	risk	of	fetal	stress	(depending	on	the	substance)
•	 Increased	risk	of	fetal	morbidity	or	mortality,	including	miscarriage	and	stillbirth
•	 Possible	development	of	depression	or	anxiety	as	a	result	of	cessation	or	reduction	of	alcohol	
or illicit substance use
•	 Possible	risk	of	switching	from	one	substance	to	another	substance
•	 Damage	to	relationships/loss	of	employment
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EVIDENCE TO RECOMMENDATIONS TABLE
Values and preferences
In favour: 
Pregnant woman
Health-care 
worker
Community
•	 Increased	personal	contact	and	support
•	 Opportunity	to	be	substance	free
•	 Belief	that	it	will	lead	to	a	healthier	baby
•	 Belief	in	positive	response	from	family/society
•	 Opportunity	to	intervene	and	assist	with	achievement	of	substance-free	status
•	 Opportunity	to	support	health	of	fetus
•	 Possible	reduction	of	crime	in	the	community
•	 Possible	reduction	of	STI	risk	in	the	community
•	 Possible	positive	responses	from	some	health-care	providers,	partners,	family	and	co-workers
Against:
Pregnant woman
Health-care 
worker
Community
•	 Fear	of	stigmatization	for	needing	detoxification	or	for	refusing	detoxification	in	favour	of	
maintenance medication treatments (being seen as ‘weak-willed’)
•	 Dislike	approach,	sense	of	coercion
•	 Fear	of	negative	responses	from	partners,	family	and	co-workers
•	 Resent	time	and	resources	used	
•	 Do	not	believe	treatment	is	appropriate	or	effective
•	 Resent	resources	spent	on	detoxification	programmes
•	 Partner/family/employer	may	resent	time	and	commitment	to	detoxification
Costs and feasibility
Costs •	 Trained	staff	and	sustainable	detoxification	programme	required
•	 Financial	implications	for	woman-care	of	other	children,	time	lost	from	work	
Feasibility 
(including 
economic 
consequences)
•	 Inconvenient	for	women	
•	 Likely	to	fail	any	other	goal	beyond	being	drug-free	at	the	completion	of	detoxification
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Draft recommendations: 
 o Pregnant women dependent on alcohol, amphetamine type stimulants, cocaine, cannabis, volatile agents, 
(everything except opioids and benzodiazepines), should be advised and encouraged to cease their alcohol 
or other substance use, and provided with the opportunity to do so in a safe and supportive manner, both 
for the health of the pregnant woman and to reduce the possibility of damage to the fetus.
 o Pregnant women dependent on opioids should be advised to use opioid-agonist maintenance treatment 
(such as methadone or buprenorphine) rather than to attempt opioid detoxification.
 o Pregnant patients with benzodiazepine-use disorder should be transferred to a long-acting benzodiazepine 
(e.g., diazepam) and undergo a gradual dose reduction, with the goal of being benzodiazepine-free at birth, 
if possible. Psychosocial treatment should serve as an integral component of any dose-reduction strategy.
 o Pregnant women who wish to undergo detoxification should be invited to withdraw from substance use in 
an inpatient or hospital facility to increase the chances of successful completion of substance withdrawal 
and to monitor the health of the fetus. 
 o The health of the fetus should be monitored during detoxification by fetal heart monitoring, and by the 
monitoring of fetal movements. If there are signs of fetal distress associated with the detoxification, then 
medication should be used to reduce the severity of withdrawal and the process of withdrawal should be 
slowed or temporarily halted.
 o Withdrawal symptoms from the cessation of alcohol consumption should be managed with a long-acting 
benzodiazepine, titrated to the severity of withdrawal.
 o Psychotropic medication should not be routinely used in pregnant women to assist detoxification from 
stimulants (including cocaine), cannabis and volatile agents, but should be reserved for specific symptoms 
which emerge.
 o Given the high risk of relapse in opioid dependence, detoxification from opioids should be advised only 
for carefully selected patients. Such pregnant women who make an informed choice to cease opioid use 
should be supported to do so either with gradual tapering of opioids in an ambulatory treatment setting or 
with more rapid tapering in a residential treatment facility.
Final recommendations: 
RECOMMENDATION 
Health-care providers should, at the earliest opportunity, advise pregnant women dependent on alcohol or drugs 
to cease their alcohol or drug use and offer, or refer to, detoxification services under medical supervision where 
necessary and applicable. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Pregnant	women	dependent	on	alcohol	or	drugs	who	agree	to	undergo	detoxification	should	be	offered	the	
supported withdrawal from substance use in an inpatient or hospital facility, if medically indicated. 
•	 Detoxification	can	be	undertaken	at	any	stage	in	pregnancy,	but	at	no	stage	should	antagonists	(such	as	naloxone,	
or naltrexone – in the case of opioid withdrawal) be used to accelerate the detoxification process. 
•	 Equal	attention	should	be	paid	to	the	health	of	mother	and	fetus	during	detoxification	and	treatment	adjusted	
accordingly.
•	 The	exceptions	to	this	recommendation	are	opioid	and	benzodiazepine	dependence,	which	are	covered	by	
recommendations 5 and 6 separately. 
•	 It	was	decided	that	this	recommendation	should	be	strong,	despite	the	very	low	quality	of	evidence	of	the	
effectiveness of the health-care intervention because there is clear evidence of harm to the fetus of ongoing 
maternal substance use, and the benefit to both mother and fetus of ceasing alcohol and/or substance use under 
medical supervision strongly outweighs any potential harms. 
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RECOMMENDATION 
Pregnant women dependent on opioids should be encouraged to use opioid maintenance treatment whenever 
available rather than to attempt opioid detoxification. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Opioid	maintenance	treatment	in	this	context	refers	to	either	methadone	maintenance	treatment	or	buprenorphine	
maintenance treatment.
•	 Pregnant	patients	with	opioid	dependence	who	wish	to	undergo	detoxification	should	be	advised	that	relapse	to	
opioid use is more likely following medication-assisted withdrawal than while undertaking opioid maintenance 
treatment.
•	 Such	medication-assisted	withdrawal	from	opioids	should	be	attempted	only	in	an	inpatient	unit,	using	a	gradual	
reduction in methadone or buprenorphine doses. Inpatient care should also be considered for the initiation and 
optimization of maintenance treatment.
•	 Psychosocial	treatment	should	be	an	integral	component	of	such	treatment.	
•	 Pregnant	women	who	fail	to	complete	medication-assisted	withdrawal	should	be	offered	opioid	agonist	
pharmacotherapy.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	low	quality	of	evidence	of	effectiveness	from	
randomized controlled trials, as the rate of relapse to opioid use following detoxification has been shown to be high 
and the risks of harm to both mother and fetus from failed detoxification are catastrophic compared to the very low 
risks of harm from opioid maintenance treatment. 
RECOMMENDATION 
Pregnant women with benzodiazepine dependence should undergo a gradual dose reduction, using long-acting 
benzodiazepines.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Long-acting	benzodiazepines	should	only	be	used	for	as	short	a	time	as	is	medically	feasible	in	managing	
benzodiazepine withdrawal.
•	 Psychosocial	interventions	should	be	offered	throughout	the	period	of	benzodiazepine	withdrawal.
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	benzodiazepine	
dependence.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	very	low	quality	of	evidence	of	effectiveness	
because ongoing benzodiazepine use in pregnancy is associated with significant risk of harm. At the same time, 
abrupt cessation of benzodiazepines can result in a severe withdrawal syndrome including seizures and psychosis. 
This leaves gradual reduction as the only practicable alternative. Significant clinical experience indicates that 
this approach is feasible and safe. Hence the GDG was in agreement that the benefits of gradual dose reduction 
outweigh the harms of both ongoing use and abrupt cessation.
RECOMMENDATION 
Pregnant women who develop withdrawal symptoms following the cessation of alcohol consumption should be 
managed with the short-term use of a long-acting benzodiazepine.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Management	of	alcohol	withdrawal	usually	also	includes	administration	of	thiamine.
•	 Alcohol	withdrawal	management	may	be	facilitated	by	the	use	of	an	alcohol	withdrawal	scale	such	as	the	CIWA-Ar.	
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	alcohol	dependence.
•	 Alcohol	withdrawal	can	be	a	severe	and	even	life-threatening	condition,	provoking	seizures	and	delirium.	Evidence	
from non-pregnant populations has demonstrated the effectiveness of long-acting benzodiazepines for preventing 
seizures and delirium in alcohol withdrawal. Given the severity of alcohol withdrawal, and the lack of significant 
harm from short-term benzodiazepine use, and the evidence supporting the use of benzodiazepines in the 
management of alcohol withdrawal in the general population, the GDG decided that this recommendation should be 
strong despite the low quality of evidence in pregnant women.
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RECOMMENDATION 
In withdrawal management for pregnant women with stimulant dependence, psychopharmacological medications 
may be useful to assist with symptoms of psychiatric disorders but are not routinely required. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Except	for	the	management	of	acute	intoxication,	withdrawal	management	in	amphetamine-type	stimulants	(ATS)	
dependence or cocaine dependence does not include psychopharmacological medications as a primary approach 
to treatment in pregnant patients. There is no evidence that medication-assisted withdrawal would benefit pregnant 
women with these respective disorders. 
•	 Inpatient	care	should	be	considered	in	the	withdrawal	management	of	pregnant	women	with	stimulant	dependence.
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	very	low	quality	of	evidence	because	the	
harms to mother and fetus of ongoing use of psychostimulants use have been shown to be high. The risks of 
providing short-term appropriate non-teratogenic medications for short-term management of psychologically 
distressing symptoms in pregnancy are very low. Therefore, the potential benefits of this approach strongly 
outweigh the harms of providing psychopharmacological treatment of symptoms, if required, during psychostimulant 
withdrawal.
Factors in considering the strength of the recommendations (recommendations 4–8): 
Research gaps
 o What type of benzodiazepine tapers work best for which types of patients?
 o What medications are the safest and most effective for mother and fetus being withdrawn from alcohol?
 o What intensity of fetal monitoring is needed to determine the relative safety of detoxification during 
pregnancy?
 o What are the best withdrawal-severity assessment tools to measure withdrawal in pregnant women?
 o What are the best ways to manage withdrawal from cocaine, marijuana, amphetamine, alcohol or volatile 
solvents in pregnant women?
Factor Decision
Is there high or moderate quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation. 
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty 
that the costs of the resources being consumed outweigh any benefit gained?
Yes
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Evidence profile 4: Pharmacological treatment (maintenance and relapse 
prevention) for alcohol and other substance dependence in pregnancy
Evidence question:
In pregnant women dependent on alcohol or other substances, does pharmacological treatment (either 
maintenance or relapse prevention) result in better maternal, fetal or infant outcomes than no pharmacological 
treatment or other pharmacological treatment?
Study selection criteria for the systematic review:
Study design: RCTs
Population: Pregnant women dependent on alcohol or other substances.
Interventions: Any pharmacotherapy used for agonist maintenance treatment (such as methadone or 
buprenorphine in opioid dependence) or relapse prevention treatment (such as naltrexone in opioid or alcohol 
dependence). 
Control: No pharmacotherapy or other pharmacotherapy.
Outcomes: The outcomes of interest were:
Ranking (0–9)
Maternal: Substance use 8.11
Maternal: Withdrawal Severity 8.00
Maternal: Retention in substance use treatment 8.00
Infant: Neonatal Abstinence Syndrome 7.56
Infant: Gestational age at delivery 7.11
Infant: Birthweight 7.00
Infant: Spontaneous abortion 6.78
EVIDENCE TO RECOMMENDATIONS TABLE
Pharmacological treatment (maintenance and relapse prevention) for alcohol and other substance dependence in 
pregnancy
Summary of evidence
•	 Siegfried	and	Clark	(2013)	have	performed	systematic	reviews	of	psychopharmacological	treatments:	methadone	
versus buprenorphine and a single study of methadone compared to slow-release morphine for pregnant 
women with substance use disorder. See GRADE tables and summary of findings tables (below) for full details. 
Pharmacotherapy has been shown to be successful in the treatment of opioid use disorder. Methadone and 
buprenorphine have similar efficacy. Methadone appears to result in better maternal retention in treatment. 
Buprenorphine is associated with a number of better neonatal outcomes including increased birthweight.
•	 Psychosocial	interventions	in	addition	to	pharmacotherapy	have	been	shown	to	be	superior	to	pharmacotherapy	
alone (Amato et al., 2011).
•	 There	was	no	evidence	found	on	the	use	of	medications	for	relapse	prevention	for	alcohol	dependence	in	
pregnancy (acamprosate, disulfiram, nalmefene, naltrexone).
•	 There	was	no	RCT	evidence	on	the	use	of	naltrexone	in	relapse	prevention	from	opioid	dependence	in	pregnancy.	
•	 There	was	no	evidence	found	on	the	use	of	benzodiazepine	maintenance	for	benzodiazepine	dependence	in	
pregnancy. 
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EVIDENCE TO RECOMMENDATIONS TABLE
Benefits and harms
Benefits •	 Pregnancy	presents	a	unique	opportunity	to	support	women	to	reduce	and	ideally	cease	
alcohol and/or illicit substance use
•	 Although	research	in	this	area	is	extremely	limited,	given	the	history	of	exclusion	of	women	
from pharmacotherapy trials, and depending on the substance of use, pharmacotherapeutic 
interventions (specifically opioid agonist treatment in opioid dependence) are thought to be 
superior to usual care (e.g., Rayburn & Bogenschutz, 2004) in terms of:
– reduction in harmful consumption
– reduction in risk to the fetus
– increase in birthweight
– increase in the detection of harmful use and referral to treatment
– improved general health of pregnant women
– improved maternal psychological well-being
– less risk of fetotoxicity
– improved perinatal outcomes (e.g., reduction in preterm births, increased overall 
birthweights, reduction in number of low-birthweight infants)
– reductions in congenital defects or anomalies
Harms •	 Unpleasant	side	effects	due	to	the	pharmacological	intervention	or	uncovered	withdrawal	from	
alcohol or substance use 
•	 Possible	development	of	depression	or	anxiety	as	a	result	of	cessation	or	reduction	of	alcohol	
or illicit substance use
•	 Methadone	and	buprenorphine	both	reduce	additional	opioid	use	in	pregnancy,	but	the	neonate	
often develops a withdrawal syndrome referred to as neonatal abstinence syndrome (NAS) 
•	 Possible	risk	of	drug	substitution
•	 Increased	risk	of	fetotoxicity
•	 Possible	increased	risk	of	congenital	defects	and	anomalies	related	to	exposure	to	the	
pharmacological intervention (particularly for acamprosate, naltrexone, nalmefene, disulfiram, 
benzodiazepines) 
Values and preferences
In favour:
Pregnant woman
Health-care 
worker
Community
•	 May	value	increased	personal	contact	and	support
•	 May	value	positive	responses	from	partners,	family	and	co-workers
•	 May	value	stability	of	substance	supply
•	 May	value	increased	psychosocial	support
•	 May	value	opportunity	to	intervene
•	 May	value	opportunity	for	improved	monitoring	of	health	of	mother	and	child
•	 Partners/employers	may	value	increased	stability
•	 May	value	potential	for	reduced	crime/STI
Against: 
Pregnant woman
Health-care 
worker
Community
•	 Stigmatization	when	identified	as	drinking	alcohol	or	using	illicit	substances	during	pregnancy
•	 Stigmatization	for	being	in	need	of	drug	treatment
•	 Little	development	of	coping	strategies
•	 Little	commitment	to	behaviour	change
•	 Fear	of	negative	responses	from	partners,	family	and	co-workers
•	 Resentment	of	intensive	time	and	resources	required	for	treatment
•	 Ideological	objection	to	maintenance	treatment
•	 Anxiety	about	ability	to	manage	complex	interactions	with	substance	users
•	 Dislike	working	with	population	considered	difficult
•	 May	consider	resource	use	inappropriate
•	 Ideological	objection	to	maintenance	of	substance	use/or	failure	to	withdraw
•	 Employers/partners	/families	may	resent	extra	time	devoted	to	management	
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EVIDENCE TO RECOMMENDATIONS TABLE
Costs and feasibility
Costs •	 Potentially	substantial	additional	cost	beyond	costs	of	detoxification,	depending	on	the	
medication
•	 Trained	professional	staff	and	sustainable	programme	required
Feasibility 
(including 
economic 
consequences)
•	 Inconvenient	for	women,	particularly	maintenance	treatment	requiring	daily	dosing
•	 There	are	some	suggestions	in	the	literature	that	pregnant	and	postpartum	women	maintained	
on opioid agonists may have pain management needs different from those of non-opioid-
agonist-maintained women (Jones et al., 2009; Höflich et al., 2012)
•	 Requires	patient	monitoring	to	ensure	patient	continues	taking	her	medication
•	 A	comprehensive	care	model	in	which	pharmacotherapy	is	part	of	a	women-centred,	trauma-
informed programme would be the best model of care – and also the costliest
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Draft recommendations: 
 o Pharmacotherapy is not recommended for routine treatment of dependence on amphetamine-type 
stimulants, cannabis, cocaine, or volatile agents in pregnant patients
 o Medications for the treatment of alcohol dependence (acamprosate, naltrexone and disulfiram) should 
generally not be used in pregnancy).
 o Pregnant patients with benzodiazepine dependence should undergo a gradual taper. 
 o Pregnant patients with an opioid use disorder should be encouraged to commence opioid agonist 
pharmacotherapy with either methadone or buprenorphine, in preference to detoxification, or detoxification 
followed by naltrexone. 
Final recommendations: 
RECOMMENDATION 
Pharmacotherapy is not recommended for routine treatment of dependence on amphetamine-type stimulants, 
cannabis, cocaine or volatile agents in pregnant patients. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 For	pregnant	patients	who	use	cannabis,	amphetamine-type	stimulants,	cocaine,	and	volatile	agents,	the	focus	of	
treatment should be on psychosocial interventions.
•	 The	recommendation	was	considered	conditional	given	the	complete	lack	of	research	on	this	issue.	
RECOMMENDATION 
Given that the safety and efficacy of medications for the treatment of alcohol dependence has not been established in 
pregnancy, an individual risk benefit analysis should be conducted for each woman. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Pregnant	patients	with	alcohol	dependence	should	be	offered	psychosocial	interventions.
•	 The	recommendation	was	considered	conditional	given	the	complete	lack	of	research	on	this	issue.
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RECOMMENDATION 
Pregnant patients with opioid dependence should be advised to continue or commence opioid maintenance therapy 
with either methadone or buprenorphine. 
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Pregnant	patients	with	opioid	dependence	should	be	encouraged	to	commence	opioid	agonist	pharmacotherapy,	
which should be combined with psychosocial interventions.
•	 Opioid-dependent	pregnant	women	who	are	already	taking	opioid	maintenance	therapy	with	methadone	should	
not be advised to switch to buprenorphine due to the risk of opioid withdrawal. Pregnant opioid-dependent women 
taking buprenorphine should not be advised to switch to methadone unless they are not responding well to their 
current treatment.
•	 In	opioid-dependent	pregnant	women,	the	buprenorphine	mono	formulation	should	be	used	in	preference	to	the	
buprenorphine/naloxone formulation. 
•	 Regardless	of	the	choice	of	medication,	psychosocial	interventions	should	be	an	integral	component	of	treatment.
•	 Opioid-dependent	pregnant	patients	who	wish	to	receive	opioid	antagonist	pharmacotherapy	should	be	discouraged	
from such a choice. 
•	 It	was	decided	that	this	recommendation	should	be	strong	despite	the	low	quality	of	evidence	as	the	rate	of	relapse	
to opioid use following detoxification is high and the risks of harm from failed detoxification are catastrophic 
compared to the small risks of harm from opioid maintenance treatment.
Factors in considering the strength of the recommendations (recommendations 9–11): 
Factor
Recommendations 
9 & 10
Recommendation 
11
Is there high or moderate quality evidence?
The higher the quality of evidence, the more likely is a strong 
recommendation. 
No No
Is there certainty about the balance of benefits versus harms and 
burdens? 
In case of positive recommendations (a recommendation to do 
something), do the benefits outweigh harms? 
In case of negative recommendations (a recommendation not to do 
something), do the harms outweigh benefits?
No Yes
Are the expected values and preferences clearly in favour of the 
recommendation? Yes Yes
Is there certainty about the balance between benefits and 
resources being consumed?
In case of positive recommendations (recommending to do 
something) is there certainty that the benefits are worth the costs of 
the resources being consumed? 
In case of negative recommendations (recommending not to do 
something) is there certainty that the costs of the resources being 
consumed outweigh any benefit gained?
Yes Yes
Research recommendations
 o A potential case registry of pregnancies exposed to different substances, including psychotropic medication 
used for the treatment of substance use disorders in pregnancy, which can help explore the potential risks 
and benefits of pharmacotherapy in substance use disorders in pregnancy.
 o The optimal treatment with methadone and buprenorphine in pregnancy (including further dose/response 
studies).
 o Safety of pharmacotherapy for alcohol dependence in pregnancy.
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ca
re
. N
eo
na
te
s 
w
er
e 
ho
sp
ita
liz
ed
 fo
r a
 
m
in
im
um
 o
f 4
 d
ay
s 
an
d 
as
se
ss
ed
 fo
r N
A
S 
fo
r a
t 
le
as
t 1
0 
da
ys
.
B
ef
or
e 
ra
nd
om
iz
at
io
n,
 a
ll 
pa
rt
ic
ip
an
ts
 re
ce
iv
ed
 ra
pi
d-
re
le
as
e 
m
or
ph
in
e 
su
lfa
te
 a
s 
in
pa
tie
nt
s 
to
 a
ch
ie
ve
 m
ed
ic
al
 s
ta
bi
liz
at
io
n 
an
d 
to
 e
as
e 
th
e 
tr
an
si
tio
n 
to
 th
e 
do
ub
le
-b
lin
d 
m
ed
ic
at
io
n.
 
A
 b
lin
de
d 
in
di
vi
du
al
is
ed
 d
os
in
g 
sc
he
du
le
 w
as
 u
se
d 
to
 im
pl
em
en
t d
os
e-
un
it 
in
cr
ea
se
s 
or
 
de
cr
ea
se
s 
w
ith
 d
os
e 
ad
ju
st
m
en
ts
 o
f 2
m
g 
fo
r b
up
re
no
rp
hi
ne
 a
nd
 5
 o
r 1
0 
m
g 
fo
r m
et
ha
do
ne
. 
D
os
e 
ad
ju
st
m
en
ts
 w
er
e 
ba
se
d 
on
 c
lin
ic
al
 d
ec
is
io
ns
, p
ar
tic
ip
an
t r
eq
ue
st
, u
rin
e 
to
xi
co
lo
gy
 a
nd
 
se
lf-
re
po
rt
ed
 w
ith
dr
aw
al
 s
ym
pt
om
s.
B
up
re
no
rp
hi
ne
: D
ai
ly
 s
ev
en
 ta
bl
et
s 
(th
re
e 
in
 th
e 
si
ze
 o
f a
n 
8-
m
g 
ta
bl
et
 a
nd
 fo
ur
 in
 th
e 
si
ze
 
of
 a
 2
-m
g 
ta
bl
et
) t
o 
pl
ac
e 
un
de
r t
he
 to
ng
ue
 fo
r 5
 m
in
ut
es
, o
r u
nt
il 
th
e 
ta
bl
et
s 
di
ss
ol
ve
d.
 
Ea
ch
 ta
bl
et
 c
on
ta
in
ed
 b
up
re
no
rp
hi
ne
 o
r p
la
ce
bo
. A
 fl
ex
ib
le
 d
os
e 
ra
ng
e 
of
 2
 to
 3
2 
m
g 
of
 
bu
pr
en
or
ph
in
e 
in
 s
ub
lin
gu
al
 ta
bl
et
s 
w
as
 e
st
im
at
ed
 to
 b
e 
eq
ui
va
le
nt
 to
 2
0 
to
 1
40
 m
g 
of
 
m
et
ha
do
ne
 o
n 
th
e 
ba
si
s 
of
 p
re
vi
ou
sl
y 
pu
bl
is
he
d 
da
ta
 fr
om
 c
lin
ic
al
 tr
ia
ls
. A
fte
r r
ec
ei
vi
ng
 th
es
e 
ta
bl
et
s,
 p
ar
tic
ip
an
ts
 re
ce
iv
ed
 li
qu
id
 c
on
ta
in
in
g 
m
et
ha
do
ne
 p
la
ce
bo
. O
ra
l m
et
ha
do
ne
 p
la
ce
bo
 
w
as
 g
iv
en
 in
 th
e 
sa
m
e 
fix
ed
 v
ol
um
e 
an
d 
in
cl
ud
ed
 th
e 
sa
m
e 
fla
vo
ur
-m
as
ki
ng
 c
on
ce
nt
ra
te
s 
as
 
th
e 
ac
tiv
e 
dr
ug
 c
on
ce
nt
ra
te
.
M
et
ha
do
ne
: D
ai
ly
 s
ev
en
 ta
bl
et
s 
of
 p
la
ce
bo
 b
up
re
no
rp
hi
ne
 fo
llo
w
ed
 b
y 
m
et
ha
do
ne
 d
os
e 
in
 
liq
ui
d 
pr
ep
ar
at
io
n 
di
lu
te
d 
to
 p
ro
vi
de
 th
e 
do
se
 in
 a
 fi
xe
d 
vo
lu
m
e 
(e
.g
., 
40
 m
l a
t U
.S
. s
ite
s 
an
d 
50
 
m
l i
n 
Vi
en
na
). 
Co
-i
nt
er
ve
nt
io
ns
: M
on
et
ar
y 
vo
uc
he
rs
 in
 e
xc
ha
ng
e 
fo
r p
ro
vi
di
ng
 u
rin
e 
sa
m
pl
es
 th
at
 w
er
e 
ne
ga
tiv
e 
fo
r o
pi
oi
ds
 (o
th
er
 th
an
 b
up
re
no
rp
hi
ne
 a
nd
 m
et
ha
do
ne
), 
ot
he
r i
lli
ci
t d
ru
gs
, a
nd
 
m
is
us
e 
of
 p
re
sc
rip
tio
n 
m
ed
ic
at
io
ns
.
IN
FA
N
T:
•	
N
um
be
r	o
f	n
eo
na
te
s	
re
qu
iri
ng
 tr
ea
tm
en
t 
fo
r N
A
S
•	
Pe
ak
	N
AS
	s
co
re
•	
To
ta
l	a
m
ou
nt
	o
f	
m
or
ph
in
e 
ne
ed
ed
 fo
r 
N
A
S 
tr
ea
tm
en
t
•	
Le
ng
th
	o
f	h
os
pi
ta
l	
st
ay
•	
He
ad
	c
irc
um
fe
re
nc
e
RC
T 
– 
Ra
nd
om
ize
d 
co
nt
ro
lle
d 
tri
al
R 
– 
N
um
be
r r
an
do
m
ize
d
A 
– 
N
um
be
r a
na
ly
se
d
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RISK OF BIAS IN EACH TRIAL INCLUDED IN THE METHADONE VS BUPRENORPHINE COMPARISON
FOREST PLOTS OF METHADONE VS BUPRENORPHINE COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Fischer 2006
Jones 2005
Jones 2010
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Methadone Buprenorphine
Maternal toxicology 
positive at delivery
Urine screening
145 per 1000 80 per 1000
(30 to 207)
RR 0.55 
(0.21 to 1.43)
149
(2 studies)
⊕⊕
LOW1,2
Jones 2010 
applied Poisson 
regression with 
OR = 0.5 (95% CI: 
0.1, 2.7). RevMan 
OR = 0.53 (95% 
CI: 0.17, 1.63). 
Meta-analysis 
was deemed 
appropriate.
Maternal 
withdrawal
Wang Withdrawal 
Scale
See comment See comment Not 
estimable
0
(2 studies)
⊕
VERY	LOW3,4
Jones 2005 
reported no 
difference (F 
0.67(df 1,16); p = 
0.426); Fischer 
2006 provided 
overall sample 
means but 
reported no 
differences 
between groups 
in text
Maternal retention in 
substance treatment 
– Retention in trial 
(proxy measure) 
Follow-up: 14–? 
weeks
796 per 1000 653 per 1000
(565 to 757)
RR 0.82 
(0.71 to 0.95)
223
(3 studies)
⊕⊕⊕
MODERATE5,6
Birthweight The mean 
birthweight in 
the intervention 
groups was
321.85 higher
(30.81 to 612.88 
higher)
164
(3 studies)
⊕⊕
LOW5,7
Premature delivery 
before week 37 
Intention to treat 
(ITT) analysis
230 per 1000 74 per 1000
(37 to 150)
RR 0.32 
(0.16 to 0.65)
223
(3 studies)
⊕⊕
LOW5,7
Jones 2010 
applied Poisson 
regression with 
OR = 0.3 (95% CI: 
0.1, 2.0). RevMan 
OR = 0.32 (95% CI: 
0.12, 0.85). Meta-
analysis using 
ITT was deemed 
appropriate.
Neonatal Abstinence 
Syndrome requiring 
treatment Intention 
to treat (ITT) analysis
540 per 1000 464 per 1000
(286 to 756)
RR 0.86 
(0.53 to 1.4)
223
(3 studies)
⊕⊕
LOW2,5
Jones 2010 
applied Poisson 
regression with 
OR = 0.7 (95% CI: 
0.2, 1.8). RevMan 
OR = 0.83 (95% CI: 
0.62, 1.11). Meta-
analysis using 
ITT was deemed 
appropriate.
BUPRENORPHINE COMPARED TO METHADONE FOR MATERNAL SUBSTANCE DEPENDENCE
Patient or population: Maternal substance dependence
Settings: Residential and clinic-based
Intervention: Buprenorphine 
Comparison: Methadone 
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of Bias: Both trials (Jones 2005 and Jones 2010) were well-conducted with appropriate randomization and blinding. However, the high rate of attrition in Jones 
2010 and the magnitude of the differential between the groups (18% in methadone and 33% in the buprenorphine groups) results in the overall risk of bias rated as 
serious
2 Imprecision: The event rate is low and the confidence interval is wide.
3 Risk of Bias: Attrition was high and poses a serious risk of bias. 
4 Imprecision: Two trial reported withdrawal data (Jones 2005 and Fischer 2006). Trial samples sizes were very small (18 in each trial) and there is a high likelihood of 
imprecision in the results although confidence intervals are not reported for the estimates. 
5 Risk of Bias: All three trials were well-conducted but attrition was high in all three trials. In the larger trial (Jones 2010) the magnitude of the differential attrition 
between the groups (18% in methadone and 33% in the buprenorphine groups) results in the overall risk of bias rated as serious.
6 Indirectness: Retention in the trial was deemed a suitable proxy measure for retention in substance use treatment. The evidence was not downgraded for 
indirectness.
7 Imprecision: The confidence interval is wide and the sample size is less than 400 (GRADE guideline for assessing continuous data)
8 Imprecision: Event rate was very low and the confidence interval was wide.
9 Imprecision: Event rate is very low and the confidence interval is very wide.
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Methadone Buprenorphine
Spontaneous 
abortion
27 per 1000 0 per 1000
(0 to 0)
Not 
estimable
223
(3 studies)
⊕
VERY	LOW5,9
There were zero 
events in the 
buprenorphine 
group and 3 
events in the 
methadone group.
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1  
Ri
sk
 o
f B
ia
s:
 B
ot
h 
tri
al
s 
(J
on
es
 2
00
5 
an
d 
Jo
ne
s 
20
10
) w
er
e 
w
el
l-c
on
du
ct
ed
 w
ith
 a
pp
ro
pr
ia
te
 ra
nd
om
iza
tio
n 
an
d 
bl
in
di
ng
. H
ow
ev
er
, t
he
 h
ig
h 
ra
te
 o
f a
ttr
iti
on
 in
 J
on
es
 2
01
0 
an
d 
th
e 
m
ag
ni
tu
de
 o
f t
he
 d
iff
er
en
tia
l b
et
w
ee
n 
th
e 
gr
ou
ps
 (1
8%
 in
 m
et
ha
do
ne
 
an
d 
33
%
 in
 th
e 
bu
pr
en
or
ph
in
e 
gr
ou
ps
) r
es
ul
ts
 in
 th
e 
ov
er
al
l r
is
k 
of
 b
ia
s 
ra
te
d 
as
 s
er
io
us
2  
Im
pr
ec
is
io
n:
 T
he
 e
ve
nt
 ra
te
 is
 lo
w
 a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
3  
Ri
sk
 o
f B
ia
s:
 A
ttr
iti
on
 w
as
 h
ig
h 
an
d 
po
se
s 
a 
se
rio
us
 ri
sk
 o
f b
ia
s.
 
4  
Im
pr
ec
is
io
n:
 T
w
o 
tri
al
 re
po
rte
d 
w
ith
dr
aw
al
 d
at
a 
(J
on
es
 2
00
5 
an
d 
Fi
sc
he
r 2
00
6)
. T
ria
l s
am
pl
es
 s
ize
s 
w
er
e 
ve
ry
 s
m
al
l (
18
 in
 e
ac
h 
tri
al
) a
nd
 th
er
e 
is
 a
 h
ig
h 
lik
el
ih
oo
d 
of
 im
pr
ec
is
io
n 
in
 th
e 
re
su
lts
 a
lth
ou
gh
 c
on
fid
en
ce
 in
te
rv
al
s 
ar
e 
no
t r
ep
or
te
d 
fo
r t
he
 
es
tim
at
es
. 
5  
Ri
sk
 o
f B
ia
s:
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ll 
th
re
e 
tri
al
s 
w
er
e 
w
el
l-c
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du
ct
ed
 b
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ttr
iti
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ig
h 
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 a
ll 
th
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tri
al
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 d
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 m
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) r
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l r
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 b
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di
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 d
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m
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 d
ow
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r i
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FOREST PLOTS OF METHDAONE VS MORPHINE COMPARISON
RISK OF BIAS IN EACH TRIAL INCLUDED IN THE METHADONE VS MORPHINE COMPARISON
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Fischer 1999
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Slow-release 
Morphine Methadone
Maternal substance 
use 
Proxy measure 
for opiate use is 
identification of 
injection sites
208 per 1000 500 per 1000
(208 to 1000)
RR 2.4 
(1 to 5.77)
48
(1 study)
⊕
VERY	LOW1,2,3
Statistically 
significantly 
fewer 
benzodiazepines 
were consumed 
by women in the 
morphine group 
compared with 
the methadone 
group. Cocaine 
use was low for 
both.
Maternal 
withdrawal –
not reported
See comment See comment Not 
estimable
— See comment
Maternal retention 
in treatment – Proxy 
measure of retention 
in trial
1000 per 1000 1000 per 1000
(920 to 1000)
RR 1 
(0.92 to 1.08)
48
(1 study)
⊕⊕
LOW1,4
No women were 
lost from the trial.
Infant birthweight in 
grammes
The mean infant 
birthweight in 
the intervention 
groups was
123.54 higher
(187.58 lower to 
434.66 higher)
48
(1 study)
See comment
Infant prematurity
Estimated 
gestational age at 
delivery in weeks
The mean infant 
prematurity in 
the intervention 
groups was
1.13 higher
(0.11 lower to 2.37 
higher)
48
(1 study)
⊕⊕
LOW1,5,6
Methadone group 
EGA at delivery 
range 36–42 wks 
and Morphine 
EGA at delivery 
range 31–41 wks. 
N of premature 
delivery was not 
reported.
Neonatal Abstinence 
Syndrome (NAS) 
Mean duration of 
NAS in days
The mean neonatal 
abstinence 
syndrome (nas) in 
the intervention 
groups was
5 lower
(11.2 lower to 1.2 
higher)
48
(1 study)
⊕⊕
LOW1,7
No reported 
statistical 
differences 
between groups 
for consumption 
of phenobarbitone 
or intensity 
of NAS. N for 
numbers with 
NAS in each 
group was not 
reported.
METHADONE COMPARED TO SLOW-RELEASE MORPHINE FOR PREGNANT OR POSTPARTUM WOMEN WITH OPIATE 
DEPENDENCE
Patient or population: Pregnant or postpartum women with opiate dependence
Settings: Outpatient in specialist substance use treatment setting
Intervention: Methadone 
Comparison: Slow-release Morphine 
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Slow-release 
Morphine Methadone
Spontaneous 
abortion
See comment See comment Not 
estimable
48
(1 study)
⊕⊕
LOW1,6
No women 
experienced a 
spontaneous 
abortion in the 
trial
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Risk of Bias: Rated as Serious. Lack of reporting results in the randomization process being marked as unclear. The lack of blinding is a high risk due to the possible 
presence of performance and detection bias.
2 Indirectness: Rated as Serious. Illicit opiate use could not be determined by urinalysis so identification of injection sites served as a proxy measure.
3 Imprecision: Rated as Serious. The event rate is low and the confidence interval is wide.
4 Indirectness: The proxy measure of retention in the trial is used to indicate treatment retention. The report states that women participated actively in the treatment 
programme but no comparison between groups is provided.
5 Indirectness: The number of premature births was not reported. The range of EGA indicates that there were some premature < 37 week births.
6 Imprecision: Rated as Serious: There is a likelihood of imprecision due to the small overall sample size.
7 Imprecision: Rated as Serious: The confidence interval is wide.
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Evidence profile 5: Breastfeeding
Evidence question:
In the management of postpartum women using alcohol or drugs or with substance use disorders, does 
encouraging breastfeeding result in better maternal or infant outcomes than not encouraging breastfeeding, 
discouraging breastfeeding (recommending breast milk substitutes), or recommending intermittent use of 
breast milk substitutes following periods of substance use?
Study selection criteria for the systematic review:
Study design: RCTs
Population: Postpartum women using alcohol or drugs or with substance use disorders.
Interventions: Encouraging breastfeeding. 
Control: Not encouraging breastfeeding (treatment-as-usual), discouraging breastfeeding (recommending 
breast milk substitutes), or recommending short-term use of breast milk substitutes for periodic substance use.
Outcomes: The following outcomes were of interest:
BREASTFEEDING (exclusive or mixed) compared with FORMULA FEEDING for infants of 
postpartum women who are using psychoactive substances Importance (0–9)
Infant: Weight gain 7.78
Infant: Attachment 7.56
Infant: Failure to thrive 7.44
Infant: Neurobehaviour (lethargy, sedation, irritability) 7.44
Infant: Neonatal Abstinence Syndrome 7.22
Infant: Infections 7.11
Infant: Feeding issues 7.00
Maternal: Bonding with child 6.89
Maternal: Substance use 6.33
Maternal: Well-being 6.22
Infant: Death 6.00
Maternal: Mastitis 5.11
Termination of maternal rights (e.g. baby taken into care) 4.11
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Breastfeeding with maternal alcohol and/or other substance dependence
There were no randomized controlled trials identified for this evidence profile. The evidence summary is based on a 
narrative review of the evidence.
Summary of evidence (see the longer narrative review of evidence following this table)
•	 Enhanced	maternal-infant	attachment	through	breastfeeding	(Luijk	et	al.,	2012)	is	especially	important,	particularly	
for women feeling guilty about their prenatal drug use and those with lack of self-confidence in parenting skills. 
•	 Breastfeeding	and/or	breast	milk	may	reduce	the	incidence	and/or	severity	of	neonatal	abstinence	syndrome	in	
opioid exposed infants (McQueen et al., 2012).
•	 Evidence	of	decreased	stress	response	(Mezzacappa	et	al.,	2005)	and	increased	vagal	tone,	indicating	better	
autonomic regulation, in lactating versus non-lactating women is salient for drug dependent women. Stress can 
be a major factor in the development of psychiatric symptoms, and has been linked to relapse to substance abuse 
(Sinha, et al. 2007) and maternal dysregulation of the stress and reward systems is associated with drug seeking and 
neglectful parenting behaviors (Rutherford et al., 2011).
•	 For	alcohol,	binge	alcohol,	tobacco	and	marijuana	use,	rates	rebound	substantially	in	the	postpartum	period	
compared with use during pregnancy (National Survey on Drug Use and Health, combined data from 2002-2007). 
Depression correlates with substance use, and new mothers with postpartum depression may be at high risk for 
substance use or return to substance use (Chapman & Wu, 2013).
•	 The	mother’s	decision	to	breastfeed	does	not	necessarily	reflect	a	lifestyle	that	would	preclude	toxic	exposures	in	
her offspring (Frank et al., 1992). Chronic drug use can lead to altered maternal ability to respond appropriately to 
infant cues. 
•	 Maternal	psychopathology	is	more	common	in	substance	dependent	women	than	in	the	general	population	
(Fitzsimons et al., 2007) and is not infrequently related to poor judgment, enhancing the physical risk to the breastfed 
infant. Maternal somnolence, lack of adequate sleep-wake cycling, or decreased reaction times due to psychiatric 
medication, more sedation from methadone during the postpartum period or drug use may additionally result in 
infant injury. Substance users tend to minimize risks and have less self-control and disregard for own and other’s 
safety in situations that can be risky for the breastfed infant, further enhancing possibility of harm.
•	 The	breastfed	infant	necessarily	accompanies	his	mother	and	requires	attention	more	frequently.	For	women	
who are medically or psychiatrically unstable, have continued drug use, or live in environments that are unsafe or 
chaotic, this translates to increased infant exposures to violence, maternal drug seeking/drug trade, or maternal 
prostitution. Due to brain changes that are associated with drug use, drug dependent women often view normal 
infant cues as stressful instead of rewarding (Rutherford et al., 2011).
•	 Women	who	are	regular	cocaine	or	amphetamines/methamphetamines	users	and	unstable	should	be	advised	
against breastfeeding. Mothers who use these stimulants infrequently may be candidates for breastfeeding, 
provided that they express and throw away the milk after using, have a supplementary feeding plan in place, and 
do not breastfeed for 24 hours after use. Mothers need to be advised that these substances have been found in the 
breast milk, and has been shown to cause toxicity in the infant.
•	 There	is	insufficient	information	regard	breastfeeding	during	marijuana	use,	although	it	has	been	found	in	breast	
milk. Its effects on the infant are unknown. 
Benefits and harms
Benefits •	 Pregnancy	and	the	immediate	postpartum	period	represents	an	ideal	time	for	mother-child	
bonding and breastfeeding may increase this bonding
•	 Breastfeeding	represents	the	single	best	way	for	a	mother	to	feed	her	child
•	 Breastfeeding	is	likely	to	lead	to	better	short-	and	long-term	child	development	outcomes
•	 Breastfeeding	may	serve	as	a	protective	factor	from	many	illnesses
•	 Breastfeeding	may	help	protect	babies	from	developing	allergies
•	 Breastfeeding	may	boost	a	child's	intelligence
•	 Breastfeeding	may	protect	a	child	from	obesity
•	 Breastfeeding	may	lower	a	baby's	risk	of	SIDS
•	 Breastfeeding	can	reduce	maternal	stress	level	and	risk	of	postpartum	depression
•	 Breastfeeding	is	less	costly,	more	hygienic	and	easier	to	deliver	than	other	feeding	methods
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Harms •	 Potential	higher	risk	of	difficulties	bonding	due	to	neonatal	withdrawal	symptoms
•	 Short	and	long	term	risks	of	the	child	being	exposed	via	breast	milk	to	varying	amounts	of	
substances consumed by the mother. These risks depend on the substance consumed by the 
mother, with little data available for several substances (e.g., hallucinogens, volatile agents). 
The most harmful exposures are alcohol (>50gms in one occasion)
•	 Risk	that	a	mother	who	is	using	sedative	substances	may	inadvertently	suffocate	the	child
•	 Greater	risk	exposure	of	breastfed	child	to	chaotic	lifestyle	harms	such	as	violence,	maternal	
drug seeking/ prostitution.
•	 Maternal	psychopathology	may	enhance	risk	to	breast	fed	child	
Values and preferences
In favour:
Mother
Health-care 
worker
Community
•	 More	convenient,	less	costly	means	of	feeding	child
•	 Value	support	from	HCW	for	breastfeeding	
•	 Value	breastfeeding	for	reduction	in	gastrointestinal	and	other	childhood	infectious	disease
•	 Value	breastfeeding	for	potential	to	reduce	NAS
•	 Value	breastfeeding	as	optimal	means	of	child	nutrition
•	 Value	breast	feeding	as	means	of	superior	child	development
•	 Possible	positive	responses	from	partners,	family	and	co-workers
Against: 
Mother
Health-care 
worker
Community
•	 Fatigue,	irritability,	poor	bonding	may	make	breastfeeding	undesirable	
•	 Lifestyle-need	to	seek	drugs/engage	in	prostitution	may	make	breastfeeding	undesirable
•	 Physical	effects	–	painful	enlarged	breasts,	poor	lactation	–	may	make	breast	feeding	
undesirable to mother
•	 May	believe	breastfeeding	will	harm	infant
•	 May	believe	mother	is	incapable	of	breastfeeding
•	 May	believe	mother	is	likely	to	smother	infant
•	 May	find	time	and	commitment	needed	to	support	mother	burdensome
•	 May	believe	infant	is	at	risk	from	mother’s	substance	use
•	 Partners/family/employers	may	believe	breast	feeding	is	inappropriate	and	actively	oppose	it	
Costs and feasibility
Feasibility 
(including 
economic 
consequences)
•	 Managing	breastfeeding	in	women	who	use	alcohol	requires	support,	trust	and	clear	advice:	
e.g. women who use alcohol should be discouraged from breastfeeding for 2 hours after 
consuming one drink, and 4 to 8 hours after consuming more than one drink in a single sitting.
•	 The	availability	of	safe	and	affordable	breast	milk	substitutes,	including	access	to	clean	water,	
sterilizing equipment, the affordability of breast milk substitutes and the age of the infant/child 
needs to be considered and balanced against risks of breastfeeding. 
•	 Breastfeeding	itself	imposes	little	additional	cost	beyond	providing	basic	services	to	the	
mother and child. However, trained staff and a sustainable programme is needed to support 
breastfeeding and bonding and teach and support mother with care of the infant.
•	 A	comprehensive	care	model	in	which	there	is	a	focus	on	the	mother-infant	dyad	and	is	part	of	
a women-centred, trauma-informed programme would be the best model of care – and also the 
costliest.
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Draft recommendations: 
 o The decision to breastfeed should take into account the specifics risks of and benefits breastfeeding 
compared to alternatives in each case. In most instances, the benefits will outweigh the risks of 
breastfeeding and in this situation women with substance use disorders should be encouraged to breastfeed 
with appropriate support and precautions. 
 o Skin-to-skin contact is important regardless of feeding choice and needs to be actively encouraged for the 
mother who is fully conscious and aware and able to respond to her baby’s needs.
 o Mothers who are stably maintained on opioid agonist medication, either methadone or buprenorphine, 
should be encouraged to breastfeed. Strength of recommendation.
 o Mothers who are stably maintained on opioid antagonist medication, such as naltrexone, should be 
discouraged from breastfeeding because naltrexone does pass into breastmilk, and naltrexone has been 
shown to cause tumors in animal studies.
Final recommendations:
 
RECOMMENDATION 
A. Mothers with substance use disorders should be encouraged to breastfeed unless the risks clearly outweigh the 
benefits.
B. Breastfeeding women using alcohol or drugs should be advised and supported to cease alcohol or drug use; 
however, substance use is not necessarily a contraindication to breastfeeding.
Strength of recommendation: Conditional      Quality of evidence: Low
Remarks:
•	 A	risk	assessment	should	take	into	account	the	risks	of	exposure	to	alcohol	and	drugs	in	breast	milk,	HIV	status,	the	
specific pattern of substance use in each case, the availability of safe and affordable breast milk substitutes, as well 
as access to clean water, sterilizing equipment, and the age of the infant/child. Heavy daily alcohol consumption, 
such as in alcohol dependence, would constitute high risk to the infant, for example, and in the presence of safe 
breast milk alternatives, it would be preferable not to breastfeed. 
•	 The	message	to	breastfeeding	women	who	have	used	alcohol	and	drugs,	to	cease	using	alcohol	and	drugs	while	
breastfeeding should be given in such a way that it does not undermine the potential benefits of breastfeeding. 
•	 It	is	possible	to	reduce	the	risk	of	exposure	through	breastfeeding	by	altering	the	timing	of	breastfeeding,	or	by	the	
use of temporary alternatives, such as stored (frozen) breast milk or breast milk substitutes where they are available 
and can be safely used. Women who use alcohol intermittently should be discouraged from breastfeeding for 2 
hours after consuming one standard drink (10 g of pure alcohol), and 4 to 8 hours after consuming more than one 
drink in a single occasion. Breastfeeding advice for women with HIV should also take into consideration the risk of 
HIV transmission (refer to WHO guidelines on breastfeeding and HIV). 
•	 Mothers	of	infants	with	a	neonatal	withdrawal	syndrome	should	be	offered	appropriate	breastfeeding	information	
and support.
•	 This	recommendation	was	considered	conditional	because	the	different	values	and	preferences	of	women	and	the	
lack of strong evidence of harms of low levels of substance use in pregnancy.
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RECOMMENDATION 
Skin-to-skin contact is important regardless of feeding choice and needs to be actively encouraged for the mother 
with substance use disorder who is able to respond to her baby’s needs. 
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 It	was	decided	that	the	recommendation	should	be	strong	despite	the	very	low	quality	evidence	as	the	risk	of	harm	
is minimal, it consumes no resources, the values and preferences were in favour of the recommendation, and there 
was considered to be certainty about the balance between benefits and harms.
RECOMMENDATION 
Mothers who are stable on opioid maintenance treatment with either methadone or buprenorphine, should be 
encouraged to breastfeed unless the risks clearly outweigh the benefits.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Women	prescribed	opioids	such	as	methadone	and	buprenorphine	and	wishing	to	stop	breastfeeding	should	wean	
their children off breast milk gradually to reduce the risk of developing withdrawal symptoms.
•	 It	was	decided	that	the	recommendation	should	be	strong,	as,	despite	the	low	quality	of	evidence	of	effect,	it	was	
considered highly likely that the benefit of avoiding withdrawal symptoms in the infant strongly outweighed any 
potential harms. The values and preferences expressed by end-users surveyed were strongly in favour of the 
recommendation and there was certainty about the balance between benefits and resources being consumed.
Factors in considering the strength of the recommendations (recommendations 12–14):
 
Factor Decision
Is there high or moderate quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation. 
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty 
that the costs of the resources being consumed outweigh any benefit gained?
Yes
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Breastfeeding and substance use/misuse: A review of the evidence and estimates of risks 
associated with individual substances
Lauren M. Jansson
Illicit substance abuse and licit substance misuse remain a significant problem among women of childbearing 
age. The 2007 National Survey on Drug Use and Health (NSDUH) revealed that among pregnant women aged 
15 to 44 years, 5.2 percent used illicit drugs in the past month in the US. Although the prevalence of prescribed 
opioid pain relievers/narcotic analgesics, such a hydrocodone and oxycodone, among pregnant women is not 
well known, there is growing evidence that misuse of opioid pain relievers/narcotic analgesics is increasing 
internationally (RADARs system report 2012; Maxwell & McCance-Katz, 2009). In the US, the incidence of NAS 
and maternal opiate use has tripled between 2000 and 2009 (Patrick et al., 2012). Adolescents are a particular 
concern; in 2010-11, among young pregnant women between 15 and 17 years the rate of illicit drug use was 
20.9% and smoking rates are higher in pregnant vs non-pregnant teens in this group (NIDA). Other substance 
use during pregnancy is also of significant concern throughout the world: In Barcelona, 11% of meconium 
tested was positive for drugs of abuse in a random survey of 175 newborns (Concheiro et al., 2012); 14% of 
Canadian women report alcohol use during their last pregnancy in 2005 (Health Canada, 2005), and worldwide, 
the incidence on fetal alcohol syndrome is 1:2000 live births (Sachdeva et.al., 2009).
Breast milk is well-known as optimal nutrition for the newborn. There are myriad other recognized benefits from 
breast milk and lactation that are likely to provide a particular benefit to the drug dependent dyad who are, in 
general, at higher risk for many acute and chronic physical and psychological conditions. These include reduced 
infections in the neonate, a diminution of certain chronic health conditions in later life, such as Types I and II 
diabetes and obesity, and improved cognition and brain development (Isaacs et al., 2010). Breastfeeding is an 
analgesic for newborns (Gray, et al., 2002) and there is some evidence that breast milk and/or breastfeeding 
can ameliorate the incidence or severity of neonatal abstinence syndrome (NAS, or withdrawal, typically 
found in opioid exposed infants after delivery) (Welle-Strand et al., 2013, McQueen, 2011). Mothers also have 
significant health benefits, such as reduced incidence of breast and ovarian cancer, decreased stress response 
(Mezzacappa et al., 2005) and increased vagal tone, indicating better autonomic regulation, in lactating vs non-
lactating women. This may be a particularly salient benefit for drug dependent women, as stress can be a major 
factor in the development of psychiatric symptoms, and has been linked to relapse to substance abuse (Sinha, 
et al. 2007) and maternal dysregulation of the stress and reward systems is associated with drug seeking and 
neglectful parenting behaviors (Rutherford et al., 2011). Enhanced maternal-infant attachment (Luijk et al., 
2012) may be another especially important benefit, particularly for women who may harbor guilt in regards to 
their prenatal drug use and lack of self-confidence in parenting skills. 
Despite the significant and specific benefits of breast milk and breastfeeding for the substance exposed dyad, 
when considering lactation among this high risk population, there must necessarily be a discussion regarding 
the risk: benefit ratio of this practice, and several risk factors must be considered. These factors stem from: 1) 
maternal functioning, 2) infant functioning, and 3) toxicities associated with the substance(s) used. 
1. The Substance Dependent Mother
Substance dependent women may have health or other conditions that can increase the risk to the breast fed 
infant. These include HIV or other infections, poor nutrition, and psychiatric disorders that require psychotropic 
medications with known toxicity. Research has indicated that the mother’s decision to breastfeed does not 
necessarily reflect a lifestyle including drug abstinence that would preclude toxic exposures in her offspring 
(Frank et al., 1992). Drug dependent women frequently use more than one substance (illicit and/or licit), 
and the incidence of concurrent alcohol use and cigarette smoking is high. Exposure to alcohol or drugs can 
significantly impair the mother’s judgment and ability to care for the baby, and for chronic drug users, repetitive 
exposures increase this risk and lead to brain changes that enhance this risk. For women who are able to achieve 
abstinence during pregnancy, relapse to substance use after delivery is a significant concern. For alcohol, binge 
alcohol, tobacco and marijuana use, rates rebound substantially in the postpartum period compared with use 
during pregnancy (National Survey on Drug Use and Health, combined data from 2002-2007). Some women 
relapse on substances that are not usually detected in the urine toxicology tests that are part of the regular 
screening for drug use in treatment programs or hospitals (e.g. clonidine, some benzodiazepines). In most 
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societies, pregnant and parenting drug dependent women are usually under considerable social pressure to 
deny substance use, making detection of perinatal substance dependence both important and problematic. 
Depression correlates with substance use, and new mothers with postpartum depression may be at high 
risk for substance use or return to substance use (Chapman & Wu, 2013). Additionally, substance using and/
or dependent women frequently display some behaviors or conditions that can be harmful for the breastfed 
infant independently or in addition to the drug exposure per se. Maternal psychopathology is more common 
in substance dependent women than in the general population (Fitzsimons et al., 2007) and is not infrequently 
related to poor judgment, enhancing the physical risk to the breastfed infant. Maternal somnolence, lack 
of adequate sleep-wake cycling, or decreased reaction times due to psychiatric medication, sedation from 
methadone during the postpartum period, or drug use may additionally result in infant injury. Substance users 
tend to minimize risks and have less self-control and disregard for own and other’s safety in situations that can 
be risky for the breastfed infant, further enhancing the possibility of harm to offspring.
2. The Substance exposed infant
The risks associated with substances in breast milk to the infant are also influenced by factors beyond what 
is known about the pharmacokinetics of the drug. Certain drugs may accumulate in the infant due to reduced 
clearance or immature metabolic pathways (AAP, 2013). Specific genotypes may provide increased vulnerability, 
such as those associated with ultra-rapid metabolism of codeine (Berlin, et al., 2009). The substance exposed 
infant, particularly the opioid exposed infant, may undergo NAS after birth, which can entail significant morbidity 
and prolonged pharmacotherapeutic treatment. Infants with NAS may be particularly difficult to breastfeed 
due to symptoms of the disorder, such as hypertonicity, suck-swallow incoordination, or other feeding 
difficulties (Jansson et.al., 2004), which can lead to failure to thrive for infants relying solely on breast milk for 
nutrition in addition to maternal frustration or feelings of guilt or inadequacy which can lead to depression or 
relapse. An important consideration is that the breastfed infant, as opposed to the infant receiving formula, 
necessarily accompanies his mother and requires attention more frequently. For women who are medically 
or psychiatrically unstable, have continued drug use, or live in environments that are unsafe and/or chaotic, 
this translates to increased infant exposures to harmful situations. Infants in these situations can be at risk for 
exposure to violence, maternal drug seeking/drug trade, or maternal prostitution. Due to brain changes that 
are associated with drug use, drug dependent women often view normal infant cues as stressful instead of 
rewarding (Rutherford et al., 2011), and this can additionally lead to situations of infant neglect and/or abuse.
3. Substances and breast milk/breastfeeding
Risks of breastfeeding in substance dependent women include direct toxicities of the substances transmitted 
into breast milk and ingested by the infant, as well as secondary exposures resulting in additional toxicities to 
the infant due to maternal substance use or the environment in which the substance dependent woman lives. 
Drugs with long half lives are more likely to accumulate in human milk, and drugs with high bioavailability are 
more easily absorbed by the infant (Hale, 2004). Illicit substances can be cut with dangerous and unknown 
adulterants. Vaporized substances can provide a secondary exposure to the infant; for example, there are 
over 450 compounds in THC smoke, many of which are toxic; 6 to 53% of ∆9-THC is released into the air 
during smoking by side stream (Huestis et al., 1992). For women living in poor environments, as many drug 
dependent women are, additional environmental exposures such as heavy metals, insecticides, inhaled aromatic 
hydrocarbons, etc. should be considered (Erlin & van den Anker, 2012). 
There exists sparse literature on the subject of substances of abuse and transmission into breast milk in total, 
as this research is, in general, fraught with ethical and practical dilemmas, and is additionally difficult to perform. 
There is a near absence of literature on long term effects of exposures via breast milk. Most clinical trials in 
this arena explore the issues of lactation and medications used to treat opioid dependence. The large majority 
of literature in the area of illicit substance use and lactation consists primarily of case reports. All suffer from 
small numbers. While any discussion of individual substances of abuse is somewhat artificial in this population 
of women due to the high prevalence of poly-substance use, individual substances and toxicities related to 
infant exposures via breast milk are considered below. Estimates of risk for each substance are included, but it 
is important to note that most are largely author opinion based on a review and synthesis of available literature. 
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Cocaine: 
Both the parent drug and the metabolite are present in milk, and high concentrations are expected due to the 
chemical nature of cocaine (Bailey, 1998), which can result in significant exposures (Winecker et al., 2001). 
There is considerable variability in the concentrations of cocaine reported in breast milk, and cocaine is not 
consistently detected in the breast milk of known users, so analysis of breast milk is not a sensitive method 
of exposure. For a 4 kg infant feeding every 3 hours, the blood concentration of cocaine can reach 200ng/mL 
comparable to an adult blood cocaine concentration measured after administration of 1.5 mg/kg intranasal 
or 16 mg IV dose of cocaine (Winecker et al., 2001). Newborns are particularly sensitive to cocaine because 
metabolism of cocaine to benzoylecgonine, its principal metabolite, is delayed due to immaturity of the 
cholinesterase system. Intoxication in the breastfed infant of the intranasal cocaine using mother has been 
reported (Chasnoff et al., 1987) as has intoxication in an infant whose mother used cocaine for nipple soreness 
(Chaney et al., 1988). Guidelines have been developed for the lactating cocaine occasionally using woman 
(Sarkar et al., 2005). A 24-hour period of breastfeeding abstinence has been recommended for women who 
occasionally use cocaine (Cressman, 2012).
Estimate of risk: Due to the immaturity of the newborn’s ability to metabolize cocaine ingested via breast milk, 
high concentrations are possible, and reported intoxications, risks of lactation in chronically cocaine using, or 
cocaine dependent, women are significant. It is likely that the risks associated with lactation in heavy or chronic 
cocaine users outweigh benefit when safe alternatives to breastfeeding are available. In non dependent or 
intermittent users the risk is lower, and can be further reduced by a 24-hours cessation in breastfeeding (when 
safe and affordable alternatives to breastfeeding are available). 
Methamphetamine:
Methamphetamine undergoes demethylation to amphetamine which is the active metabolite. Amphetamines 
often contain other substances with unpredictable effects. Amphetamines are concentrated in breast milk 
and 2.8 to 7.5 times maternal plasma (ACOG, 2011) and infant symptoms, including irritability and agitation 
(AAP, 2001) and infant death (Ariagno et al., 1995) have been reported. In one study, two women taking street 
methamphetamine (doses unknown) intravenously had drug levels measures in plasma and breast milk. 
Calculated infant doses were 16.7 and 42.2 mcg/kg/day of methamphetamine and 0.8 and 2.5 mcg/kg/day of 
amphetamine (Bartu, et al., 2009), which are less that therapeutic doses of equipotent dextroamphetamine 
for older children with ADHD. 
Estimate of risk: Accurate information regarding the safety of methamphetamine abuse/misuse is unavailable. 
Marijuana:
∆9-THC is the main compound in marijuana, and it is very fat soluble, and it persists in the body fat of users 
and can be released over long periods of time depending on extent of use. There are many compounds, most 
toxic, in ∆9-THC smoke. It appears that active components of marijuana are excreted into breast milk in small 
quantities. There is some concern about marijuana’s effect of neurotransmitters, CNS development and endo-
cannabinoid functions in the infant exposed via breast milk (Fernandez-Ruiz, et.al., 2004; Schuel, et.al.,2002). 
∆9-THC is concentrated to a milk/plasma ratio of 8 in breast milk in heavy users, secreted into breast milk and 
absorbed and metabolized by the infant (THC metabolites are found in infant feces) (Perez-Reyes & Wall, 
1982). In one feeding the infant could ingest 0.8% of the weight adjusted maternal intake of one joint (Bennett, 
1997). Marijuana exposure via breast milk in the first month of infant life was associated with decreased motor 
development, but not growth or intellectual development, at one year (Astley & Little, 1990), and infant effects, 
such as sedation, growth delay (Hale & Hartman, 2006) low tone and poor sucking (Liston, 1998) have been 
described. Two studies (Astley & Little, 1990; Tennes, et.al., 1985) found that occasional marijuana use during 
breastfeeding did not have any discernable effects on breastfed infants. However, because an important phase 
of brain growth occurs in the period just after birth, THC could theoretically alter brain cell metabolism (Garry et 
al., 2009) and hence development. Among chronic THC users, 50% report “impaired control over their use”, 
and THC use itself is associated with a wide range of psychiatric conditions (Hall & Degenhardt, 2004), which 
implies an additional risk to the breastfed infant of the THC using mother. 
Estimate of risk: Due to the potentially high concentrations of THC in breast milk of chronic/heavy users and 
toxicities present in smoke, the potential for altered development in exposed infants, and frequently altered 
sensorium of heavily using mothers, there is a significant risk. It is likely that the risks associated with lactation 
in heavy or chronic THC users outweigh benefit when safe alternatives to breastfeeding are available. However, 
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small amounts of available literature regarding light or occasional use point to little effect on the infant. It may 
be, in the case of light or infrequent maternal THC use, that the benefits of breast milk/breastfeeding, with 
appropriate supports for infant care during period of maternal use, may outweigh risk in certain circumstances. 
In cases of heavy cannabis use the risk is greater and it may be safer not to breastfeed when safe and affordable 
alternatives are available. 
Benzodiazepines:
The medications are frequently prescribed to drug dependent women, and also frequently abused/misused. 
Based on relatively small numbers, adverse event rates of 0–50% have been reported for various agents (17% 
alprazolam, 22% diazepam, and 50% clonazepam). These events include lethargy, irritability, poor weight gain 
and apnea. No adverse events have been reported for other agents (oxazepam, lorazepam, or temazepam) 
(Rubin et al., 2004). When used as an adjunctive medication, there exists the potential for drug-drug interactions 
and increased risk for CNS depression (for example, the opioid analgesic morphine and anxiolytic diazepam when 
taken together potentiate CNS depression) but use alone may present minimal risk. In one study among 124 
benzodiazepine prescribed women, adverse outcomes, specifically sedation, was reported in 1.6% of infants. 
Benzodiazepine use in the postpartum period that is prescribed is usually compatible with breastfeeding (Kelly 
et al., 2012). 
Estimate of risk: While it has been found that prescribed benzodiazepine use is usually compatible with 
lactation, there is no available literature on benzodiazepine abuse/misuse and breastfeeding. Particularly in 
women who are polydrug dependent, where the potential exists for drug synergy to produce untoward effects 
in the infant, the risks are significant and it would appear that the risk of lactation in this population would 
outweigh benefit, when safe alternatives to breastfeeding are available.
Alcohol:
There are many international beliefs that alcohol (particularly beer) intake improves breastfeeding success 
(Koletzka & Lehner, 2000) and that alcohol will increase milk yield and relax both the mother and the infant 
(Menella, 2002). Despite these beliefs, the opposite is true. Alcohol blocks the release of oxytocin, resulting 
in decreased milk yield and milk ejection reflex (Bowen & Tumbach, 2011). Alcohol exposure via breast milk 
can alter the infant’s milk intake by decreased milk production and increased infant sucking, which may be 
compensatory (Giglia et al., 2006). Animal research has found that alcohol changes the structure of the mammary 
gland in rats, leading to impaired mammary gland function during the first few days of lactation (Steven et al., 
1989). Early cessation of breastfeeding has been associated with a high frequency of alcohol consumption 
during lactation, even after controlling for confounders (Howard & Lawrence, 1998). Animal models have 
demonstrated diminished infant growth (Detering et al., 1979; Hekmatpanah et al., 1994; Vilaro et al., 1985). 
Alcohol enters breast milk by passive diffusion and reflects maternal blood levels within 30-60 minutes after 
ingestion (Lawton, 1985, Kesaniemi, 1974, Mennella & Beauchamp, 1993); for heavy drinkers, alcohol levels 
are higher in breast milk than in blood (Lawton et al., 1985). The infant brain is extremely sensitive to alcohol 
even in small quantities, and the small quantities ingested during lactation are accumulated in the infant because 
it is metabolized and excreted more slowly than in adults (Little et al., 1989). Alterations in infant sleep-wake 
cycles (Menella & Gerrish, 1998), development (Little et al., 1990), and infant growth (Backstrand et al., 2004) 
have been reported. There has been reported a strong inverse linear relationship between chronic exposure of 
ethanol in breast milk and the psychomotor developmental index on the Bayley Scales of infant development 
at one year (Little et al., 1989). Alcohol intake by lactating mothers recommended as “safe” for non-lactating 
women may have a negative effect on infant development and behavior (Giglia et al., 2006). The Institute of 
Medicine National Academy of Sciences (1991) concluded that alcohol consumption by lactating women in 
excess of 0.5 g/kg of maternal weight may be harmful to the infant. The American Academy of Pediatrics 
advises breastfeeding mothers to avoid alcohol consumption in general (AAP, 2005).
Estimate of risk: Lower levels of alcohol use (i.e. 1 standard drink per day) are unlikely to cause significant short 
or long term problems in the nursing infant, especially if the mother waits 2 to 2.5 hours per drink before nursing, 
and the risks are likely to be less than not breastfeeding. Daily heavy use of alcohol (i.e. more than 2 drinks per 
day) may affect infants negatively and appears to be eliminated from breast milk more slowly and decrease the 
length of time that mothers breastfeed their infants, resulting in a significant risk. Chronically alcohol dependent 
women, or women who binge drink heavily represent a high risk to the infant, and breastfeeding is high risk 
and not recommended.
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Opioids:
The first reports of problems with maternal opioid use and nursing were in 1985, when 4 infants became apneic 
after breastfeeding from mothers prescribed codeine every 4-6 hours (Davis & Bhutan, 1985). For codeine, 
39 adverse events and 1 infant death (Koren et al., 2006) have been reported (Hendrickson et al., 2012). Infant 
toxicities may be related to a duplication of the CYP2D6 gene, causing mothers to be ultra-rapid metabolizers 
of codeine to morphine, leading to high plasma and milk levels (Madadi et al., 2009). Since there is no tangible 
method of assessing cytochrome phenotypes, codeine is not advised in nursing mothers. Other opioids may 
be equally unsafe. Twenty percent of oxycodone using mothers report neonatal CNS depression after breast 
feedings (Lam, 2012). One toddler death in a methadone misusing opioid naïve breastfeeding mother has 
been described (West et al., 2009). Heroin transfers into breast milk and is converted to morphine. Morphine, 
in acceptable doses and used in the short term for pain control, is safe for breastfeeding women (Wittels et 
al., 1990; Hendrickson et al., 2012), however, heroin using women frequently consume larger (or unknown) 
doses making this practice dangerous (D’Appolito, 2013).
In general, agents used for the treatment of opioid dependence are likely to be compatible with breastfeeding. 
Maternal methadone and buprenorphine maintenance in opioid dependent pregnant woman are associated 
with improved maternal and neonatal outcomes in the context of comprehensive drug treatment and prenatal 
care. Methadone is distributed into breast milk in low concentrations, there are low ratios of milk to plasma 
concentrations (~0.4) and calculated theoretic infant doses are low (0.038-0.0152 mg/day) (Jansson et al., 
2008; Bogen et al., 2011). Additionally, concentrations in infant plasma at two weeks of age are low (2.2 – 
8.1 ng/mL), making breastfeeding among stable and otherwise abstinent methadone maintained women 
recommended (Jansson et al., 2004) regardless of maternal methadone dose, as dose is unrelated to milk 
concentrations (Jansson et al., 2008). Reports on buprenorphine exposure via breast milk are somewhat limited. 
Buprenorphine is excreted into human milk and achieves a level similar to that in maternal plasma (Johnson, 
2001). Extant literature finds low concentrations and low calculated theoretic infant doses (Ilett et al., 2012, 
Lindemalm et al., 2009); in addition this agent is poorly bioavailable, making it likely that breastfeeding should 
be encouraged in otherwise abstinence, stable buprenorphine maintained women. It is unlikely that either 
agent, when delivered to the breastfeeding infant from a medically maintained mother, would be present in 
substantial amounts necessary to prevent or ameliorate neonatal abstinence syndrome. There is a single report 
of a naltrexone maintained woman with low concentrations of naltrexone in breast milk and low calculated 
infant dose. Naltrexone is concentrated in breast milk at a milk:plasma ratio of 1.9 (Chan et al., 2004).
Estimate of risk: Opioid dependent women using heroin or misusing prescription opioid containing medications 
in a way that results in cycles of intoxication and withdrawal are likely to present a significant risk to their 
breastfed infant, and therefore this practice is discouraged. Prescribed oxycodone for lactating women has 
also been found to be unsafe. Prescribed morphine for pain control in the postpartum period is low risk and 
compatible with lactation. Breastfeeding in methadone and buprenorphine maintained and otherwise abstinent 
women women is low risk should be encouraged if they meet other criteria. 
Guidelines for lactation in drug dependent women
Advising the substance using woman on breastfeeding can present a dilemma to the treating practitioner. A 
complete and thorough evaluation of the dyad in the perinatal period would consider several factors, including:
 o Maternal medical and psychiatric status
 o Maternal drug use and substance abuse treatment histories and medication requirements
 o Infant health status, to include neonatal abstinence syndrome display and features if evident that have 
impact on breastfeeding
 o Maternal family and community support systems
 o Maternal plans for postpartum health and psychiatric care, substance abuse treatment and pediatric care.
 o Access to and capacity to afford breastmilk substitutes, access to clean water and capacity to sterilize 
feeding equipment.
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Evidence profile 6: Management of infants exposed to alcohol and other 
psychoactive substances
Evidence question
Does the identification and treatment of neonates with disorders due to alcohol or drug exposure in utero result 
in better maternal, neonatal or infant outcomes, compared to treatment-as-usual or other forms of treatment 
of neonatal disorders due to alcohol or drug exposure in utero? 
Study selection criteria for the systematic review:
Study design: RCTs
Population: Neonates with disorders due to alcohol or drug exposure in utero such as neonatal substance 
withdrawal and fetal alcohol syndrome.
Interventions: Systematic methods of identification and treatment of disorders due to alcohol and drug 
exposure in utero, including medication for neonatal withdrawal. 
Control: Treatment-as-usual, non systematic identification, other treatments of disorders due to alcohol or 
drug exposure in utero.
Outcomes: The following outcomes were of interest:
Importance (0–9)
Infant: Death 8.22
Infant: Treatment failure 8.11
Infant: Seizures 8.11
Infant: Total length of hospital stay 7.78
Infant: Weight gain 7.78
Infant: Days to regain birthweight 7.67
Infant: Duration of withdrawal treatment 7.67
Infant: Attachment 6.44
Maternal: Bonding with child 6.44
Infant: Infections 5.89
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Identification and treatment of neonatal disorders due to exposure to alcohol or drugs in utero – including 
pharmacotherapy (opioids and/or barbiturates) and/or supportive treatment (swaddling, skin to skin care) for 
neonatal withdrawal
Summary of evidence
•	 Osborn	et	al.	(2013)	conducted	a	Cochrane	review	in	which	they	evaluated	(1)	the	contribution	of	opioids	in	
addition to supportive therapy; (2) opioids compared to phenobarbitone; (3) opioids compared to diazepam; (4) 
buprenorphine compared to an opium solution; (5) oral morphine compared to tincture of opium in the treatment of 
neonatal withdrawal/neonatal abstinence syndrome (NWS/NAS). See accompanying GRADE tables for evaluation 
of treatment effect against critical outcomes. The small size and risk of bias in the studies evaluated means the 
evidence of treatment effect is very uncertain. 
•	 Protocols	for	the	management	of	NAS	have	seen	significant	development	over	the	past	40+	years.	Initial	NAS	
treatment guidelines were weight-based, and tables for treatment with phenobarbital and paregoric were published 
(Finnegan et al., 1975). Current treatment follows similar practices. Either an opioid such as morphine sulfate or 
tincture of opium, or a sedative, typically phenobarbital, predominate, with infrequent use of a benzodiazepine. 
Score of a NAS measure such as the Finnegan is typically used to guide treatment initiation, maintenance, and 
weaning. Because there is neither a uniform assessment method to measure NAS nor an established treatment 
protocol, and health-care practices and costs worldwide are not uniform, it is difficult to state with any precision 
how NAS is treated across the globe. It is certainly the case that some countries, particularly post-Soviet nations, 
do not formally recognize NAS. Moreover, the availability of opioids as a treatment for NAS varies worldwide, further 
complicating the ability to make general statements regarding NAS treatment. Patrick and colleagues (Patrick et al., 
2012) found that, between 2000 and 2009, per 1,000 hospital live births, prenatal exposure to opioids increased from 
1.2 to 5.6 and the incidence of NAS increased from 1.2 to 3.4. Hospital charges for discharges with NAS increased 
more than 46% during this same 10-year period. 
•	 An	opiate	probably	confers	greater	benefit	than	either	phenobarbitone	or	diazepam	as	first-line	pharmacotherapy	
for NAS (Osborne et al., 2013). Buprenorphine may prove to be an effective alternative front-line pharmacotherapy 
for	NAS	(Kraft	et	al.,	2008).Buprenorphine	may	be	superior	to	methadone	in	the	reduction	in	NAS	severity	and	time	in	
treatment for NAS [Jones et al. (2005), Fischer et al. (2006), and Jones et al. (2010)].
•	 Jones	et	al.	(2012a,b)	reviewed	the	comparative	efficacy	studies	of	buprenorphine	versus	methadone.	Regardless	
of whether the study was a randomized controlled trial, prospective study, or case report, there is clear evidence 
that prenatal buprenorphine exposure is related to NAS, and that such NAS may be less frequent, less severe, and/
or of shorter duration. However, conclusions are limited in regard to NAS due to the fact that most studies fail to 
adequately define and/or measure NAS and/or specify a treatment protocol. 
•	 There	is	limited	experience	with	opioid	antagonists	in	pregnancy	outside	of	its	investigation	in	Australia	(Hulse	et	
al., 2000, 2001, 2003, 2004; Hulse & O’Neil, 2002). Rapid opioid detoxification using sedation followed by naltrexone, 
as well as oral and implantable formulations of naltrexone, has been investigated. In all cases, there have been 
no reports of adverse fetal effects, and neonatal birth parameters were within normal limits. However, maternal 
outcomes were not reported and relapse to maternal opioid use was evident. Neonatal outcomes following prenatal 
exposure to implanted naltrexone were within normal limits, with some suggestion of a lower risk of prematurity 
and a higher 1-minute Apgar scores in naltrexone than methadone-exposed neonates. The small samples sizes and 
limited focus on outcomes suggest caution in the interpretation of the results of these studies; however, findings do 
not indicate that prenatal naltrexone exposure results in an increased risk for poor neonatal outcomes.
•	 A	rooming-in	approach	may	help	reduce	the	need	for	NAS	pharmacotherapy,	NICU	admissions,	and	length	of	stay	
for term infants (Abrahams et al., 2007; Abrahams et al., 2010; Hodgson and Abrahams, 2012). Feeding on demand 
and	swaddling	may	be	sufficient	to	treat	mild	withdrawal	symptoms	(Kieviet	et	al.	(2012)).	
•	 Early	identification	of	Fetal	Alcohol	Syndrome	(FAS)	is	feasible	and	can	increase	the	uptake	of	early	intervention	
programmes for children with FAS and their families, enabling children with FAS to reach their full potential 
(Bertrand, Floyd & Weber, 2005).
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Benefits and harms
Benefits •	 Pregnancy	and	the	immediate	postpartum	period	represents	an	ideal	time	for	mother-child	
bonding, an opportunity to develop basic parenting skills.
•	 Considerable	research	(e.g.,	Hudak	&	Tan,	2012)	has	found	pharmacotherapy	for	NAS	yields	
these benefits:
– Less risk of seizures
– Less risk of neonatal morbidity and mortality
– Improved outcomes (e.g. weight gain, maternal bonding – provided mother and child are 
allowed to be together)
– Possible reduction in congenital anomalies
•	 In	non-opioid-agonist	maintained	postpartum	women,	immediate	and	uninterrupted	skin-to-
skin contact at birth, and rooming-in during the postpartum period is beneficial for establishing 
maternal-child bonding (Dumas 2013).
•	 Early	identification	of	Fetal	Alcohol	Syndrome	(FAS)	can	improve	the	chances	that	children	with	
FAS will reach their full potential.
Harms •	 Risk	of	adverse	neonatal	response	to	pharmacological	agent.	Buprenorphine	may	have	less	
adverse impact than methadone on fetal neurobehaviour (Jansson et al., 2012; Salisbury et al., 
2012). 
•	 Jones	et	al	(2010)	found	there	may	be	a	higher	incidence	of	non-serious	maternal	adverse	
events, particularly non-serious maternal cardiovascular events, associated with methadone 
than buprenorphine. They found no differences in between the two medications for neonatal 
adverse events. 
•	 Early	identification	of	Fetal	Alcohol	Syndrome	(FAS)	may	stigmatize	children	and	their	mothers.
Values and preferences
In favour:
Mother
Health-care 
worker
Community
•	 Value	care	to	support	health	of	baby
•	 Value	opportunity	to	have	baby	more	settled	after	withdrawal,	ultimately	easier	to	look	after
•	 Value	opportunity	to	bond	with,	and	learn	to	care,	for	baby
•	 Value	greater	chance	of	normal	neonatal	development
•	 Value	opportunity	to	intervene	in	care	of	compromised	neonate
•	 Value	opportunity	to	support	mother	with	bonding,	breastfeeding,	childcare
•	 Value	opportunity	to	monitor	health	of	fragile	neonate
•	 Value	better	neonatal	outcomes-healthier,	developmentally	normal	children
•	 Partners,	family	co-workers	value	chance	of	healthier,	developmentally	normal	baby
Against: 
Mother
Health-care 
worker
Community
•	 Stigmatization	as	person	who	‘made	her	baby	dependent	to	drugs	or	alcohol’
•	 Anxiety	about	negative	responses	from	partners,	family	and	co-workers
•	 Resent	longer	hospital	stay
•	 Resent	interference	by	hospital	staff	and	other	‘authorities’
•	 Resent	extra	time	and	resources	devoted	to	managing	mother	and	infant	with	NAS	
•	 Negative	view	of	mother’s	ability	to	care	for	child
•	 Community	may	have	punitive	view-may	demand	incarceration	of	mother	or	removal	of	child
•	 Community	may	consider	extra	resources	needed	to	manage	mother	and	child	wasteful	
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EVIDENCE TO RECOMMENDATIONS TABLE
Costs and feasibility
Feasibility 
(including 
economic 
consequences)
•	 Inconvenient	for	women	because	infant	may	need	an	extended	stay	in	the	hospital	and/or	
outpatient pharmacotherapy
•	 Potentially	substantial	additional	cost	beyond	no	treatment
•	 Trained	professional	staff	and	sustainable	programme	required
•	 Consistent	and	frequent	monitoring	of	child
•	 Requires	long	term	patient	monitoring	to	ensure	patient	continues	taking	her	medication
•	 A	comprehensive	care	model	in	which	pharmacotherapy	is	part	of	a	women-centred,	trauma-
informed program would be the best model of care – and also the costliest
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Draft recommendations: 
 o Infants of all opioid-dependent mothers should be monitored for NAS. 
 o Hospitals providing obstetrical care should have a protocol in place for identifying, assessing, monitoring 
and intervening using non-pharmacological and pharmacological methods for neonates prenatally exposed 
to opioids.
 o Pharmacological treatment of infants with NAS due to opioids should be initiated according to a validated 
NAS treatment protocol.
 o Non-pharmacological treatments including low lights, quiet environment, swaddling and skin to skin contact 
should be used with all prenatally opioid exposed neonates.
 o An opioid should be used as initial treatment for infants with NAS symptoms severe enough to need 
intervention due to opioid withdrawal. 
 o If there has been concurrent use of other drugs in pregnancy, particularly benzodiazepines, and symptoms 
of NAS are not adequately suppressed by an opioid alone, phenobarbitone may be indicated as an additional 
therapy. If opioids are unavailable, phenobarbitone may be used as an alternative therapy. 
 o If an infant has signs of NAS and reaches the treatment threshold and the drugs used by the mother are 
unknown, or are sedatives, or the infant was born to a mother intoxicated with alcohol, then phenobarbitone 
may be a preferable initial treatment.
 o Mothers of infants at risk of NAS should receive appropriate breastfeeding information and support, 
parenting support and assessment, and should be taught settling techniques. Women and their partners/ 
support persons should also receive information about safe sleeping practices, especially if using sedative 
substances.
Final recommendations:
 
RECOMMENDATION 
Health-care facilities providing obstetric care should have a protocol in place for identifying, assessing, monitoring 
and intervening, using non pharmacological and pharmacological methods, for neonates prenatally exposed to 
opioids.
Strength of recommendation: Strong      Quality of evidence: Low
Remarks:
•	 Evidence	of	a	dose-response	relationship	between	opioid	maintenance	treatment	and	neonatal	withdrawal	
syndrome has been inconsistent, which implies that all infants should be assessed. 
•	 Infants	exposed	to	opioids	during	pregnancy	should	remain	in	the	hospital	at	least	4-7	days	following	birth	and	
be monitored for neonatal withdrawal symptoms using a validated assessment instrument which should be first 
administered 2 hours after birth and then every 4 hours thereafter.
•	 Non-	pharmacological	interventions	including	low	lights,	quiet	environments	swaddling	and	skin	to	skin	contact	
should be used with all neonates prenatally exposed to alcohol and drugs.
•	 It	was	decided	that	the	recommendation	should	be	strong	despite	the	low	quality	of	evidence	of	effect,	as	the	
GDG agreed that the benefits of such an approach strongly outweighed any potential harms. The values and 
preferences of end-users were in favour of the recommendation and there was certainty that while resources would 
be consumed, the benefits strongly outweighed costs. There was a high value placed on identifying preventable 
suffering in affected neonates.
139
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
RECOMMENDATION 
If an infant has signs of a neonatal withdrawal syndrome due to withdrawal from sedatives, or alcohol, or the 
substance the infant was exposed to is unknown, then phenobarbital may be a preferable initial treatment option.
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Infants	with	signs	of	a	neonatal	withdrawal	syndrome	in	the	absence	of	known	maternal	opioid	use	should	be	fully	
assessed for possible benzodiazepine, sedative, or alcohol exposure.
•	 This	recommendation	was	considered	conditional	because	of	the	lack	of	high	quality	evidence	and	the	lack	of	
certainty of the balance between benefits and harms.
RECOMMENDATION 
An opioid should be used as initial treatment for an infant with neonatal opioid withdrawal syndrome if required.
Strength of recommendation: Strong      Quality of evidence: Very low
Remarks:
•	 Prolonged	treatment	of	neonatal	opioid	withdrawal	syndrome	with	opioids	is	generally	not	necessary	and	aiming	for	
shorter treatment is preferable. 
•	 Phenobarbital	can	be	considered	as	an	additional	therapy	if	there	has	been	concurrent	use	of	other	drugs	in	
pregnancy, particularly benzodiazepines, and if symptoms of neonatal opioid withdrawal are not adequately 
suppressed by an opioid alone. If opioids are unavailable, phenobarbital can be used as an alternative therapy.
•	 Infants	with	signs	of	a	neonatal	withdrawal	syndrome	in	the	absence	of	known	maternal	opioid	use	should	be	fully	
assessed for possible benzodiazepine, sedative, or alcohol exposure.
•	 The	strong	recommendation	to	use	opioids	rather	than	phenobarbital	despite	the	very	low	quality	of	evidence	of	
effectiveness was based on vast clinical experience with opioids in the management of both adult and neonatal 
opioid withdrawal. There has only been very limited clinical experience with phenobarbital use. In addition, the 
values and preferences of end-users were in favour of the recommendation and the GDG agreed that there was 
certainty about the balance between benefits and resources being consumed.
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RECOMMENDATION 
All infants born to women with alcohol use disorders should be assessed for signs of fetal alcohol syndrome. 
Strength of recommendation: Conditional      Quality of evidence: Very low
Remarks:
•	 Signs	of	fetal	alcohol	syndrome	(FAS)	include	growth	impairment,	dysmorphic	facial	features	(short	palpebral	
fissures, smooth or flattened philtrum, thin upper lip) and central nervous system abnormalities, including 
microcephaly. 
•	 When	assessing	such	infants	the	following	information	should	be	recorded:	
– birthweight and length
– head circumference
– dysmorphic facial features
– gestation
– prenatal exposure to alcohol
– follow-up of infants with signs of FAS should be provided
•	 This	recommendation	was	considered	conditional	because	of	the	lack	of	high	quality	evidence,	and	questions	about	
the faesibility of implementation in all settings.
Factors in considering the strength of the recommendations (recommendations 15–18): 
Factor 15 & 16 17 18
Is there high or moderate quality evidence?
The higher the quality of evidence, the more likely is a strong 
recommendation. 
No No No
Is there certainty about the balance of benefits versus harms and 
burdens? 
In case of positive recommendations (a recommendation to do 
something), do the benefits outweigh harms? 
In case of negative recommendations (a recommendation not to do 
something), do the harms outweigh benefits?
Yes No Yes
Are the expected values and preferences clearly in favour of the 
recommendation? Yes No Yes
Is there certainty about the balance between benefits and resources 
being consumed?
In case of positive recommendations (recommending to do 
something) is there certainty that the benefits are worth the costs of 
the resources being consumed? 
In case of negative recommendations (recommending not to do 
something) is there certainty that the costs of the resources being 
consumed outweigh any benefit gained?
Yes Yes No
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Supportive 
therapy 
Opiates and 
supportive therapy
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Finnegan score
118 per 1000 152 per 1000
(48 to 479)
RR 1.29 
(0.41 to 4.07)
80
(1 study)
⊕
VERY	LOW1,2,3
Supportive 
treatment 
included pacifier, 
swaddling, close 
wrapping, small 
frequent feeds, 
and close skin 
contact by sling 
or other methods.
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Total length of 
hospital stay
Days in hospital
The mean 
total length of 
hospital stay in 
the intervention 
groups was
15 higher
(8.86 to 21.14 
higher)
80
(1 study)
⊕
VERY	LOW1,2,4
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight
The mean days to 
regain birthweight 
in the intervention 
groups was
2.8 lower
(5.33 to 0.27 lower)
72
(1 study)
⊕
VERY	LOW1,2,5
Duration of 
treatment for NAS
Days
See comment The mean duration 
of treatment 
for nas in the 
intervention 
groups was
12.5 higher
(7.52 to 17.48 
higher)
Not 
estimable
80
(1 study)
⊕
VERY	LOW1,2,4
OPIATES AND SUPPORTIVE THERAPY COMPARED TO SUPPORTIVE THERAPY FOR OPIATE WITHDRAWAL IN 
NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Opiates and supportive therapy 
Comparison: Supportive therapy 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This is reported as a quasi-randomized trial which allocated participants to groups using the last number of the participant's hospital number. Both random 
generation and allocation concealment were judged to be inadequate and there is thus a high risk of selection bias. There was no blinding of providers or parents 
so performance bias may be present. Blinding was unreported for short-term outcomes and the risk of detection bias is unclear. Long-term outcomes were not 
measured.
2 Not applicable as results are from one study only.
3 The sample size is small and the event rate is extremely low so imprecision is highly likely in the results.
4 The sample size is small and the confidence interval is very wide. 
5 The sample size is small and the confidence interval is wide.
Summary of findings and GRADE tables
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Phenobarbitone Opiates
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
See footnote 1
279 per 1000 212 per 1000
(142 to 309)
RR 0.76 
(0.51 to 1.11)
302
(4 studies)
⊕⊕
LOW2,3,4
The meta-
analysis included 
both randomized 
(RCT) and quasi-
randomized 
controlled 
trials. GRADE 
assessment was 
done within the 
RCT study design.
Seizures 113 per 1000 9 per 1000
(0 to 163)
RR 0.08 
(0 to 1.44)
111
(1 study)
⊕⊕
LOW5,6,7
As this was a 
RCT, the GRADE 
assessment was 
done within the 
RCT study design 
category.
Total length of 
hospital stay
Days in hospital
The mean 
total length of 
hospital stay in 
the intervention 
groups was
2.54 lower
(7.06 lower to 1.98 
higher)
106
(2 studies)
⊕
VERY	LOW8,9
As this was a 
meta-analysis 
of two quasi-
trials, the GRADE 
assessment was 
done within the 
observational 
study design 
category.
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight
The mean days to 
regain birthweight 
in the intervention 
groups was
1.4 lower
(3.47 lower to 0.67 
higher)
71
(1 study)
⊕
VERY	LOW10,11
As this was 
a quasi-trial, 
the GRADE 
assessment was 
done within the 
observational 
study design 
category.
Duration of 
treatment for NAS
Days
The mean duration 
of treatment 
for nas in the 
intervention 
groups was
3.73 lower
(7.75 lower to 0.29 
higher)
106
(2 studies)
⊕
VERY	LOW8,9
As this was a 
meta-analysis 
of two quasi-
trials, the GRADE 
assessment was 
done within the 
observational 
study design 
category.
OPIATES COMPARED TO PHENOBARBITONE FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Opiates
Comparison: Phenobarbitone
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
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1 Treatment failure defined by review as failure to reduce a standardised score of NAS from a clinically significant level to a clinically 'safe' level defined by author of 
the trial, or the use of additional pharmacological treatments for control of NAS.
2 The meta-analysis combines results from two randomized controlled trials (Jackson 2004 and Madden 1977) and two quasi-randomized trials (Finnegan 1984 
and Khoo 1995). Random generation and allocation concealment were lacking in three of the four studies and there is thus a risk of selection bias. Blinding of 
participants and providers was only performed in one study so performance and measurement bias may be present in the other studies. In Jackson 2004, infants 
randomly allocated to phenobarbitone tended to have been exposed to benzodiazepines and other classes of drugs compared with those randomized to morphine. 
3 Statistical heterogeneity was not present (I squared = 0%). Some clinical heterogeneity may be present as drug types and doses differed but it was not downgraded 
for unexplained inconsistency. The opiates and dosages used in the four studies were: Finnegan 1984 - Paregoric, dose not reported; Jackson 2004 - Morphine 50 
microg/kg/dose four times a day with no titration; Khoo 1995 - Morphine 0.5mg/kg/day in 4–6 divided doses, titrated up to maximum 0.9mg/kg/day; Madden 1977 - 
Methadone 0.25mg 6 hourly increased every 6 hours to maximum 0.5mg 6 hourly 
4 The combined sample size is 302. The event rate is very low. Although the confidence interval is narrow, according to GRADE criteria for dichotomous data, event 
rates less than 300 are downgraded for imprecision.
5 This RCT (Kandall 1983) was judged to be at unclear risk of selection bias as no method of random generation was reported. The randomized groups were very 
imbalanced (49 vs 62), increasing the likelihood of selection bias. Detection and performance bias may be present as no blinding was reported. Attrition was not 
reported and the risk of selective reporting was unclear.
6 Not applicable as results are from one trial only.
7 The sample size is small, the event rate very low (zero events in the opiate group) and the confidence interval is wide.
8 The two studies (Khoo 1995 and Madden 1977) included in this meta-analysis are quasi-randomized trials. There is a high risk of selection bias as random 
generation and allocation concealment were inadequate. Blinding was not reported and there is thus an unclear risk of detection and performance bias. Both studies 
accounted for incomplete outcome data and attrition bias is thus a low risk. Selective reporting bias was unclear.
9 The sample size is small and the confidence interval is very wide.
10 This quasi-RCT (Khoo 1995) is at high risk of selection bias as random generation (use of last number of the participant's hospital number) and allocation 
concealment were judged to be inadequate. Blinding was not reported and performance and detection bias may be present. 
11 The sample size is small and the confidence interval is wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Diazepam Opiate
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
See footnote 1
389 per 1000 167 per 1000
(89 to 311)
RR 0.43 
(0.23 to 0.8)
86
(2 studies)
⊕
VERY	LOW2,3,4
The meta-
analysis included 
one quasi-trial 
(Finnegan 
1984) and one 
RCT (Madden 
1977). GRADE 
assessment was 
done within the 
RCT study design 
category.
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Total length of 
hospital stay
Days in hospital
The mean 
total length of 
hospital stay in 
the intervention 
groups was
2.33 higher
(1.79 lower to 6.45 
higher)
33
(1 study)
⊕
VERY	LOW5,6,7
Madden 1977 
is an RCT 
and GRADE 
assessment was 
done within the 
RCT study design 
category.
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS
Days
The mean duration 
of treatment 
for nas in the 
intervention 
groups was
1.56 higher
(1.59 lower to 4.71 
higher)
33
(1 study)
⊕
VERY	LOW5,6,7
Madden 1977 
is an RCT 
and GRADE 
assessment was 
done within the 
RCT study design 
category.
OPIATE COMPARED TO DIAZEPAM FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Opiates
Comparison: Diazepam
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Treatment failure defined by review as failure to reduce a standardised score of NAS from a clinically significant level to a clinically 'safe' level defined by author of 
the trial, or the use of additional pharmacological treatments for control of NAS.
2 The risk of selection bias is high for the quasi-trial (Finnegan 1988) as random generation and allocation concealment were judged as inadequate. No method was 
reported in the Madden 1977 RCT. Blinding was lacking or unclear and performance and detection bias may be present. Both studies accounted for incomplete 
outcomes so attrition bias is a low risk.
3 The meta-analysis reported here was conducted using a fixed effects model and a RR = 0.43 (95%CI: 0.23, 0.80) with Finnegan 1984 showing a statistically 
significant benefit of opiates over diazepam and Madden 1977 showing a benefit of diazepam over opiates. Clinical heterogeneity may explain this result as 
Finnegan compared Paregoric with diazepam and Madden compared methadone with diazepam. In this situation when heterogeneity is present, a random effects 
model is more appropriate. This would change the RR = 0.55 (95% CI: 0.10, 2.89) and is no longer statistically significant. The relatively large difference in results 
following sensitivity analyses reduces the robustness of the results. The assessment is downgraded for unexplained inconsistency. 
4 The sample size is very small with very few events. 
5 This RCT (Madden 1977) was judged to be at unclear risk of selection bias as no random generation or allocation concealment was reported. Blinding was not 
reported for the trial so performance and detection bias may be present. Incomplete outcome data was addressed so attrition bias was minimal.
6 Not applicable as only one study included.
7 The sample size is very small and the confidence interval is wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Neonatal Opium 
Solution 
Sublingual 
Buprenorphine
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Need for adjunctive 
treatment
77 per 1000 308 per 1000
(39 to 1000)
RR 4 
(0.51 to 31.13)
26
(1 study)
⊕
VERY	LOW1,2,3
Primary aim of 
this RCT was 
safety, tolerability 
and feasibility. 
Efficacy was 
a secondary 
goal. The report 
acknowledges 
that the RCT was 
not powered for 
this.
Seizures 0 per 1000 0 per 1000
(0 to 0)
RR 3 
(0.13 to 67.51)
26
(1 study)
⊕
VERY	LOW1,2,3
One infant 
developed 
generalised 
seizures in the 
Buprenorphine 
group.
Total length of 
hospital stay
Days
The mean 
total length of 
hospital stay in 
the intervention 
groups was
11 lower
(21.69 to 0.31 
lower)
25
(1 study)
⊕
VERY	LOW1,2,3
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS
The mean duration 
of treatment 
for nas in the 
intervention 
groups was
10 lower
(20.69 lower to 0.69 
higher)
25
(1 study)
⊕
VERY	LOW1,2,3
SUBLINGUAL BUPRENORPHINE COMPARED TO NEONATAL OPIUM SOLUTION FOR OPIATE WITHDRAWAL IN 
NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Sublingual Buprenorphine
Comparison: Neonatal Opium Solution
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This RCT (Kraft 2009) was judged to be at low risk of selection bias. Random generation and allocation concealment were adequate as the sequence was generated 
centrally by the Hospital Investigational Drug Service. The study was not blinded and detection and performance bias may be present. All outcomes were accounted 
for and attrition bias was judged to be low. Selective outcome reporting was not present.
2 Not applicable as only one study.
3 The sample size is very small with very few events and the confidence interval is very wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Tincture of Opium 
(TO) Morphine 
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Mean Finnegan 
score: proxy 
measure for 
treatment failure
See comment See comment 33
(1 study)
⊕
VERY	LOW1,2,3,4
Mean maximum 
Finnegan score 
values for each 
group: Morphine: 
15.4g and 
Tincture: 15.5g. 
No SD reported. 
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Total length of 
hospital stay
Days in hospital
The mean 
total length of 
hospital stay in 
the intervention 
groups was
0 higher
(0 to 0 higher)
33
(1 study)
⊕⊕
LOW1,2,4
The mean 
duration of 
hospitalization in 
the Morphine = 
37.5 days; range: 
20-66) and in the 
Tincture of Opium 
group = 32.4 days; 
range: 17-55). Not 
significant.
Infant weight gain The mean infant 
weight gain in 
the intervention 
groups was
0 higher
(0 to 0 higher)
33
(1 study)
⊕⊕
LOW1,5
Mean weight gain 
per day in the 
Morphine group = 
18.9g and in Tincture 
of Opium = 24.9g 
(p = 0.24; 95% CI of 
mean difference: 
15.9g, -4.1g).
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS
Skewed data
The mean duration 
of treatment 
for nas in the 
intervention 
groups was
0 higher
(0 to 0 higher)
0
(1 study)
⊕⊕
LOW1,4
The mean 
duration of 
treatment for NAS 
in the morphine 
group = 29.8 days; 
range: 10- 62; in 
the TO Opium 
group (26.9 days; 
range: 8- 51). Not 
significant.
MORPHINE COMPARED TO TINCTURE OF OPIUM (TO) FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Morphine
Comparison: Tincture of Opium (TO)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
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1 This RCT (Langefeld 2005) was well-conducted with adequate random generation and allocation concealment, blinding (solutions identical in appearance and flasks 
were only identified with a number and name of the newborn) and no attrition nor selection reporting.
2 Not applicable as only one study included.
3 The report did not provide details of treatment failure, but reported mean maximum Finnegan score values for each group: Morphine: 15.4g and Tincture: 15.5g. No 
SD reported. 
4 The mean and ranges were reported, not standard deviations or a confidence interval of the difference. Based on the sample size being very small and the wide 
ranges, the results are judged to be very imprecise.
5 The sample size is very small. As no variance estimates are reported for means, it is not possible to calculate the mean difference nor the variance. The mean 
weight gain per day is reported for each group, but not for the mean difference between the groups. However, a 95% confidence interval for the mean difference in 
weight gain per day between the groups (15.9; -4.1g) is reported. 
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Specific sedative Specific opiate
Treatment failure – 
Paregoric versus 
phenobarbitone
317 per 1000 174 per 1000
(95 to 320)
RR 0.55 
(0.3 to 1.01)
178
(2 studies)
⊕
VERY	LOW1,2,3
Treatment failure – 
Methadone versus 
phenobarbitone
62 per 1000 56 per 1000
(4 to 817)
RR 0.89 
(0.06 to 13.08)
34
(1 study)
⊕
VERY	LOW4,5,6
Treatment failure –
Morphine versus 
phenobarbitone
403 per 1000 254 per 1000
(157 to 403)
RR 0.63 
(0.39 to 1)
149
(2 studies)
⊕⊕
LOW3,7,8
Treatment failure – 
Paregoric versus 
diazepam
800 per 1000 192 per 1000
(112 to 344)
RR 0.24 
(0.14 to 0.43)
85
(2 studies)
⊕
VERY	LOW1,9,10
Treatment failure –
Methadone versus 
diazepam
0 per 1000 0 per 1000
(0 to 0)
RR 2.68 
(0.12 to 61.58)
34
(1 study)
⊕
VERY	LOW4,5,6
SPECIFIC OPIATE COMPARED TO SPECIFIC SEDATIVE FOR TREATMENT FAILURE IN OPIATE WITHDRAWAL IN 
NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Specific opiate
Comparison: Specific sedative 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This meta-analysis combined two quasi-trials (Finnegan 1984 and Kaltenbach 1986). It was unclear whether some of the infants reported in the study were also 
included in Finnegan 1984, and there is a risk of double-counting the participants. The studies allocated groups from envelopes designated according to the first 
letter of the last name. Allocation concealment was judged to be inadequate and selection bias may is a high risk. Blinding was not clearly reported for short-term 
outcomes but it is unlikely as the treatment regimens were different so there is a high risk of performance and detection bias. Selective reporting of outcomes was 
unclear and could not be judged. 
2 Statistical heterogeneity is present (I squared = 85%). The studies were similar but doses are not reported except for Phenobarbitone in Finnegan 1984), so the 
heterogeneity is unexplained. This was downgraded for unexplained inconsistency.
3 The sample size is small and the event rate is low and the confidence interval is wide.
4 No method of random generation was reported in the Madden 1977 RCT and allocation concealment was unlikely. There is a high risk of selection bias. Blinding was 
not reported performance and detection bias may be present. The study accounted for incomplete outcomes so attrition bias is a low risk. 
5 Not applicable as only one trial.
6 The sample size is very small, the event rate is very low and the confidence interval is very wide.
7 This meta-analysis combines a quasi-RCT (Khoo 1995) and a RCT (Jackson 2004). In Khoo 1995 there is a high risk of selection bias as random generation (use of last 
number of the participant's hospital number) and allocation concealment were judged to be inadequate. Blinding was not performed for treatment and not reported 
for assessment so performance and detection bias may be present. Jackson 2004 was well-conducted and at low risk of selection, performance and detection bias. 
However, the GRADE assessment is done according to the lower quality of evidence so the analysis is downgraded for bias.
8 Statistical heterogeneity is not present and there did not appear to be unexplained clinical heterogeneity. 
9 There is statistical heterogeneity (I squared = 67%). The studies were similar but doses are not reported so the heterogeneity is unexplained. This was downgraded 
for unexplained inconsistency.
10 Although the confidence interval is narrow, it was downgraded for imprecision due to the small sample size and low event rate.
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 s
tu
di
es
 a
nd
 th
er
e 
is
 th
us
 a
 ri
sk
 o
f s
el
ec
tio
n 
bi
as
. B
lin
di
ng
 o
f p
ar
tic
ip
an
ts
 a
nd
 p
ro
vi
de
rs
 w
as
 o
nl
y 
pe
rfo
rm
ed
 in
 o
ne
 s
tu
dy
 s
o 
pe
rfo
rm
an
ce
 a
nd
 m
ea
su
re
m
en
t b
ia
s 
m
ay
 b
e 
pr
es
en
t i
n 
th
e 
ot
he
r s
tu
di
es
. I
n 
Ja
ck
so
n 
20
04
, i
nf
an
ts
 ra
nd
om
ly
 a
llo
ca
te
d 
to
 p
he
no
ba
rb
ito
ne
 te
nd
ed
 to
 h
av
e 
be
en
 e
xp
os
ed
 to
 b
en
zo
di
az
ep
in
es
 a
nd
 o
th
er
 c
la
ss
es
 o
f d
ru
gs
 c
om
pa
re
d 
w
ith
 th
os
e 
ra
nd
om
ize
d 
to
 m
or
ph
in
e.
 
3  
St
at
is
tic
al
 h
et
er
og
en
ei
ty
 w
as
 n
ot
 p
re
se
nt
 (I
 s
qu
ar
ed
 =
 0
%
). 
So
m
e 
cl
in
ic
al
 h
et
er
og
en
ei
ty
 m
ay
 b
e 
pr
es
en
t a
s 
dr
ug
 ty
pe
s 
an
d 
do
se
s 
di
ffe
re
d 
bu
t i
t w
as
 n
ot
 d
ow
ng
ra
de
d 
fo
r u
ne
xp
la
in
ed
 in
co
ns
is
te
nc
y. 
Th
e 
op
ia
te
s 
an
d 
do
sa
ge
s 
us
ed
 in
 th
e 
fo
ur
 s
tu
di
es
 
w
er
e:
 F
in
ne
ga
n 
19
84
 - 
Pa
re
go
ric
, d
os
e 
no
t r
ep
or
te
d;
 J
ac
ks
on
 2
00
4 
- M
or
ph
in
e 
50
 m
ic
ro
g/
kg
/d
os
e 
fo
ur
 ti
m
es
 a
 d
ay
 w
ith
 n
o 
tit
ra
tio
n;
 K
ho
o 
19
95
 - 
M
or
ph
in
e 
0.
5m
g/
kg
/d
ay
 in
 4
 - 
6 
di
vi
de
d 
do
se
s,
 ti
tra
te
d 
up
 to
 m
ax
im
um
 0
.9
m
g/
kg
/d
ay
; M
ad
de
n 
19
77
 - 
M
et
ha
do
ne
 0
.2
5m
g 
6 
ho
ur
ly
 in
cr
ea
se
d 
ev
er
y 
6 
ho
ur
s 
to
 m
ax
im
um
 0
.5
m
g 
6 
ho
ur
ly
 
4  
Th
e 
co
m
bi
ne
d 
sa
m
pl
e 
si
ze
 is
 3
02
. T
he
 e
ve
nt
 ra
te
 is
 v
er
y 
lo
w
. A
lth
ou
gh
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 n
ar
ro
w
, a
cc
or
di
ng
 to
 G
RA
DE
 c
rit
er
ia
 fo
r d
ic
ho
to
m
ou
s 
da
ta
, e
ve
nt
 ra
te
s 
le
ss
 th
an
 3
00
 a
re
 d
ow
ng
ra
de
d 
fo
r i
m
pr
ec
is
io
n.
5  
Th
is
 R
CT
 (K
an
da
ll 
19
83
) w
as
 ju
dg
ed
 to
 b
e 
at
 u
nc
le
ar
 ri
sk
 o
f s
el
ec
tio
n 
bi
as
 a
s 
no
 m
et
ho
d 
of
 ra
nd
om
 g
en
er
at
io
n 
w
as
 re
po
rte
d.
 T
he
 ra
nd
om
ize
d 
gr
ou
ps
 w
er
e 
ve
ry
 im
ba
la
nc
ed
 (4
9 
vs
 6
2)
, i
nc
re
as
in
g 
th
e 
lik
el
ih
oo
d 
of
 s
el
ec
tio
n 
bi
as
. D
et
ec
tio
n 
an
d 
pe
rfo
rm
an
ce
 b
ia
s 
m
ay
 b
e 
pr
es
en
t a
s 
no
 b
lin
di
ng
 w
as
 re
po
rte
d.
 A
ttr
iti
on
 w
as
 n
ot
 re
po
rte
d 
an
d 
th
e 
ris
k 
of
 s
el
ec
tiv
e 
re
po
rti
ng
 w
as
 u
nc
le
ar
.
6  
N
ot
 a
pp
lic
ab
le
 a
s 
re
su
lts
 a
re
 fr
om
 o
ne
 tr
ia
l o
nl
y.
7  
Th
e 
sa
m
pl
e 
si
ze
 is
 s
m
al
l, 
th
e 
ev
en
t r
at
e 
ve
ry
 lo
w
 (z
er
o 
ev
en
ts
 in
 th
e 
op
ia
te
 g
ro
up
) a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
8  
Th
e 
tw
o 
st
ud
ie
s 
(K
ho
o 
19
95
 a
nd
 M
ad
de
n 
19
77
) i
nc
lu
de
d 
in
 th
is
 m
et
a-
an
al
ys
is
 a
re
 q
ua
si
-ra
nd
om
ize
d 
tri
al
s.
 T
he
re
 is
 a
 h
ig
h 
ris
k 
of
 s
el
ec
tio
n 
bi
as
 a
s 
ra
nd
om
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
in
ad
eq
ua
te
. B
lin
di
ng
 w
as
 n
ot
 re
po
rte
d 
an
d 
th
er
e 
is
 th
us
 a
n 
un
cl
ea
r r
is
k 
of
 d
et
ec
tio
n 
an
d 
pe
rfo
rm
an
ce
 b
ia
s.
 B
ot
h 
st
ud
ie
s 
ac
co
un
te
d 
fo
r i
nc
om
pl
et
e 
ou
tc
om
e 
da
ta
 a
nd
 a
ttr
iti
on
 b
ia
s 
is
 th
us
 a
 lo
w
 ri
sk
. S
el
ec
tiv
e 
re
po
rti
ng
 b
ia
s 
w
as
 u
nc
le
ar
.
9  
Th
e 
sa
m
pl
e 
si
ze
 is
 s
m
al
l a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 v
er
y 
w
id
e.
10
 T
hi
s 
qu
as
i-R
CT
 (K
ho
o 
19
95
) i
s 
at
 h
ig
h 
ris
k 
of
 s
el
ec
tio
n 
bi
as
 a
s 
ra
nd
om
 g
en
er
at
io
n 
(u
se
 o
f l
as
t n
um
be
r o
f t
he
 p
ar
tic
ip
an
t's
 h
os
pi
ta
l n
um
be
r) 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
ju
dg
ed
 to
 b
e 
in
ad
eq
ua
te
. B
lin
di
ng
 w
as
 n
ot
 re
po
rte
d 
an
d 
pe
rfo
rm
an
ce
 a
nd
 
de
te
ct
io
n 
bi
as
 m
ay
 b
e 
pr
es
en
t. 
11
 T
he
 s
am
pl
e 
si
ze
 is
 s
m
al
l a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
Q
ua
lit
y 
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se
ss
m
en
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N
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 o
f p
at
ie
nt
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Ef
fe
ct
Q
ua
lit
y
Im
po
rt
an
ce
N
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f s
tu
di
es
D
es
ig
n
Ri
sk
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f b
ia
s
In
co
ns
is
te
nc
y
In
di
re
ct
ne
ss
Im
pr
ec
is
io
n
O
th
er
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id
er
at
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ns
O
pi
at
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en
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to
ne
Re
la
tiv
e
(9
5%
 C
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A
bs
ol
ut
e
D
ur
at
io
n 
of
 tr
ea
tm
en
t f
or
 N
A
S 
(m
ea
su
re
d 
w
ith
: D
ay
s;
 b
et
te
r i
nd
ic
at
ed
 b
y 
lo
w
er
 v
al
ue
s)
2
ob
se
rv
at
io
na
l 
st
ud
ie
s
se
rio
us
8
no
 s
er
io
us
 
in
co
ns
is
te
nc
y
no
 s
er
io
us
 
in
di
re
ct
ne
ss
se
rio
us
9
no
ne
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M
D
 3
.7
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lo
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lo
w
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Q
ua
lit
y 
as
se
ss
m
en
t
N
o.
 o
f p
at
ie
nt
s
Ef
fe
ct
Q
ua
lit
y
Im
po
rt
an
ce
N
o.
 o
f s
tu
di
es
D
es
ig
n
Ri
sk
 o
f b
ia
s
In
co
ns
is
te
nc
y
In
di
re
ct
ne
ss
Im
pr
ec
is
io
n
O
th
er
 
co
ns
id
er
at
io
ns
O
pi
at
e
D
ia
ze
pa
m
Re
la
tiv
e
(9
5%
 C
I)
A
bs
ol
ut
e
D
ea
th
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 n
ot
 re
po
rt
ed
0
—
—
—
—
—
no
ne
—
—
—
—
CR
IT
IC
A
L
Tr
ea
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en
t f
ai
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 (a
ss
es
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w
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: S
ee
 fo
ot
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 1 )
2
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iz
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tr
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se
rio
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2
se
rio
us
3
no
 s
er
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in
di
re
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ne
ss
se
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4
no
ne
9/
50
 
(1
8%
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14
/3
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9%
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RR
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3 
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3 
to
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fe
w
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 p
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: D
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 b
ir
th
w
ei
gh
t –
 n
ot
 re
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t f
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: D
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 C
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D
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3-
01
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Q
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st
io
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H
O
U
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AT
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 D
IA
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M
 B
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U
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D
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PI
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W
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H
D
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W
A
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B
O
RN
 IN
FA
N
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os
pi
ta
l
B
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lio
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hy
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D
A
, J
ef
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E,
 C
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e 
M
J.
 O
pi
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e 
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 o
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w
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ew
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 C
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D
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at
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1  
Tr
ea
tm
en
t f
ai
lu
re
 d
efi
ne
d 
by
 re
vi
ew
 a
s 
fa
ilu
re
 to
 re
du
ce
 a
 s
ta
nd
ar
di
se
d 
sc
or
e 
of
 N
AS
 fr
om
 a
 c
lin
ic
al
ly
 s
ig
ni
fic
an
t l
ev
el
 to
 a
 c
lin
ic
al
ly
 's
af
e'
 le
ve
l d
efi
ne
d 
by
 a
ut
ho
r o
f t
he
 tr
ia
l, 
or
 th
e 
us
e 
of
 a
dd
iti
on
al
 p
ha
rm
ac
ol
og
ic
al
 tr
ea
tm
en
ts
 fo
r c
on
tro
l o
f N
AS
.
2  
Th
e 
ris
k 
of
 s
el
ec
tio
n 
bi
as
 is
 h
ig
h 
fo
r t
he
 q
ua
si
-tr
ia
l (
Fi
nn
eg
an
 1
98
8)
 a
s 
ra
nd
om
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
ju
dg
ed
 a
s 
in
ad
eq
ua
te
. N
o 
m
et
ho
d 
w
as
 re
po
rte
d 
in
 th
e 
M
ad
de
n 
19
77
 R
CT
. B
lin
di
ng
 w
as
 la
ck
in
g 
or
 u
nc
le
ar
 a
nd
 p
er
fo
rm
an
ce
 
an
d 
de
te
ct
io
n 
bi
as
 m
ay
 b
e 
pr
es
en
t. 
Bo
th
 s
tu
di
es
 a
cc
ou
nt
ed
 fo
r i
nc
om
pl
et
e 
ou
tc
om
es
 s
o 
at
tri
tio
n 
bi
as
 is
 a
 lo
w
 ri
sk
.
3  
Th
e 
m
et
a-
an
al
ys
is
 re
po
rte
d 
he
re
 w
as
 c
on
du
ct
ed
 u
si
ng
 a
 fi
xe
d 
ef
fe
ct
s 
m
od
el
 a
nd
 a
 R
R 
= 
0.
43
 (9
5%
CI
: 0
.2
3,
 0
.8
0)
 w
ith
 F
in
ne
ga
n 
19
84
 s
ho
w
in
g 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t b
en
efi
t o
f o
pi
at
es
 o
ve
r d
ia
ze
pa
m
 a
nd
 M
ad
de
n 
19
77
 s
ho
w
in
g 
a 
be
ne
fit
 o
f 
di
az
ep
am
 o
ve
r o
pi
at
es
. C
lin
ic
al
 h
et
er
og
en
ei
ty
 m
ay
 e
xp
la
in
 th
is
 re
su
lt 
as
 F
in
ne
ga
n 
co
m
pa
re
d 
Pa
re
go
ric
 w
ith
 d
ia
ze
pa
m
 a
nd
 M
ad
de
n 
co
m
pa
re
d 
m
et
ha
do
ne
 w
ith
 d
ia
ze
pa
m
. I
n 
th
is
 s
itu
at
io
n 
w
he
n 
he
te
ro
ge
ne
ity
 is
 p
re
se
nt
, a
 ra
nd
om
 e
ffe
ct
s 
m
od
el
 is
 m
or
e 
ap
pr
op
ria
te
. T
hi
s 
w
ou
ld
 c
ha
ng
e 
th
e 
RR
 =
 0
.5
5 
(9
5%
 C
I: 
0.
10
, 2
.8
9)
 a
nd
 is
 n
o 
lo
ng
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t. 
Th
e 
re
la
tiv
el
y 
la
rg
e 
di
ffe
re
nc
e 
in
 re
su
lts
 fo
llo
w
in
g 
se
ns
iti
vi
ty
 a
na
ly
se
s 
re
du
ce
s 
th
e 
ro
bu
st
ne
ss
 o
f t
he
 re
su
lts
. T
he
 a
ss
es
sm
en
t i
s 
do
w
ng
ra
de
d 
fo
r u
ne
xp
la
in
ed
 in
co
ns
is
te
nc
y. 
4  
Th
e 
sa
m
pl
e 
si
ze
 is
 v
er
y 
sm
al
l w
ith
 v
er
y 
fe
w
 e
ve
nt
s.
 
5  
Th
is
 R
CT
 (M
ad
de
n 
19
77
) w
as
 ju
dg
ed
 to
 b
e 
at
 u
nc
le
ar
 ri
sk
 o
f s
el
ec
tio
n 
bi
as
 a
s 
no
 ra
nd
om
 g
en
er
at
io
n 
or
 a
llo
ca
tio
n 
co
nc
ea
lm
en
t w
as
 re
po
rte
d.
 B
lin
di
ng
 w
as
 n
ot
 re
po
rte
d 
fo
r t
he
 tr
ia
l s
o 
pe
rfo
rm
an
ce
 a
nd
 d
et
ec
tio
n 
bi
as
 m
ay
 b
e 
pr
es
en
t. 
In
co
m
pl
et
e 
ou
tc
om
e 
da
ta
 w
as
 a
dd
re
ss
ed
 s
o 
at
tri
tio
n 
bi
as
 w
as
 m
in
im
al
.
6  
N
ot
 a
pp
lic
ab
le
 a
s 
on
ly
 o
ne
 s
tu
dy
 in
cl
ud
ed
.
7  
Th
e 
sa
m
pl
e 
si
ze
 is
 v
er
y 
sm
al
l a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
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 C
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no
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Guidelines for the identification and management of substance use and substance use disorders in pregnancy
1  
Th
is
 R
CT
 (K
ra
ft 
20
09
) w
as
 ju
dg
ed
 to
 b
e 
at
 lo
w
 ri
sk
 o
f s
el
ec
tio
n 
bi
as
. R
an
do
m
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
ad
eq
ua
te
 a
s 
th
e 
se
qu
en
ce
 w
as
 g
en
er
at
ed
 c
en
tra
lly
 b
y 
th
e 
Ho
sp
ita
l I
nv
es
tig
at
io
na
l D
ru
g 
Se
rv
ic
e.
 T
he
 s
tu
dy
 w
as
 n
ot
 b
lin
de
d 
an
d 
de
te
ct
io
n 
an
d 
pe
rfo
rm
an
ce
 b
ia
s 
m
ay
 b
e 
pr
es
en
t. 
Al
l o
ut
co
m
es
 w
er
e 
ac
co
un
te
d 
fo
r a
nd
 a
ttr
iti
on
 b
ia
s 
w
as
 ju
dg
ed
 to
 b
e 
lo
w
. S
el
ec
tiv
e 
ou
tc
om
e 
re
po
rti
ng
 w
as
 n
ot
 p
re
se
nt
.
2  
N
ot
 a
pp
lic
ab
le
 a
s 
on
ly
 o
ne
 s
tu
dy
.
3  
Th
e 
sa
m
pl
e 
si
ze
 is
 v
er
y 
sm
al
l w
ith
 v
er
y 
fe
w
 e
ve
nt
s 
an
d 
th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 v
er
y 
w
id
e.
Q
ua
lit
y 
as
se
ss
m
en
t
N
o.
 o
f p
at
ie
nt
s
Ef
fe
ct
Q
ua
lit
y
Im
po
rt
an
ce
N
o.
 o
f s
tu
di
es
D
es
ig
n
Ri
sk
 o
f b
ia
s
In
co
ns
is
te
nc
y
In
di
re
ct
ne
ss
Im
pr
ec
is
io
n
O
th
er
 
co
ns
id
er
at
io
ns
Su
bl
in
gu
al
 
B
up
re
no
rp
hi
ne
N
eo
na
ta
l 
O
pi
um
 S
ol
ut
io
n
Re
la
tiv
e
(9
5%
 C
I)
A
bs
ol
ut
e
D
ur
at
io
n 
of
 tr
ea
tm
en
t f
or
 N
A
S 
(b
et
te
r i
nd
ic
at
ed
 b
y 
lo
w
er
 v
al
ue
s)
1
ra
nd
om
iz
ed
 
tr
ia
ls
se
rio
us
1
no
 s
er
io
us
 
in
co
ns
is
te
nc
y2
no
 s
er
io
us
 
in
di
re
ct
ne
ss
ve
ry
 s
er
io
us
3
no
ne
12
13
—
M
D
 1
0 
lo
w
er
 
(2
0.
69
 lo
w
er
 to
 
0.
69
 h
ig
he
r)
⊕



VE
RY
	L
OW
CR
IT
IC
A
L
157
Guidelines for the identification and management of substance use and substance use disorders in pregnancy
Q
ua
lit
y 
as
se
ss
m
en
t
N
o.
 o
f p
at
ie
nt
s
Ef
fe
ct
Q
ua
lit
y
Im
po
rt
an
ce
N
o.
 o
f s
tu
di
es
D
es
ig
n
Ri
sk
 o
f b
ia
s
In
co
ns
is
te
nc
y
In
di
re
ct
ne
ss
Im
pr
ec
is
io
n
O
th
er
 
co
ns
id
er
at
io
ns
M
or
ph
in
e 
Ti
nc
tu
re
 o
f 
O
pi
um
 (T
O
)
Re
la
tiv
e
(9
5%
 C
I)
A
bs
ol
ut
e
D
ea
th
 –
 n
ot
 re
po
rt
ed
0
—
—
—
—
—
no
ne
—
—
—
—
CR
IT
IC
A
L
Tr
ea
tm
en
t f
ai
lu
re
 (m
ea
su
re
d 
w
ith
: M
ea
n 
Fi
nn
eg
an
 s
co
re
: p
ro
xy
 m
ea
su
re
 fo
r t
re
at
m
en
t f
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et
te
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 b
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ra
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iz
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er
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 b
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er
io
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3
ve
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Guidelines for the identification and management of substance use and substance use disorders in pregnancy
1  
Th
is
 R
CT
 (L
an
ge
fe
ld
 2
00
5)
 w
as
 w
el
l-c
on
du
ct
ed
 w
ith
 a
de
qu
at
e 
ra
nd
om
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t, 
bl
in
di
ng
 (s
ol
ut
io
ns
 id
en
tic
al
 in
 a
pp
ea
ra
nc
e 
an
d 
fla
sk
s 
w
er
e 
on
ly
 id
en
tifi
ed
 w
ith
 a
 n
um
be
r a
nd
 n
am
e 
of
 th
e 
ne
w
bo
rn
) a
nd
 n
o 
at
tri
tio
n 
no
r 
se
le
ct
io
n 
re
po
rti
ng
.
2  
N
ot
 a
pp
lic
ab
le
 a
s 
on
ly
 o
ne
 s
tu
dy
 in
cl
ud
ed
.
3  
Th
e 
re
po
rt 
di
d 
no
t p
ro
vi
de
 d
et
ai
ls
 o
f t
re
at
m
en
t f
ai
lu
re
, b
ut
 re
po
rte
d 
m
ea
n 
m
ax
im
um
 F
in
ne
ga
n 
sc
or
e 
va
lu
es
 fo
r e
ac
h 
gr
ou
p:
 M
or
ph
in
e:
 1
5.
4g
 a
nd
 T
in
ct
ur
e:
 1
5.
5g
. N
o 
SD
 re
po
rte
d.
 
4  
Th
e 
m
ea
n 
an
d 
ra
ng
es
 w
er
e 
re
po
rte
d,
 n
ot
 s
ta
nd
ar
d 
de
vi
at
io
ns
 o
r a
 c
on
fid
en
ce
 in
te
rv
al
 o
f t
he
 d
iff
er
en
ce
. B
as
ed
 o
n 
th
e 
sa
m
pl
e 
si
ze
 b
ei
ng
 v
er
y 
sm
al
l a
nd
 th
e 
w
id
e 
ra
ng
es
, t
he
 re
su
lts
 a
re
 ju
dg
ed
 to
 b
e 
ve
ry
 im
pr
ec
is
e.
5  
Th
e 
sa
m
pl
e 
si
ze
 is
 v
er
y 
sm
al
l. 
As
 n
o 
va
ria
nc
e 
es
tim
at
es
 a
re
 re
po
rte
d 
fo
r m
ea
ns
, i
t i
s 
no
t p
os
si
bl
e 
to
 c
al
cu
la
te
 th
e 
m
ea
n 
di
ffe
re
nc
e 
no
r t
he
 v
ar
ia
nc
e.
 T
he
 m
ea
n 
w
ei
gh
t g
ai
n 
pe
r d
ay
 is
 re
po
rte
d 
fo
r e
ac
h 
gr
ou
p,
 b
ut
 n
ot
 fo
r t
he
 m
ea
n 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
gr
ou
ps
. H
ow
ev
er
, a
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
 fo
r t
he
 m
ea
n 
di
ffe
re
nc
e 
in
 w
ei
gh
t g
ai
n 
pe
r d
ay
 b
et
w
ee
n 
th
e 
gr
ou
ps
 (1
5.
9;
 -4
.1
g)
 is
 re
po
rte
d.
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Guidelines for the identification and management of substance use and substance use disorders in pregnancy
1  
Th
is
 m
et
a-
an
al
ys
is
 c
om
bi
ne
d 
tw
o 
qu
as
i-t
ria
ls
 (F
in
ne
ga
n 
19
84
 a
nd
 K
al
te
nb
ac
h 
19
86
). 
It 
w
as
 u
nc
le
ar
 w
he
th
er
 s
om
e 
of
 th
e 
in
fa
nt
s 
re
po
rte
d 
in
 th
e 
st
ud
y 
w
er
e 
al
so
 in
cl
ud
ed
 in
 F
in
ne
ga
n 
19
84
, a
nd
 th
er
e 
is
 a
 ri
sk
 o
f d
ou
bl
e-
co
un
tin
g 
th
e 
pa
rti
ci
pa
nt
s.
 T
he
 
st
ud
ie
s 
al
lo
ca
te
d 
gr
ou
ps
 fr
om
 e
nv
el
op
es
 d
es
ig
na
te
d 
ac
co
rd
in
g 
to
 th
e 
fir
st
 le
tte
r o
f t
he
 la
st
 n
am
e.
 A
llo
ca
tio
n 
co
nc
ea
lm
en
t w
as
 ju
dg
ed
 to
 b
e 
in
ad
eq
ua
te
 a
nd
 s
el
ec
tio
n 
bi
as
 m
ay
 is
 a
 h
ig
h 
ris
k.
 B
lin
di
ng
 w
as
 n
ot
 c
le
ar
ly
 re
po
rte
d 
fo
r s
ho
rt-
te
rm
 o
ut
co
m
es
 
bu
t i
t i
s 
un
lik
el
y 
as
 th
e 
tre
at
m
en
t r
eg
im
en
s 
w
er
e 
di
ffe
re
nt
 s
o 
th
er
e 
is
 a
 h
ig
h 
ris
k 
of
 p
er
fo
rm
an
ce
 a
nd
 d
et
ec
tio
n 
bi
as
. S
el
ec
tiv
e 
re
po
rti
ng
 o
f o
ut
co
m
es
 w
as
 u
nc
le
ar
 a
nd
 c
ou
ld
 n
ot
 b
e 
ju
dg
ed
. 
2  
St
at
is
tic
al
 h
et
er
og
en
ei
ty
 is
 p
re
se
nt
 (I
 s
qu
ar
ed
 =
 8
5%
). 
Th
e 
st
ud
ie
s 
w
er
e 
si
m
ila
r b
ut
 d
os
es
 a
re
 n
ot
 re
po
rte
d 
ex
ce
pt
 fo
r P
he
no
ba
rb
ito
ne
 in
 F
in
ne
ga
n 
19
84
), 
so
 th
e 
he
te
ro
ge
ne
ity
 is
 u
ne
xp
la
in
ed
. T
hi
s 
w
as
 d
ow
ng
ra
de
d 
fo
r u
ne
xp
la
in
ed
 in
co
ns
is
te
nc
y.
3  
Th
e 
sa
m
pl
e 
si
ze
 is
 s
m
al
l a
nd
 th
e 
ev
en
t r
at
e 
is
 lo
w
 a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
4  
N
o 
m
et
ho
d 
of
 ra
nd
om
 g
en
er
at
io
n 
w
as
 re
po
rte
d 
in
 th
e 
M
ad
de
n 
19
77
 R
CT
 a
nd
 a
llo
ca
tio
n 
co
nc
ea
lm
en
t w
as
 u
nl
ik
el
y. 
Th
er
e 
is
 a
 h
ig
h 
ris
k 
of
 s
el
ec
tio
n 
bi
as
. B
lin
di
ng
 w
as
 n
ot
 re
po
rte
d 
pe
rfo
rm
an
ce
 a
nd
 d
et
ec
tio
n 
bi
as
 m
ay
 b
e 
pr
es
en
t. 
Th
e 
st
ud
y 
ac
co
un
te
d 
fo
r i
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Supportive care Phenobarbitone 
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Failure to settle 
measured with 
Finnegan score
118 per 1000 321 per 1000
(111 to 934)
RR 2.73 
(0.94 to 7.94)
62
(1 study)
⊕
VERY	LOW1,2,3
 
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment (days)
The mean duration 
of treatment (days) 
in the intervention 
groups was
17.9 higher
(11.98 to 23.82 
higher)
62
(1 study)
⊕
VERY	LOW1,2,4
Total length of 
hospital stay
Days in hospital
The mean 
total length of 
hospital stay in 
the intervention 
groups was
20.8 higher
(13.64 to 27.96 
higher)
62
(1 study)
⊕
VERY	LOW1,2,4
GRADE does 
not allow for 
upgrading for 
large effect sizes 
unless there 
are no threats 
to validity (not 
downgraded for 
any other reason).
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight
The mean days to 
regain birthweight 
in the intervention 
groups was
1.4 lower
(4.07 lower to 1.27 
higher)
55
(1 study)
⊕
VERY	LOW1,2,5
Measurements 
were available for 
55 of the 62 study 
participants. 
Duration of 
treatment for NAS – 
not reported
See comment See comment Not 
estimable
— See comment
PHENOBARBITONE COMPARED TO SUPPORTIVE CARE FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Phenobarbitone
Comparison: Supportive care 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This quasi-randomized trial (Khoo 1995) allocated participants to groups using the last number of the participant's hospital number. Both random generation and 
allocation concealment were judged to be inadequate and there is thus a high risk of selection bias. The group numbers are also not balanced (29 vs 36). There was 
no blinding of providers or parents so performance bias may be present. Blinding was unreported for short-term outcomes and the risk of detection bias is unclear. 
2 Not applicable as only one study is included.
3 The sample size is very small and the event rate is very low so imprecision is likely in these results. 
4 The sample size is small and the confidence interval is wide. Notwithstanding the very large difference in means and the highly statistically significant finding, the 
lack of information about the primary outcome and power of the trial reduces our confidence in this estimate. 
5 The sample size is small. The primary outcome is not clearly defined and it is therefore not possible to determine the power of the study for this outcome: time to 
regain birthweight. In the light of this uncertainty, the GRADE criteria recommend that a sample size of less than 400 for continuous outcomes be downgraded for 
imprecision.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Diazepam Phenobarbitone 
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure 389 per 1000 152 per 1000
(93 to 241)
RR 0.39 
(0.24 to 0.62)
139
(2 studies)
⊕
VERY	LOW1,2,3
The meta-
analysis included 
one quasi-trial 
(Finnegan 
1984) and one 
RCT (Madden 
1977). GRADE 
assessment was 
done within the 
RCT study design 
category.
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Total length of 
hospital stay
Days
The mean 
total length of 
hospital stay in 
the intervention 
groups was
3.07 higher
(2.02 lower to 8.16 
higher)
31
(1 study)
⊕
VERY	LOW4,5,6
Madden 1977 
is an RCT 
and GRADE 
assessment was 
done within the 
RCT study design 
category. 
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS 
Days
The mean duration 
of treatment 
for nas in the 
intervention 
groups was
4.3 higher
(0.73 lower to 9.33 
higher)
31
(1 study)
⊕
VERY	LOW4,5,6
Madden 1977 
is an RCT 
and GRADE 
assessment was 
done within the 
RCT study design 
category. 
PHENOBARBITONE COMPARED TO DIAZEPAM FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Phenobarbitone
Comparison: Diazepam 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 The risk of selection bias is high for the quasi-trial (Finnegan 1984) as random generation and allocation concealment were judged as inadequate. No method was 
reported in the Madden 1977 RCT so risk is unclear. Blinding of clinical and research staff was not reported in Madden 1977 and was unlikely as the treatment 
regimens were different so performance bias may be present. In Finnegan 1984 the nurses were not blinded but the research staff were blinded for short-term 
outcome assessment. Detection bias may be present. Both studies accounted for incomplete outcomes so attrition bias is a low risk. The groups are unbalanced in 
Finnegan 1984 (87 vs 20) as the Diazepam group was found to have excessive complications at interim analysis and enrolment was stopped.
2 The meta-analysis reported here was conducted using a fixed effects model and a RR = 0.39 (95%CI: 0.24, 0.62) with Finnegan 1984 showing a statistically 
significant benefit of phenobarbitone over diazepam and Madden 1977 showing a non-significant benefit of diazepam over phenobarbitone. In this situation when 
heterogeneity is present, a random effects model is more appropriate. This would change the RR = 0.60 (95% CI: 0.08, 4.56) and is no longer statistically significant. 
The relatively large difference in results following sensitivity analyses reduces the robustness of these results. The assessment is downgraded for unexplained 
inconsistency. 
3 The overall sample size is small and there are very few events.
4 This RCT (Madden 1977) was judged to be at unclear risk of selection bias as no random generation or allocation concealment was reported. Blinding was not 
reported for the trial so performance and detection bias may be present. Incomplete outcome data was addressed so attrition bias was minimal.
5 Not applicable as only one trial included.
- The sample size is very small and the confidence interval is very wide. 163
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Chlorpromazine Phenobarbitone 
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
See comment
316 per 1000 104 per 1000
(25 to 458)
RR 0.33 
(0.08 to 1.45)
38
(1 study)
⊕
VERY	LOW1,2,3
Treatment failure 
was rated on 
a three point 
severity scale 
of tremor and 
irritability with 
failure being 
persistent 
symptoms  
> 4 days
Seizures See comment See comment Not 
estimable
40
(1 study)
⊕
VERY	LOW1,2,4
Zero events in 
both groups.
Total length of 
hospital stay – not 
reported
See comment See comment Not 
estimable
— See comment
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS – 
not reported
See comment See comment Not 
estimable
— See comment
PHENOBARBITONE COMPARED TO CHLORPROMAZINE FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Phenobarbitone
Comparison: Chlorpromazine 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 In this RCT (Kahn 1969) the method of random generation was not reported and the risk of selection bias is unclear. The study was blinded for personnel and 
assessors so the risk of performance and detection bias is low. The risk of selective outcome reporting was unclear as the primary outcome was not explicitly stated 
and the trial pre-dates trial registration.
2 Not applicable as only one trial included.
3 The sample size is very small and the event rate low with a wide confidence interval.
4 The sample size is very small and zero events.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Phenobarbitone 
titration alone
Phenobarbitone 
titration with 
loading dose 
Treatment failure
Need for a second 
drug
500 per 1000 550 per 1000
(295 to 1000)
RR 1.1 
(0.59 to 2.07)
36
(1 study)
⊕
VERY	LOW1,2,3
Death – not reported See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Total length of 
hospital stay – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Duration of 
treatment for NAS
See comment See comment Not 
estimable
87
(1 study)
See comment Finnegan 1984 
(quasi-RCT) 
reported reduced 
time to symptom 
control in loading 
dose vs none 
(33 vs 64 hrs; p 
< 0.01). No other 
data reported. N = 
87 (assumed)
PHENOBARBITONE TITRATION WITH LOADING DOSE COMPARED TO PHENOBARBITONE TITRATION ALONE FOR 
OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Phenobarbitone titration with loading dose 
Comparison: Phenobarbitone titration alone 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 The quasi-trial (Kaltenbach 1986) allocated groups from envelopes designated according to the first letter of the last name. Allocation concealment was judged to 
be inadequate and selection bias may be present. There was no blinding for short-term outcomes and there is a risk of performance and detection bias. Selective 
reporting of outcomes was unclear and could not be judged. 
2 Not applicable as only one trial included.
3 The sample size is small, the event rate low and the confidence interval is wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Long course 
Phenobarbitone 
(8.4 mg/kg/day in 
four divided doses 
x 10 days, then 
reduced by 1/3rd 
every 2nd day)
Short course 
Phenobarbitone 
(8.4 mg/kg/day in 
four divided doses 
x 4 days, then 
stopped) 
Death – not reported See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Treatment failure 143 per 1000 83 per 1000
(6 to 1000)
RR 0.58 
(0.04 to 7.94)
19
(1 study)
⊕
VERY	LOW1,2,3
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Total length of 
hospital stay – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
Duration of 
treatment for NAS – 
not reported
See comment See comment Not 
estimable
— See comment Not reported for 
this comparison
SHORT COURSE PHENOBARBITONE COMPARED TO LONG COURSE PHENOBARBITONE FOR OPIATE WITHDRAWAL IN 
NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Short course Phenobarbitone (8.4 mg/kg/day in four divided doses x 4 days, then stopped)
Comparison: Long course Phenobarbitone (8.4 mg/kg/day in four divided doses x 10 days, then reduced by 1/3rd every 
2nd day) 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 In this RCT (Kahn 1969) the method of random generation was not reported and the risk of selection bias is unclear. The study was blinded for personnel and 
assessors so the risk of performance and detection bias is low. The risk of selective outcome reporting was unclear as the primary outcome was not explicitly stated 
and the trial pre-dates trial registration.
2 Not applicable as only one trial is included.
3 The sample size is very small, the number of events is is low and the confidence interval is very wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Long course of 
chlorpromazine 
(2.8 mg/kg/day in 
four divided doses 
x 10 days, then 
gradual reduction 
over six days)
Short course of 
chlorpromazine 
(2.8 mg/kg/day in 
four divided doses 
x 4 days, then 
stopped)
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Persistent symptoms 
> 4 days
125 per 1000 455 per 1000
(65 to 1000)
RR 3.64 
(0.52 to 25.41)
19
(1 study)
⊕
VERY	LOW1,2,3
Seizures – not 
reported
See comment See comment Not 
estimable
— See comment
Total length of 
hospital stay – not 
reported
See comment See comment Not 
estimable
— See comment
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS – 
not reported
See comment See comment Not 
estimable
— See comment
SHORT COURSE OF CHLORPROMAZINE COMPARED TO LONG COURSE OF CHLORPROMAZINE FOR OPIATE 
WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Short course of chlorpromazine (2.8 mg/kg/day in four divided doses x 4 days, then stopped)
Comparison: Long course of chlorpromazine (2.8 mg/kg/day in four divided doses x 10 days, then gradual reduction over 
six days) 
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 In this RCT (Kahn 1969) the method of random generation was not reported and the risk of selection bias is unclear. The study was blinded for personnel and 
assessors so the risk of performance and detection bias is low. The risk of selective outcome reporting was unclear as the primary outcome was not explicitly stated 
and the trial pre-dates trial registration
2 Not applicable as only one trial is included.
3 The sample size is very small, the number of events is low and the confidence interval is very wide.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Opiate alone
Phenobarbitone 
and opiate
Death – not reported See comment See comment Not 
estimable
— See comment
Treatment failure
Needing another 
drug
See comment See comment Not 
estimable
20
(1 study)
⊕
VERY	LOW1,2,3
There were no 
events in either 
group.
Seizures See comment See comment Not 
estimable
20
(1 study)
⊕
VERY	LOW1,3
There were no 
events in either 
group.
Total length of 
hospital stay
Days
The mean 
total length of 
hospital stay in 
the intervention 
groups was
41 lower
(59.85 to 22.15 
lower)
20
(1 study)
⊕
VERY	LOW1,4
Infant weight gain – 
not reported
See comment See comment Not 
estimable
— See comment
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS – 
not reported
See comment See comment Not 
estimable
— See comment
PHENOBARBITONE AND OPIATE COMPARED TO OPIATE ALONE FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Phenobarbitone and opiate
Comparison: Opiate alone
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This study (Coyle 2002) is probably a quasi-randomized trial. Infants were matched on Finnegan scores but the method is incompletely described. If no match was 
possible, then infants were randomly assigned. Allocation concealment was judged to be inadequate. Selection bias is a high risk. Performance bias is a low risk as 
the trial was placebo-controlled and nurses were blinded to the treatment assignments. However, weekly phenobarbitone levels were reported to the physician so 
there is an unclear risk of detection bias as it is not certain if the physicians were also assessing the outcomes. Of note is that an earlier abstract reported 35 infants 
but the principal article only reports on 21 infants.
2 Not applicable as only one study included.
3 The sample size is small. Although a sample size calculation was done a priori the outcome used in the formula is reduction in hospital days. This calculation found 
that 48 patients were required. However, the trial was stopped early on the basis of significance but no details are provided if formal stopping rules were applied to 
determine the significance level. A systematic review of RCTs stopped early for benefit found that such RCTs were found to overestimate treatment effects. When 
trials with events fewer than the median number (n=66) were compared with those with event numbers above the median, the odds ratio for a magnitude of effect 
greater than the median was 28 (95% CI 11–73) (Montori VM, Devereaux PJ and Adhikari NK et al.. Randomized trials stopped early for benefit: a systematic review. 
JAMA 2005;294:2203-09.)
4 The sample size is small and the confidence interval is wide. Although a sample size calculation was done a priori for this outcome: reduction in hospital days. This 
calculation found that 48 patients were required. However, the trial was stopped early on the basis of significance but no details are provided if formal stopping 
rules were applied to determine the significance level. A systematic review of RCTs stopped early for benefit found that such RCTs were found to overestimate 
treatment effects. When trials with events fewer than the median number (n=66) were compared with those with event numbers above the median, the odds ratio 
for a magnitude of effect greater than the median was 28 (95% CI 11-73) (Montori VM, Devereaux PJ and Adhikari NK et al.. Randomized trials stopped early for 
benefit: a systematic review. JAMA 2005;294:2203-09.)
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Opiate alone
Clonidine and 
opiate
Death 0 per 1000 0 per 1000
(0 to 0)
RR 7 
(0.37 to 131.28)
80
(1 study)
⊕⊕
LOW1,2
All deaths (n = 
3) were in the 
Clonidine and 
Opiate group. 
Death occurred 
after discharge 
and cessation of 
clonidine. Causes: 
myocarditis, 
SIDS, homicide.
Treatment failure
Required >= 0.9ml of 
diluted Tincture of 
Opium every 3 hours
125 per 1000 11 per 1000
(1 to 199)
RR 0.09 
(0.01 to 1.59)
80
(1 study)
⊕⊕
LOW1,3
All infants with 
treatment failure 
were (n = 5) in 
the Opiate alone 
group.
Seizures 75 per 1000 10 per 1000
(1 to 201)
RR 0.14 
(0.01 to 2.68)
80
(1 study)
⊕⊕
LOW1,4
All seizures (n = 3) 
were in the Opiate 
alone group.
Total length of 
hospital stay – not 
reported
See comment See comment Not 
estimable
— See comment
Infant maximum 
weight loss – % of 
birthweight5
The mean 
infant maximum 
weight loss in 
the intervention 
groups was
0.88 lower
(2.33 lower to 0.57 
higher)
80
(1 study)
⊕⊕
LOW4
Days to regain 
birthweight – not 
reported
See comment See comment Not 
estimable
— See comment
Duration of 
treatment for NAS
Medians reported 80
(1 study)
⊕⊕
LOW1,4
Median duration 
was 11 days 
(95% CI: 8–15) 
vs 15 days (95% 
CI: 13–17) in the 
Clonidine and 
opiate group vs 
the Opiate alone 
respectively.
CLONIDINE AND OPIATE COMPARED TO OPIATE ALONE FOR OPIATE WITHDRAWAL IN NEWBORN INFANTS
Patient or population: Opiate withdrawal in newborn infants
Settings: Hospital
Intervention: Clonidine and opiate
Comparison: Opiate alone
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE Working Group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 This placebo-controlled RCT (Agthe 2009) was well-conducted and judged to be at low risk of selection, performance and detection bias. The infants in the Clonidine 
and Tincture of Opium group had statistically significantly lower mean birthweights. 61% of infants were also exposed to cocaine in utero and 6 of 80 infants had 
positive benzodiazepine urine screens.
2 The event rates are very low and the confidence interval is very wide.
3 The event rate is very low and the confidence interval is wide.
4 The sample size is small and according to GRADE criteria for rating continuous data, a sample size of less than 400 indicates imprecision and should be downgraded.
5 Inverse measure for infant weight gain (proxy outcome)
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1  
Th
is
 q
ua
si
-ra
nd
om
ize
d 
tri
al
 (K
ho
o 
19
95
) a
llo
ca
te
d 
pa
rti
ci
pa
nt
s 
to
 g
ro
up
s 
us
in
g 
th
e 
la
st
 n
um
be
r o
f t
he
 p
ar
tic
ip
an
t's
 h
os
pi
ta
l n
um
be
r. 
Bo
th
 ra
nd
om
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
ju
dg
ed
 to
 b
e 
in
ad
eq
ua
te
 a
nd
 th
er
e 
is
 th
us
 a
 h
ig
h 
ris
k 
of
 
se
le
ct
io
n 
bi
as
. T
he
 g
ro
up
 n
um
be
rs
 a
re
 a
ls
o 
no
t b
al
an
ce
d 
(2
9 
vs
 3
6)
. T
he
re
 w
as
 n
o 
bl
in
di
ng
 o
f p
ro
vi
de
rs
 o
r p
ar
en
ts
 s
o 
pe
rfo
rm
an
ce
 b
ia
s 
m
ay
 b
e 
pr
es
en
t. 
Bl
in
di
ng
 w
as
 u
nr
ep
or
te
d 
fo
r s
ho
rt-
te
rm
 o
ut
co
m
es
 a
nd
 th
e 
ris
k 
of
 d
et
ec
tio
n 
bi
as
 is
 u
nc
le
ar
. 
2  
N
ot
 a
pp
lic
ab
le
 a
s 
on
ly
 o
ne
 s
tu
dy
 is
 in
cl
ud
ed
.
3  
Th
e 
sa
m
pl
e 
si
ze
 is
 v
er
y 
sm
al
l a
nd
 th
e 
ev
en
t r
at
e 
is
 v
er
y 
lo
w
 s
o 
im
pr
ec
is
io
n 
is
 li
ke
ly
 in
 th
es
e 
re
su
lts
. 
4  
Th
e 
sa
m
pl
e 
si
ze
 is
 s
m
al
l a
nd
 th
e 
co
nfi
de
nc
e 
in
te
rv
al
 is
 w
id
e.
 N
ot
w
ith
st
an
di
ng
 th
e 
ve
ry
 la
rg
e 
di
ffe
re
nc
e 
in
 m
ea
ns
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nd
 th
e 
hi
gh
ly
 s
ta
tis
tic
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ly
 s
ig
ni
fic
an
t fi
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in
g,
 th
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la
ck
 o
f i
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m
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io
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t t
he
 p
rim
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y 
ou
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om
e 
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d 
po
w
er
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f t
he
 tr
ia
l r
ed
uc
es
 o
ur
 
co
nfi
de
nc
e 
in
 th
is
 e
st
im
at
e.
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 d
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ne
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no
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 d
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th
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 re
ga
in
 b
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ty
, t
he
 G
RA
DE
 c
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1  
Th
e 
ris
k 
of
 s
el
ec
tio
n 
bi
as
 is
 h
ig
h 
fo
r t
he
 q
ua
si
-tr
ia
l (
Fi
nn
eg
an
 1
98
4)
 a
s 
ra
nd
om
 g
en
er
at
io
n 
an
d 
al
lo
ca
tio
n 
co
nc
ea
lm
en
t w
er
e 
ju
dg
ed
 a
s 
in
ad
eq
ua
te
. N
o 
m
et
ho
d 
w
as
 re
po
rte
d 
in
 th
e 
M
ad
de
n 
19
77
 R
CT
 s
o 
ris
k 
is
 u
nc
le
ar
. B
lin
di
ng
 o
f c
lin
ic
al
 a
nd
 re
se
ar
ch
 
st
af
f w
as
 n
ot
 re
po
rte
d 
in
 M
ad
de
n 
19
77
 a
nd
 w
as
 u
nl
ik
el
y 
as
 th
e 
tre
at
m
en
t r
eg
im
en
s 
w
er
e 
di
ffe
re
nt
 s
o 
pe
rfo
rm
an
ce
 b
ia
s 
m
ay
 b
e 
pr
es
en
t. 
In
 F
in
ne
ga
n 
19
84
 th
e 
nu
rs
es
 w
er
e 
no
t b
lin
de
d 
bu
t t
he
 re
se
ar
ch
 s
ta
ff 
w
er
e 
bl
in
de
d 
fo
r s
ho
rt-
te
rm
 o
ut
co
m
e 
as
se
ss
m
en
t. 
De
te
ct
io
n 
bi
as
 m
ay
 b
e 
pr
es
en
t. 
Bo
th
 s
tu
di
es
 a
cc
ou
nt
ed
 fo
r i
nc
om
pl
et
e 
ou
tc
om
es
 s
o 
at
tri
tio
n 
bi
as
 is
 a
 lo
w
 ri
sk
. T
he
 g
ro
up
s 
ar
e 
un
ba
la
nc
ed
 in
 F
in
ne
ga
n 
19
84
 (8
7 
vs
 2
0)
 a
s 
th
e 
Di
az
ep
am
 g
ro
up
 w
as
 fo
un
d 
to
 h
av
e 
ex
ce
ss
iv
e 
co
m
pl
ic
at
io
ns
 a
t 
in
te
rim
 a
na
ly
si
s 
an
d 
en
ro
lm
en
t w
as
 s
to
pp
ed
.
2  
Th
e 
m
et
a-
an
al
ys
is
 re
po
rte
d 
he
re
 w
as
 c
on
du
ct
ed
 u
si
ng
 a
 fi
xe
d 
ef
fe
ct
s 
m
od
el
 a
nd
 a
 R
R 
= 
0.
39
 (9
5%
CI
: 0
.2
4,
 0
.6
2)
 w
ith
 F
in
ne
ga
n 
19
84
 s
ho
w
in
g 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t b
en
efi
t o
f p
he
no
ba
rb
ito
ne
 o
ve
r d
ia
ze
pa
m
 a
nd
 M
ad
de
n 
19
77
 s
ho
w
in
g 
a 
no
n-
si
gn
ifi
ca
nt
 b
en
efi
t o
f d
ia
ze
pa
m
 o
ve
r p
he
no
ba
rb
ito
ne
. I
n 
th
is
 s
itu
at
io
n 
w
he
n 
he
te
ro
ge
ne
ity
 is
 p
re
se
nt
, a
 ra
nd
om
 e
ffe
ct
s 
m
od
el
 is
 m
or
e 
ap
pr
op
ria
te
. T
hi
s 
w
ou
ld
 c
ha
ng
e 
th
e 
RR
 =
 0
.6
0 
(9
5%
 C
I: 
0.
08
, 4
.5
6)
 a
nd
 is
 n
o 
lo
ng
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t. 
Th
e 
re
la
tiv
el
y 
la
rg
e 
di
ffe
re
nc
e 
in
 re
su
lts
 fo
llo
w
in
g 
se
ns
iti
vi
ty
 a
na
ly
se
s 
re
du
ce
s 
th
e 
ro
bu
st
ne
ss
 o
f t
he
se
 re
su
lts
. T
he
 a
ss
es
sm
en
t i
s 
do
w
ng
ra
de
d 
fo
r u
ne
xp
la
in
ed
 in
co
ns
is
te
nc
y. 
3  
Th
e 
ov
er
al
l s
am
pl
e 
si
ze
 is
 s
m
al
l a
nd
 th
er
e 
ar
e 
ve
ry
 fe
w
 e
ve
nt
s.
4  
Th
is
 R
CT
 (M
ad
de
n 
19
77
) w
as
 ju
dg
ed
 to
 b
e 
at
 u
nc
le
ar
 ri
sk
 o
f s
el
ec
tio
n 
bi
as
 a
s 
no
 ra
nd
om
 g
en
er
at
io
n 
or
 a
llo
ca
tio
n 
co
nc
ea
lm
en
t w
as
 re
po
rte
d.
 B
lin
di
ng
 w
as
 n
ot
 re
po
rte
d 
fo
r t
he
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1  
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is
 s
tu
dy
 (C
oy
le
 2
00
2)
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 p
ro
ba
bl
y 
a 
qu
as
i-r
an
do
m
ize
d 
tri
al
. I
nf
an
ts
 w
er
e 
m
at
ch
ed
 o
n 
Fi
nn
eg
an
 s
co
re
s 
bu
t t
he
 m
et
ho
d 
is
 in
co
m
pl
et
el
y 
de
sc
rib
ed
. I
f n
o 
m
at
ch
 w
as
 p
os
si
bl
e,
 th
en
 in
fa
nt
s 
w
er
e 
ra
nd
om
ly
 a
ss
ig
ne
d.
 A
llo
ca
tio
n 
co
nc
ea
lm
en
t w
as
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dg
ed
 to
 
be
 in
ad
eq
ua
te
. S
el
ec
tio
n 
bi
as
 is
 a
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ig
h 
ris
k.
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er
fo
rm
an
ce
 b
ia
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 lo
w
 ri
sk
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th
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tri
al
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 p
la
ce
bo
-c
on
tro
lle
d 
an
d 
nu
rs
es
 w
er
e 
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in
de
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e 
tre
at
m
en
t a
ss
ig
nm
en
ts
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ow
ev
er
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ee
kl
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en
ob
ar
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ne
 le
ve
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po
rte
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ia
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an
 u
nc
le
ar
 ri
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 o
f d
et
ec
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n 
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 c
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ta
in
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ic
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ss
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si
ng
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ou
tc
om
es
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f n
ot
e 
is
 th
at
 a
n 
ea
rli
er
 a
bs
tra
ct
 re
po
rte
d 
35
 in
fa
nt
s 
bu
t t
he
 p
rin
ci
pa
l a
rti
cl
e 
on
ly
 re
po
rts
 o
n 
21
 in
fa
nt
s.
2  
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pp
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le
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on
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 o
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 s
tu
dy
 in
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ud
ed
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m
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 c
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 d
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io
ri 
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om
e 
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ed
 in
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e 
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rm
ul
a 
is
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du
ct
io
n 
in
 h
os
pi
ta
l d
ay
s.
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hi
s 
ca
lc
ul
at
io
n 
fo
un
d 
th
at
 4
8 
pa
tie
nt
s 
w
er
e 
re
qu
ire
d.
 H
ow
ev
er
, t
he
 tr
ia
l w
as
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pp
ed
 e
ar
ly
 o
n 
th
e 
ba
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s 
of
 
si
gn
ifi
ca
nc
e 
bu
t n
o 
de
ta
ils
 a
re
 p
ro
vi
de
d 
if 
fo
rm
al
 s
to
pp
in
g 
ru
le
s 
w
er
e 
ap
pl
ie
d 
to
 d
et
er
m
in
e 
th
e 
si
gn
ifi
ca
nc
e 
le
ve
l. 
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st
em
at
ic
 re
vi
ew
 o
f R
CT
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st
op
pe
d 
ea
rly
 fo
r b
en
efi
t f
ou
nd
 th
at
 s
uc
h 
RC
Ts
 w
er
e 
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un
d 
to
 o
ve
re
st
im
at
e 
tre
at
m
en
t e
ffe
ct
s.
 W
he
n 
tri
al
s 
w
ith
 e
ve
nt
s 
fe
w
er
 th
an
 th
e 
m
ed
ia
n 
nu
m
be
r (
n=
66
) w
er
e 
co
m
pa
re
d 
w
ith
 th
os
e 
w
ith
 e
ve
nt
 n
um
be
rs
 a
bo
ve
 th
e 
m
ed
ia
n,
 th
e 
od
ds
 ra
tio
 fo
r a
 m
ag
ni
tu
de
 o
f e
ffe
ct
 g
re
at
er
 th
an
 th
e 
m
ed
ia
n 
w
as
 2
8 
(9
5%
 C
I 1
1–
73
) (
M
on
to
ri 
VM
, D
ev
er
ea
ux
 P
J 
an
d 
Ad
hi
ka
ri 
N
K 
et
 a
l..
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ize
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tri
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r b
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 re
vi
ew
. J
AM
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m
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 c
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l d
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re
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 b
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 p
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 d
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r b
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 b
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w
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 d
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 g
ro
up
 h
ad
 s
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 m
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w
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ANNEX 2: SYSTEMATIC REVIEW METHODOLOGY
Methods 
Criteria for considering studies for this review 
Types of studies
1. Randomized controlled trials
2. Systematic reviews and/or meta-analyses categorized as:
a. Cochrane reviews from any year
b. Non-Cochrane systematic review conducted between 2008 and 2013
c. Non-Cochrane systematic reviews conducted prior to 2008
We determined a priori that systematic reviews conducted prior to 2008 would require extensive updating 
and we therefore chose to focus on evaluating Cochrane reviews regardless of year and non-Cochrane reviews 
published since 2008.
Types of participants 
Varied according to each evidence question (see Annex 1)
Types of interventions 
Intervention
As defined by each evidence question
Comparison
As defined by each evidence question
Types of outcome measures 
Maternal outcomes:
1. Withdrawal 
2. Substance use
3. Retention in substance use treatment (if necessary, we used retention in the trial as a proxy measure)
4. Termination of maternal rights (e.g. baby taken into care)
Fetal/Infant outcomes:
1. Birthweight
2. Spontaneous abortion
3. Termination
4. Foetal death
5. Intra-uterine growth retardation (IUGR)
6. Gestational age at delivery
7. Premature delivery (before 37 weeks)
8. Neonatal Abstinence Syndrome (NAS)(drug-specific)
9. Neonatal death
10. Sudden Infant Death Syndrome
11. Birth defects
12. Head circumference at birth
13. Length at birth
14. Custody of infant
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Summary of findings table
We used the GRADE approach to interpret findings (Schünemann 2008) and used the GRADE profiler to 
import data from Review Manager (RevMan) to create 'Summary of findings' (SOF) tables. These tables 
provide outcome-specific information concerning the overall quality of evidence from each included study in 
the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all 
outcomes we rated as important to patient-care and decision making. 
The outcomes were rated independently by nine members of the Pregnancy and Substance Use Guidelines 
Committee. We selected seven patient-centred outcomes for each evidence question for inclusion in the SOF 
tables on the basis of these ratings.
Search methods for identification of studies 
The search was conducted by using a search strategy developed in consultation with the WHO Pregnancy and 
Substance Use Guidelines Technical Team. The search was iterative and the strategy was refined to ensure 
that it had maximum sensitivity to identify all relevant RCTs.
Electronic searches 
We developed the search strategy with the assistance of the World Health Organization Information Specialist. 
We formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant randomized 
controlled trials, systematic reviews and meta-analyses regardless of language or publication status (published, 
unpublished, in press, and in progress).
We combined the RCT strategy developed by The Cochrane Collaboration and detailed in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins 2011) with the PUBMED strategy for Systematic 
Reviews together with database-specific terms for pregnancy, lactation and the postpartum period. This was 
combined with database-specific terms for substance use, abuse and dependence. We did not limit the search 
to specific substances or interventions as the search was intentionally general to be applicable to all evidence 
questions to be addressed during the guideline process.
The search was iterative and a number of trial searches were run first to ensure maximal sensitivity.
We searched the following databases:
1. Journal databases
 o Medline via Pubmed – see search strategy conducted on 9 June 2013 below
 o EmBase – see search strategy conducted on 10 June 2013 below
 o PsychInfo – see search strategy conducted on 10 June 2013 below
 o CINAHL – see search strategy conducted on 10 June 2013 below
 o Cochrane Central Register of Controlled Trials (CENTRAL) – see search strategy conducted on 13 June 
2013 below
Searching other resources 
We checked the reference lists of all studies identified by the above methods and examined any systematic 
reviews, meta-analyses, or guidelines we identified during the search process for references.
We were in close contact with individual researchers working in the field, and policymakers based in inter-
governmental organizations including WHO and UNODC.
Data collection and analysis 
Selection of studies 
Two review authors (NS for all; NC for records from 2012 and an intern for records pre-2012) inspected all 
citations from the electronic search and identified relevant abstracts of trials and systematic reviews for inclusion 
criteria. The full text articles were obtained for all potentially relevant studies and NS assessed each of these 
for eligibility. This process was duplicated by NC and two interns. 
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Where there were uncertainties or disagreements, or where disputes could not be resolved, these studies 
remained in awaiting assessment or ongoing studies and the authors were contacted for clarification. NS and 
NC made final decisions regarding inclusion.
Data extraction and management 
1. Extraction
NS extracted data from included studies. NC checked each data entry. We resolved disputes by discussion. If 
it was not possible to extract data or if further information was needed, we attempted to contact the authors. 
We extracted data presented only in tables and figures whenever possible, and when further information was 
necessary, we contacted authors of studies in order to obtain missing data or for clarification of methods.
2. Management
2.1 Forms
We extracted data onto standardized, simple forms, including:
 o Administrative details: Trial or study identification number; author(s); published or unpublished; year of 
publication; number of studies included in paper; year in which study was conducted; details of other 
relevant papers cited;
 o Details of the study: Study design; type, duration and completeness of follow-up; country and location of 
study (e.g. higher-income vs. lower-income country); informed consent and ethics approval;
 o Details of participants: Setting, numbers, relevant baseline characteristics including age;
 o Details of intervention: Type of intervention, timing and duration of intervention, additional co-interventions;
 o Details of comparison: Type and comparison, timing and duration of comparative intervention;
 o Details of outcomes: Maternal and infant outcomes; 
 o Details of the analysis: For RCTs, details of the type of analysis (intention-to-treat or per protocol).
2.2 Scale-derived data
We included continuous data from rating scales only if:
 o the psychometric properties of the measuring instrument have been described in a peer-reviewed journal; 
and
 o the measuring instrument has not been written or modified by one of the trialists for that particular trial.
Ideally the measuring instrument should either be i) a self-report or ii) completed by an independent rater or 
relative (not the therapist). We realize that this is not often reported clearly and noted this to assist in the Risk 
of Bias assessment.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change data can remove a component of between-
person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline 
and endpoint), which can be difficult in unstable and difficult to measure conditions such as substance 
dependence. We decided to primarily use endpoint data, and only use change data if the former were not 
available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather 
than standardized mean differences throughout (Higgins 2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying 
parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:
 o standard deviations and means are reported in the paper or obtainable from the authors;
 o when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than 
the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution 
(Altman 1996).
Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered 
skewed endpoint data from studies of fewer than 200 participants as other data within Data and analyses rather 
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than into a statistical analysis. Skewed data pose less of a problem when looking at means if the sample size 
is large; we entered such endpoint data into syntheses.
When continuous data are presented on a scale that includes a possibility of negative values (such as change 
data), it is difficult to tell whether data are skewed or not. For these cases, we entered skewed change data 
into analyses regardless of size of study.
2.5 Common measure
To facilitate comparison between trials, we intended to convert variables that can be reported in different 
metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean 
days per month).
2.6 Direction of graphs
Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a 
favourable outcome for the treatment intervention. Where keeping to this made it impossible to avoid outcome 
titles with clumsy double-negatives (e.g. 'Not improved') we reported data where the left of the line indicates 
an unfavourable outcome. This was noted in the relevant graphs.
Assessment of risk of bias in included studies 
NS worked independently by using criteria described in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011) to assess trial quality. This set of criteria is based on evidence of associations 
between overestimate of effect and high risk of bias of the article such as sequence generation, allocation 
concealment, blinding, incomplete outcome data and selective reporting.
Full details of the Risk of Bias tool can be viewed in the table below. 
Item Low risk High risk Unclear risk
Sequence 
generation 
Investigators described a 
random component in the 
sequence generation process 
such as the use of random 
number table, coin tossing, cards 
or envelope shuffling
Investigators described a 
non-random component in the 
sequence generation process 
such as the use of odd or even 
date of birth, algorithm based on 
the day/date of birth, hospital or 
clinic record number
Insufficient information 
to permit judgment of the 
sequence generation 
process
Allocation 
concealment
Participants and the investigators 
enrolling participants cannot 
foresee assignment, e.g. central 
allocation; or sequentially 
numbered, opaque, sealed 
envelopes
Participants and investigators 
enrolling participants can 
foresee upcoming assignment, 
e.g. an open random allocation 
schedule (e.g. a list of random 
numbers); or envelopes were 
unsealed or non¬opaque or not 
sequentially numbered
Insufficient information 
to permit judgment of the 
allocation concealment or 
the method not described
Blinding Blinding of the participants, key 
study personnel and outcome 
assessor, and unlikely that the 
blinding could have been broken. 
Or lack of blinding unlikely to 
introduce bias. No blinding in the 
situation where non-blinding is 
not likely to introduce bias.
No blinding, incomplete blinding 
and the outcome is likely to be 
influenced by lack of blinding
Insufficient information 
to permit judgment of 
adequacy or otherwise of 
the blinding
Incomplete 
outcome data 
No missing outcome data, 
reasons for missing outcome 
data unlikely to be related to true 
outcome, or missing outcome 
data balanced in number across 
groups
Reason for missing outcome 
data likely to be related to true 
outcome, with either imbalance 
in number across groups or 
reasons for missing data
Insufficient reporting of 
attrition or exclusions
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Item Low risk High risk Unclear risk
Selective 
reporting
A protocol is available which 
clearly states the primary 
outcome as the same as in the 
final trial report
The primary outcome differs 
between the protocol and final 
trial report
No trial protocol is 
available or there is 
insufficient reporting to 
determine if selective 
reporting is present
Where inadequate details of randomization and other characteristics of trials were provided, we contacted 
authors of the studies in order to obtain additional information.
We have noted the level of risk of bias in the text of the review.
Measures of treatment effect 
1. Binary data
For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval 
(CI). 
2. Continuous data
For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to 
calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable 
similarity were used, we presumed there was a small difference in measurement, and we would have calculated 
effect size and transformed the effect back to the units of one or more of the specific instruments.
Unit of analysis issues 
1. Cluster trials
Studies increasingly employ 'cluster randomization' (such as randomization by clinician or practice), but analysis 
and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered 
studies, leading to a 'unit of analysis' error (Divine 1992) whereby P values are spuriously low, confidence 
intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997).
Where study authors were unable to provide the information needed to correct for flawed analysis of cluster 
randomized trials, the data was analysed as a non cluster RCT but with downgrading of the certainty of effect 
in the GRADE table.
2. Cross-over trials
None of the present included studies employed a cross-over trial design.
3. Studies with multiple treatment groups
Dealing with missing data 
1. Overall loss of credibility
At some degree of loss of follow-up data must lose credibility. We chose that, for any particular outcome, 
should more than 50% of data be unaccounted for, we would not reproduce these data or use them within 
analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss is less than 
50%, we would address this within the Summary of Findings table(s) by down-rating quality. Finally, we would 
also downgrade quality within the Summary of Findings table(s) should loss be 25-50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0 and 50% and where these data are not clearly 
described, we presented data on a 'once-randomized-always-analysed' basis (an intention to treat analysis). 
Those leaving the study early were assumed to have the same rates of negative outcome as those who 
completed in that particular arm of the trial. We undertook a sensitivity analysis testing how prone the primary 
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outcomes are to change when data only from people who complete the study to that point were compared to 
the intention to treat analysis using the above assumptions.
3. Continuous Data
3.1 Attrition
In the case where attrition for a continuous outcome is between 0 and 50%, and data only from people who 
complete the study to that point are reported, we reproduced these.
3.2 Standard deviations
If standard deviations are not reported, we first tried to obtain the missing values from the authors. If not 
available, where there are missing measures of variance for continuous data, but an exact standard error and 
confidence intervals available for group means, and either 'p' value or 't' value available for differences in mean, 
we can calculate them according to the rules described in the Cochrane Handbook for Systemic reviews of 
Interventions (Higgins 2011): when only the standard error (SE) is reported, standard deviations (SDs) are 
calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for 
Systemic reviews of Interventions (Higgins 2011) present detailed formula for estimating SDs from p-values, 
t or F values, confidence intervals, ranges or other statistics. 
3.3 Last observation carried forward
We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed 
within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty 
about the reliability of the results (Leucht 2007). Therefore, where LOCF data have been used in the trial, if 
less than 50% of the data have been assumed, we would present and use these data and indicate that they 
are the product of LOCF assumptions.
Assessment of heterogeneity 
1. Clinical heterogeneity
We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We 
inspected all studies for clearly outlying people or situations which we had not predicted would arise. When 
such situations or participant groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judge methodological 
heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise. 
When such methodological outliers arose, we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the I2 method alongside the Chi2 P value. The 
I2 provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The 
importance of the observed value of I2 depends on i) magnitude and direction of effects and ii) strength of 
evidence for heterogeneity (e.g. P value from Chi2 test, or a confidence interval for I2). I2 estimate greater than 
or equal to around 50% accompanied by a statistically significant Chi2 statistic was interpreted as evidence of 
substantial levels of heterogeneity (Higgins 2011). When substantial levels of heterogeneity were found in the 
primary outcome, we explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases 
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction 
of results (Egger 1997). These are described in Section 10 of the Handbook (Higgins 2011). We are aware 
that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study 
effects. We did not plan to use funnel plots for outcomes where there were 10 or fewer studies, or where 
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all studies were of similar sizes. As no meta-analyses of more than five studies were undertaken, we did not 
conduct funnel plot analysis.
Data synthesis 
Where RCTs are found to be methodologically or clinically comparable, we pooled trial results in a meta-analysis. 
Where we found the presence of statistical heterogeneity we combined the data using the random effects 
model. 
For meta-analysis of RCTs, we combined the results and the relative risk and the 95% confidence intervals 
for dichotomous data. For continuous data, we combined the mean differences to calculate a weighted mean 
difference and standard deviation. 
Subgroup analysis and investigation of heterogeneity 
We will explore heterogeneity by conducting sub-group analyses between:
1. Type of substance dependence
2. Setting of treatment (e.g. inpatient versus outpatient)
Main results 
Results of the search 
The number of records retrieved from each database can be seen in the table below:
Database Number of records
PUBMED 1479
EMBASE 3614
PsychInfo 512
CINAHL 754
CENTRAL 84
Total 6443
FIGURE 1: FLOW DIAGRAM OF LITERATURE SEARCH
FULL TEXT 
OBTAINED
172
ELIGIBLE 
ARTICLES
93
SCREENED
5632
After electronic and manual deduplication using ENDNOTE software, we screened 5632 records of which 
172 were identified as potentially eligible RCTs and 73 systematic reviews and the full texts for these were 
obtained – see Figure 1.
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TABLE OF EVIDENCE QUESTIONS (PICO) BY NUMBER OF ARTICLES IDENTIFIED AND NUMBER 
OF RCTS
PICO Intervention Articles RCTs
1 Screening and brief intervention 17 10
2 Psychosocial interventions 30 15
3 Detoxification 0 0
4 Dependence management 36 4
5 Lactation 0 0
6 Management of infant withdrawal 5 4
Unclassified 5
Total 93 33
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PUBMED search strategy
Search
Add to 
builder Query Items found
#9 Add Search (#5) AND #8 1476
#8 Add Search (#6) OR #7 1242301
#7 Add Search (((systematic review [ti] OR meta-analysis [pt] OR meta-analysis 
[ti] OR systematic literature review [ti] OR (systematic review [tiab] AND 
review [pt]) OR consensus development conference [pt] OR practice 
guideline [pt] OR cochrane database syst rev [ta] OR acp journal club 
[ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] 
OR drug class reviews [ti]) OR (clinical guideline [tw] AND management 
[tw])OR ((evidence based[ti] OR evidence-based medicine [mh] OR best 
practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases 
category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics 
[mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR 
pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR 
(study selection [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* 
[tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard 
of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] 
OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR 
handsearch [tw] OR analysis [tiab] OR critique [tiab] OR appraisal [tw] OR 
(reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) 
AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication 
[tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR 
unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR 
internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR 
papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical 
[tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome 
[tw] OR pmcbook))))
212906
#6 Add Search (((clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR 
"clinical trials as topic"[mesh: noexp] OR randomly [tiab] OR trial [tiab]) NOT 
(animals [mh] NOT humans [mh])))
1081782
#5 Add Search (#3) AND #4 18324
#4 Add Search (((pregnant women[mh] OR pregnancy[mh] OR pregnant[tiab] OR 
pregnancy[tiab] OR antenatal[tiab] OR ante-natal[tiab] OR prenatal[tiab] 
OR breast feeding[mh] OR breast feed*[tiab] OR breastfeed*[tiab] OR 
postnatal[tiab] OR post-natal[tiab] OR postpartum[tiab] OR postpartum 
period[mh] OR lactat*[tiab] OR maternal exposure[mh] OR maternal 
exposure*[tiab])))
942452
#3 Add Search (#1) OR #2 350542
#2 Add Search (((substance-related disorders[mh] OR prescription drug misuse[mh] 
OR street drugs[mh] OR street drugs[tiab] OR recreational drugs[tiab] OR 
illicit drugs[tiab] OR cocaine[tiab] OR designer drugs[mh] OR designer 
drugs[tiab] OR cannabis[mh] OR cannabis[tiab] OR marijuana*[tiab] OR 
hashish[tiab] OR bhang*[tiab] OR ganja*[tiab] OR hemp[tiab] OR heroin[mh] 
OR heroin[tiab] OR amphetamine[mh] OR amphetamine*[tiab] OR (drug[tiab] 
OR benzodiazepine [tiab] OR opioids[tiab] OR prescription[tiab] OR 
barbiturate[tiab] OR tramadol[tiab] OR oxycodone[tiab] OR substance[tiab]) 
AND (misuse[tiab] OR use[tiab] OR abuse[tiab] OR abuses[tiab] 
OR dependence[tiab] OR dependency[tiab] OR addiction[tiab] OR 
habituation[tiab] OR disorder*[tiab] OR consumption[tiab]))))
168206
#1 Add Search (((alcohol drinking[mh] OR alcoholism[mh] OR alcohol-related 
disorders[mh] OR fetal alcohol syndrome[mh] OR alcohol[tiab])))
227539
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EmBase search strategy 
# Searches Results
1 'drinking behavior'/exp OR 'drinking behaviour':ti,ab OR 'alcohol abstinence'/exp OR 
'alcoholism'/exp OR 'alcohol':ti,ab OR alcoholic:ti,ab OR alcoholism:ti,ab OR 'fetal alcohol 
syndrome'/exp
306,329
2 'addiction'/exp OR 'substance-related disorders' OR 'substance-related disorder' 
OR 'chemical dependence' OR 'addictive behavior' OR 'addictive behaviour' OR 
'addictive behaviors' OR 'addictive behaviours' OR 'drug misuse'/exp OR 'drug misuse' 
OR 'street drug'/exp OR 'street drugs' OR 'recreational drugs' OR 'recreational drug' 
OR 'illicit drugs' OR 'illicit drug' OR cocaine OR 'cannabis'/exp OR cannabis:ti,ab OR 
'cannabis smoking'/exp OR marijuana*:ti,ab OR hashish:ti,ab OR bhang:ti,ab OR ‘ C 
indica’:ti,ab OR cannador*:ti,ab OR charas*:ti,ab OR ganja*:ti,ab OR ganjah*:ti,ab OR 
hemp*:ti,ab OR marihuana*:ti,ab OR heroin OR 'amphetamine'/exp OR amphetamine 
OR ‘actedron’ OR ‘ actemin’ OR ‘ adderall’ OR ‘ adderall ir’ OR ‘ adderall xr’ OR ‘ adipan’ 
OR ‘ aktedrin’ OR ‘ aktedron’ OR ‘ alentol’ OR ‘ allodene’ OR ‘ alpha amphetamine’ OR ‘ 
alpha methylphenethylamine’ OR ‘ alpha methylphenylethylamine’ OR ‘ amfetamine’ OR 
‘ amphamed’ OR ‘ amphamine’ OR ‘ amphetaime’ OR ‘ amphetamin’ OR ‘ amphetamine 
base phosphate’ OR ‘ amphetamine base sulfate’ OR ‘ amphetamine detection’ OR 
‘ amphetamine hydrochloride’ OR ‘ amphetamine intoxication’ OR ‘ amphetamine 
metabolism’ OR ‘ amphetamine phosphate’ OR ‘ amphetamine resin complex’ OR ‘ 
amphetamine sulfate’ OR ‘ amphetamine toxicity’ OR ‘ amphetaminyl’ OR ‘ amphethamine’ 
OR ‘ amphezamin’ OR ‘ anara’ OR ‘ astedin’ OR ‘ badrin’ OR ‘ benzafinyl’ OR ‘ benzebar’ 
OR ‘ benzedrine’ OR ‘ benzolone’ OR ‘ benzpropamin’ OR ‘ benzpropamine’ OR ‘ beta 
aminopropylbenzene’ OR ‘ beta phenyl isopropylamine’ OR ‘ beta phenylisopropylamine’ 
OR ‘ betafen’ OR ‘ bluzedrin’ OR ‘ centramina’ OR ‘ centramine’ OR ‘ d l amphetamine’ OR ‘ 
delta amphetamine’ OR ‘ desoxynorephedrin’ OR ‘ dextro levo 2 methylphenethylamine’ OR 
‘ dextro levo 2 methylphenetylamine’ OR ‘ dextro levo alpha methylphenethylamine’ OR ‘ 
dextro levo amphetamine’ OR ‘ dextrolevo amphetamine’ OR ‘ diethamine’ OR ‘ diethanine’ 
OR ‘ dipan’ OR ‘ elastonin’ OR ‘ elastonon’ OR ‘ euphobine’ OR ‘ euphodine’ OR ‘ euphodyn’ 
OR ‘ fabedrine’ OR ‘ fenara’ OR ‘ fenedrin’ OR ‘ ibiozedrine’ OR ‘ isoamin’ OR ‘ isoamine’ 
OR ‘ isoamyn’ OR ‘ isoamyne’ OR ‘ isomyn’ OR ‘ l amphetamine’ OR ‘ levamfetamine’ OR ‘ 
levamphetamine’ OR ‘ levedrine’ OR ‘ levo amphetamine’ OR ‘ levo amphetamine sulphate’ 
OR ‘ levoamphetamine’ OR ‘ linampheta’ OR ‘ mecodrin’ OR ‘ mimetina’ OR ‘ monetamin’ 
OR ‘ monophos’ OR ‘ noclon’ OR ‘ norephedrane’ OR ‘ norphedrane’ OR ‘ novydrine’ 
OR ‘ obesin andromacro’ OR ‘ obetrol’ OR ‘ oktedrin’ OR ‘ oraldrina’ OR ‘ ortedrine’ OR ‘ 
percomon’ OR ‘ pharmamedrine’ OR ‘ pharmedrine’ OR ‘ phenamin’ OR ‘ phenedrine’ OR ‘ 
phenoprominum’ OR ‘ phenpromin’ OR ‘ phenyl isopropylamine’ OR ‘ phenylaminopropane’ 
OR ‘ profamina’ OR ‘ profetamine’ OR ‘ propisamine’ OR ‘ psychedrin’ OR ‘ psychedrine’ OR 
‘ psychoton’ OR ‘ racemic desoxy nor ephedrine’ OR ‘ racemic desoxy norephedrine’ OR ‘ 
racephen’ OR ‘ raphetamine’ OR ‘ rhinalator’ OR ‘ sedolin’ OR ‘ simpamina’ OR ‘ simpamine’ 
OR ‘ simpatedrin’ OR ‘ simpatedrine’ OR ‘ stimulan’ OR ‘ sympametin’ OR ‘ sympamine’ 
OR ‘ sympatedrine’ OR ‘ theptine’ OR ‘ vapedrine’ OR ‘ zedrin’ OR ‘ zedrine’ OR (Drug:ti,ab 
OR 'sedative agent'/exp OR benzodiazepine OR ‘opiate’/exp OR opioids OR 'tramadol'/
exp OR ‘adamon’ OR ‘ amanda’ OR ‘ analab’ OR ‘ analdol’ OR ‘ andalpha’ OR ‘ bellatram’ 
OR ‘ biodalgic’ OR ‘ calmador’ OR ‘ calmol’ OR ‘ cg 315e’ OR ‘ cg315e’ OR ‘ contramal’ 
OR ‘ contramal lp’ OR ‘ dolana’ OR ‘ dolika’ OR ‘ dolmal’ OR ‘ dolotral’ OR ‘ dolzam’ OR 
‘ dromadol’ OR ‘ e 381’ OR ‘ e 382’ OR ‘ e381’ OR ‘ e382’ OR ‘ eufindol’ OR ‘ exopen’ OR ‘ 
katrasic’ OR ‘ kontram xl’ OR ‘ kontram xl sr’ OR ‘ mabron’ OR ‘ melanate’ OR ‘ mosepan’ OR 
‘ newdorphin’ OR ‘ nobligan’ OR ‘ nonalges’ OR ‘ o.p. pain’ OR ‘ omnidol’ OR ‘ pengesic’ OR ‘ 
penimadol’ OR ‘ prontofort’ OR ‘ radol’ OR ‘ rofy’ OR ‘ ryzolt’ OR ‘ sefmal’ OR ‘ sensitram’ OR 
‘ takadol’ OR ‘ tamolan’ OR ‘ tandol’ OR ‘ tarol’ OR ‘ topalgic’ OR ‘ trabar’ OR ‘ trabilan’ OR ‘ 
trabilin’ OR ‘ tradol’ OR ‘ tradol-puren’ OR ‘ tradolan’ OR ‘ tradonal’ OR ‘ tralic’ OR ‘ tramada’ 
OR ‘ tramadex’ OR ‘ tramadol hydrochloride’ OR ‘ tramadolium chloride’ OR ‘ tramagetic’ 
OR ‘ tramagit’ OR ‘ tramahexal’ OR ‘ tramake’ OR ‘ tramal’ OR ‘ tramal sr’ OR ‘ tramazac’ OR 
‘ tramed’ OR ‘ tramol’ OR ‘ tramundin’ OR ‘ tramundin retard’ OR ‘ trans 2 [(dimethylamino) 
methyl] 1 (3 methoxyphenyl) cyclohexanol’ OR ‘ trans 2 [(dimethylamino) methyl] 1 (meta 
methoxyphenyl) cyclohexanol hydrochloride’ OR ‘ trans 2 dimethylaminomethyl 1 (3 
methoxyphenyl) cyclohexanol’ OR ‘ trasedal’ OR ‘ trasik’ OR ‘ trd-contin’ OR ‘ trexol’ OR 
‘ tridol’ OR ‘ trodon’ OR ‘ trondon’ OR ‘ u 26225a’ OR ‘ u26225a’ OR ‘ ultram’ OR ‘ ultram 
er’ OR ‘ unitral’ OR ‘ urgendol’ OR ‘ zamadol’ OR ‘ zamudol’ OR ‘ zodol’ OR ‘ zumatran’ 
OR ‘ zydol’ OR ‘ zytram bd’ OR ‘ zytram xl sr’ OR 'oxycodone'/exp OR ‘bionine’ OR ‘ 
bionone’ OR ‘ bolodorm’ OR ‘ broncodal’ OR ‘ bucodal’ OR ‘ cafacodal’ OR ‘ cardanon’ 
OR ‘ codenon’ OR ‘ codix 5’ OR ‘ col 003’ OR ‘ col003’ OR ‘ dihydrohydroxycodeinone’ OR ‘ 
dihydrohydroxydodeinone’ OR ‘ dihydrone’ OR ‘ dinarkon’ OR ‘ endone’ OR ‘ eubine’
418,269
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EmBase search strategy 
# Searches Results
OR ‘ eucodal’ OR ‘ eucodale’ OR ‘ eucodalum’ OR ‘ eudin’ OR ‘ eukdin’ OR ‘ eukodal’ OR ‘ 
eumorphal’ OR ‘ eurodamine’ OR ‘ eutagen’ OR ‘ hydrocodal’ OR ‘ hydroxycodeinoma’ OR 
‘ ludonal’ OR ‘ m-oxy’ OR ‘ medicodal’ OR ‘ narcobasina’ OR ‘ narcobasine’ OR ‘ narcosin’ 
OR ‘ nargenol’ OR ‘ narodal’ OR ‘ nsc 19043’ OR ‘ nucodan’ OR ‘ opton’ OR ‘ ossicodone’ 
OR ‘ oxanest’ OR ‘ oxecta’ OR ‘ oxicone’ OR ‘ oxicontin’ OR ‘ oxiconum’ OR ‘ oxikon’ OR ‘ 
oxy ir’ OR ‘ oxycod’ OR ‘ oxycodeinonhydrochloride’ OR ‘ oxycodone hydrochloride’ OR 
‘ oxycodonhydrochlorid’ OR ‘ oxycodyl’ OR ‘ oxycone’ OR ‘ oxycontin’ OR ‘ oxycontin cr’ 
OR ‘ oxycontin lp’ OR ‘ oxydose’ OR ‘ oxyfast’ OR ‘ oxygesic’ OR ‘ oxyir’ OR ‘ oxykon’ OR 
‘ oxynorm’ OR ‘ pancodine’ OR ‘ pavinal’ OR ‘ percolone’ OR ‘ pronarcin’ OR ‘ remoxy’ 
OR ‘ roxicodone’ OR ‘ roxycodone’ OR ‘ sinthiodal’ OR ‘ stupenal’ OR ‘ supeudol’ OR 
‘ tebodal’ OR ‘ tekodin’ OR ‘ thecodin’ OR ‘substance’:ti,ab) AND (misuse:ti,ab OR 
use:ti,ab OR abuse:ti,ab OR dependence:ti,ab OR dependency:ti,ab OR addiction:ti,ab OR 
habituation:ti,ab OR disorder*:ti,ab OR consumption:ti,ab)
3 #1 AND #2 650,852
4 'pregnant woman'/exp OR 'pregnancy'/exp OR 'child bearing':ti,ab OR 'childbearing':ti,ab 
OR pregnant:ti,ab OR pregnancy:ti,ab OR 'breast feeding education'/exp OR 
'breastfed':ti,ab OR breastfeed*:ti,ab OR breast NEXT/2 feed* OR 'puerperium'/exp 
OR 'postpartum':ti,ab OR postpartum:ti,ab OR 'ante natal':ti,ab OR prenatal:ti,ab OR 
postnatal:ti,ab OR 'postnatal':ti,ab OR lactat*:ti,ab OR 'prenatal drug exposure'/exp OR 
'maternal exposure':ti,ab
990,027
5 #3 AND #4 29,732
6 'Clinical trial'/exp OR 'Randomized controlled trial'/exp OR 'Randomization'/exp OR 'Single 
blind procedure'/exp OR 'Double blind procedure'/exp OR 'Crossover procedure'/exp OR 
'Placebo'/exp OR 'Randomized controlled trials':ti,ab OR 'Randomized controlled trial':ti,ab 
OR 'Randomized controlled trials':ti,ab OR 'Randomized controlled trial':ti,ab OR rct:ti,ab 
OR 'Random allocation':ti,ab OR 'Randomly allocated':ti,ab OR 'allocated randomly':ti,ab 
OR (allocated NEAR/2 random):ti,ab OR ('Single' NEAR/2 blind*):ti,ab OR ('double' NEAR/2 
blind*):ti,ab OR ((treble or triple) NEAR/3 blind*):ti,ab OR Placebo*:ti,ab OR 'Prospective 
study'/exp
1,361,716
7 'systematic review'/exp OR 'systematic review (topic)'/exp OR 'review'/exp/mj OR 
'medlars':ti,ab OR 'pubmed':ti,ab OR 'scisearch':ti,ab OR 'bibliographic database'/
exp OR 'psychlit':ti,ab OR 'psyclit’:ti,ab OR biosis:ti,ab OR ‘british nursing index’:ti,ab 
OR ‘cinahl’:ti,ab OR ‘cochrane library’:ti,ab OR ‘campbell library’:ti,ab OR ‘full text 
databases’:ti,ab OR ‘international pharmaceutical abstracts’:ti,ab OR toxlit:ti,ab OR 
'electronic databases':ti,ab OR 'electronic database':ti,ab OR (hand NEAR/3 search*) 
OR (manual* NEAR/3 search*) OR (bibliographic NEAR/3 database*) OR (pooled 
NEAR/3 analys*) OR pooling OR peto OR sesimonian OR (fixed NEAR/3 effect) OR 
'mantel haenszel':ti,ab OR 'meta analysis'/exp OR 'meta analysis' OR 'retracted article'/
exp OR 'retracted article' OR (systematic* NEAR/3 review*) OR (systematic* NEAR/5 
overview*) OR (quantitative* NEAR/3 review*) OR (quantitative* NEAR/3 overview*) OR 
(methodologic* NEAR/3 review*) OR (methodologic* NEAR/5 overview*) OR (integrative 
NEAR/3 review*) OR (research NEAR/3 integration) OR (quantitative* NEAR/3 synthesi*) 
OR (systematic* NEAR/3 search*) OR medline:ti,ab OR embase:ti,ab
256,647
8 #6 OR #7 1,525,780
9 #5 AND #8 3614
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PsychInfo search strategy 
# Searches Results
1 (((DE "Alcohol Drinking Attitudes" OR DE "Alcohol Drinking Patterns" OR DE "Alcohol Abuse" 
OR DE "Alcohol Intoxication" OR DE "Social Drinking" OR DE "Alcohol Intoxication" OR DE 
"Acute Alcoholic Intoxication" OR DE "Chronic Alcoholic Intoxication" OR DE "Alcohol 
Rehabilitation" OR DE "Alcoholics Anonymous" OR DE "Detoxification" OR DE "Alcohol 
Withdrawal" OR DE "Alcoholic Beverages" OR DE "Beer" OR DE "Liquor" OR DE "Wine" OR 
DE "Alcoholism" OR DE "Alcoholic Psychosis" OR DE "Alcohols" OR DE "Ethanol" OR DE 
"Isoproterenol" OR DE "Methanol" OR DE "Methoxamine") AND (DE "Alcohol Withdrawal" OR 
DE "Alcoholism")) AND (DE "Fetal Alcohol Syndrome" OR DE "Prenatal Exposure")) OR (DE 
"Fetal Alcohol Syndrome") OR TI "alcohol drinking" OR TI alcoholism OR TI alcohol OR AB 
"alcohol drinking" OR AB alcoholism OR AB alcohol
83,667
2 (DE "Addiction" OR DE "Alcoholism" OR DE "Drug Addiction" ) AND (DE "Drug Abuse" OR 
DE "Drug Addiction" OR DE "Drug Dependency") OR TI "recreational drug*" OR TI "street 
drug*" OR TI "designer drug*" OR TI "illicit drug*" OR AB "recreational drug*" OR AB 
"street drug*" OR AB "designer drug*" OR AB "illicit drug*" OR DE "Heroin" OR DE "Heroin 
Addiction" OR DE "Cannabis" OR DE "Hashish" OR DE "Marijuana" OR DE "Amphetamine" 
OR DE "Dextroamphetamine" OR DE "Methamphetamine" OR 'addiction' OR 'substance-
related disorders' OR 'substance-related disorder' OR 'chemical dependence' OR 
'addictive behavior' OR 'addictive behaviour' OR 'addictive behaviors' OR 'addictive 
behaviours' OR 'drug misuse'/exp OR 'drug misuse' OR 'street drug’ OR 'street drugs' OR 
'recreational drugs' OR 'recreational drug' OR 'illicit drugs' OR 'illicit drug' OR cocaine 
OR 'cannabis' OR cannabis OR 'cannabis smoking' OR marijuana* OR hashish OR TI 
bhang OR ‘ C indica’ OR cannador* OR charas* OR ganja* OR ganjah* OR hemp* OR 
marihuana* OR heroin OR 'amphetamine' OR amphetamine OR ‘actedron’ OR ‘ actemin’ 
OR ‘ adderall’ OR ‘ adderall ir’ OR ‘ adderall xr’ OR ‘ adipan’ OR ‘ aktedrin’ OR ‘ aktedron’ 
OR ‘ alentol’ OR ‘ allodene’ OR ‘ alpha amphetamine’ OR ‘ alpha methylphenethylamine’ OR 
‘ alpha methylphenylethylamine’ OR ‘ amfetamine’ OR ‘ amphamed’ OR ‘ amphamine’ OR 
‘ amphetaime’ OR ‘ amphetamin’ OR ‘ amphetamine base phosphate’ OR ‘ amphetamine 
base sulfate’ OR ‘ amphetamine detection’ OR ‘ amphetamine hydrochloride’ OR ‘ 
amphetamine intoxication’ OR ‘ amphetamine metabolism’ OR ‘ amphetamine phosphate’ 
OR ‘ amphetamine resin complex’ OR ‘ amphetamine sulfate’ OR ‘ amphetamine toxicity’ 
OR ‘ amphetaminyl’ OR ‘ amphethamine’ OR ‘ amphezamin’ OR ‘ anara’ OR ‘ astedin’ OR ‘ 
badrin’ OR ‘ benzafinyl’ OR ‘ benzebar’ OR ‘ benzedrine’ OR ‘ benzolone’ OR ‘ benzpropamin’ 
OR ‘ benzpropamine’ OR ‘ beta aminopropylbenzene’ OR ‘ beta phenyl isopropylamine’ 
OR ‘ beta phenylisopropylamine’ OR ‘ betafen’ OR ‘ bluzedrin’ OR ‘ centramina’ OR ‘ 
centramine’ OR ‘ d l amphetamine’ OR ‘ delta amphetamine’ OR ‘ desoxynorephedrin’ 
OR ‘ dextro levo 2 methylphenethylamine’ OR ‘ dextro levo 2 methylphenetylamine’ OR ‘ 
dextro levo alpha methylphenethylamine’ OR ‘ dextro levo amphetamine’ OR ‘ dextrolevo 
amphetamine’ OR ‘ diethamine’ OR ‘ diethanine’ OR ‘ dipan’ OR ‘ elastonin’ OR ‘ elastonon’ 
OR ‘ euphobine’ OR ‘ euphodine’ OR ‘ euphodyn’ OR ‘ fabedrine’ OR ‘ fenara’ OR ‘ fenedrin’ 
OR ‘ ibiozedrine’ OR ‘ isoamin’ OR ‘ isoamine’ OR ‘ isoamyn’ OR ‘ isoamyne’ OR ‘ isomyn’ 
OR ‘ l amphetamine’ OR ‘ levamfetamine’ OR ‘ levamphetamine’ OR ‘ levedrine’ OR ‘ levo 
amphetamine’ OR ‘ levo amphetamine sulphate’ OR ‘ levoamphetamine’ OR ‘ linampheta’ 
OR ‘ mecodrin’ OR ‘ mimetina’ OR ‘ monetamin’ OR ‘ monophos’ OR ‘ noclon’ OR ‘ 
norephedrane’ OR ‘ norphedrane’ OR ‘ novydrine’ OR ‘ obesin andromacro’ OR ‘ obetrol’ 
OR ‘ oktedrin’ OR ‘ oraldrina’ OR ‘ ortedrine’ OR ‘ percomon’ OR ‘ pharmamedrine’ OR ‘ 
pharmedrine’ OR ‘ phenamin’ OR ‘ phenedrine’ OR ‘ phenoprominum’ OR ‘ phenpromin’ OR 
‘ phenyl isopropylamine’ OR ‘ phenylaminopropane’ OR ‘ profamina’ OR ‘ profetamine’ OR 
‘ propisamine’ OR ‘ psychedrin’ OR ‘ psychedrine’ OR ‘ psychoton’ OR ‘ racemic desoxy 
nor ephedrine’ OR ‘ racemic desoxy norephedrine’ OR ‘ racephen’ OR ‘ raphetamine’ 
OR ‘ rhinalator’ OR ‘ sedolin’ OR ‘ simpamina’ OR ‘ simpamine’ OR ‘ simpatedrin’ OR ‘ 
simpatedrine’ OR ‘ stimulan’ OR ‘ sympametin’ OR ‘ sympamine’ OR ‘ sympatedrine’ 
OR ‘ theptine’ OR ‘ vapedrine’ OR ‘ zedrin’ OR ‘ zedrine’ OR (TI Drugs OR AB Drugs OR 
benzodiazepine OR ‘opiate’ OR opioids OR 'tramadol' OR ‘adamon’ OR ‘ amanda’ OR ‘ 
analab’ OR ‘ analdol’ OR ‘ andalpha’ OR ‘ bellatram’ OR ‘ biodalgic’ OR ‘ calmador’ OR ‘ 
calmol’ OR ‘ cg 315e’ OR ‘ cg315e’ OR ‘ contramal’ OR ‘ contramal lp’ OR ‘ dolana’ OR ‘ 
dolika’ OR ‘ dolmal’ OR ‘ dolotral’ OR ‘ dolzam’ OR ‘ dromadol’ OR ‘ e 381’ OR ‘ e 382’ OR ‘ 
e381’ OR ‘ e382’ OR ‘ eufindol’ OR ‘ exopen’ OR ‘ katrasic’ OR ‘ kontram xl’ OR ‘ kontram 
xl sr’ OR ‘ mabron’ OR ‘ melanate’ OR ‘ mosepan’ OR ‘ newdorphin’ OR ‘ nobligan’ OR ‘ 
nonalges’ OR ‘ o.p. pain’ OR ‘ omnidol’ OR ‘ pengesic’ OR ‘ penimadol’ OR ‘ prontofort’ OR 
‘ radol’ OR ‘ rofy’ OR ‘ ryzolt’ OR ‘ sefmal’ OR ‘ sensitram’ OR ‘ takadol’ OR ‘ tamolan’ OR 
‘ tandol’ OR ‘ tarol’ OR ‘ topalgic’ OR ‘ trabar’ OR ‘ trabilan’ OR ‘ trabilin’ OR ‘ tradol’ OR ‘ 
tradol-puren’ OR ‘ tradolan’ OR ‘ tradonal’ OR ‘ tralic’ OR ‘ tramada’ OR ‘ tramadex’ OR 
170,118
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PsychInfo search strategy 
# Searches Results
‘ tramadol hydrochloride’ OR ‘ tramadolium chloride’ OR ‘ tramagetic’ OR ‘ tramagit’ OR 
‘ tramahexal’ OR ‘ tramake’ OR ‘ tramal’ OR ‘ tramal sr’ OR ‘ tramazac’ OR ‘ tramed’ OR ‘ 
tramol’ OR ‘ tramundin’ OR ‘ tramundin retard’ OR ‘ trasedal’ OR ‘ trasik’ OR ‘ trd-contin’ 
OR ‘ trexol’ OR ‘ tridol’ OR ‘ trodon’ OR ‘ trondon’ OR ‘ u 26225a’ OR ‘ u26225a’ OR ‘ ultram’ 
OR ‘ ultram er’ OR ‘ unitral’ OR ‘ urgendol’ OR ‘ zamadol’ OR ‘ zamudol’ OR ‘ zodol’ OR ‘ 
zumatran’ OR ‘ zydol’ OR ‘ zytram bd’ OR ‘ zytram xl sr’ OR 'oxycodone' OR ‘bionine’ OR 
‘ bionone’ OR ‘ bolodorm’ OR ‘ broncodal’ OR ‘ bucodal’ OR ‘ cafacodal’ OR ‘ cardanon’ 
OR ‘ codenon’ OR ‘ codix 5’ OR ‘ col 003’ OR ‘ col003’ OR ‘ dihydrohydroxycodeinone’ OR 
‘ dihydrohydroxydodeinone’ OR ‘ dihydrone’ OR ‘ dinarkon’ OR ‘ endone’ OR ‘ eubine’ 
OR ‘ eucodal’ OR ‘ eucodale’ OR ‘ eucodalum’ OR ‘ eudin’ OR ‘ eukdin’ OR ‘ eukodal’ OR ‘ 
eumorphal’ OR ‘ eurodamine’ OR ‘ eutagen’ OR ‘ hydrocodal’ OR ‘ hydroxycodeinoma’ OR 
‘ ludonal’ OR ‘ m-oxy’ OR ‘ medicodal’ OR ‘ narcobasina’ OR ‘ narcobasine’ OR ‘ narcosin’ 
OR ‘ nargenol’ OR ‘ narodal’ OR ‘ nsc 19043’ OR ‘ nucodan’ OR ‘ opton’ OR ‘ ossicodone’ 
OR ‘ oxanest’ OR ‘ oxecta’ OR ‘ oxicone’ OR ‘ oxicontin’ OR ‘ oxiconum’ OR ‘ oxikon’ OR ‘ 
oxy ir’ OR ‘ oxycod’ OR ‘ oxycodeinonhydrochloride’ OR ‘ oxycodone hydrochloride’ OR 
‘ oxycodonhydrochlorid’ OR ‘ oxycodyl’ OR ‘ oxycone’ OR ‘ oxycontin’ OR ‘ oxycontin cr’ 
OR ‘ oxycontin lp’ OR ‘ oxydose’ OR ‘ oxyfast’ OR ‘ oxygesic’ OR ‘ oxyir’ OR ‘ oxykon’ OR ‘ 
oxynorm’ OR ‘ pancodine’ OR ‘ pavinal’ OR ‘ percolone’ OR ‘ pronarcin’ OR ‘ remoxy’ OR ‘ 
roxicodone’ OR ‘ roxycodone’ OR ‘ sinthiodal’ OR ‘ stupenal’ OR ‘ supeudol’ OR ‘ tebodal’ 
OR ‘ tekodin’ OR ‘ thecodin’ OR ‘substance’:ti,ab) AND (TI misuse OR AB misuse OR TI 
use OR AB use OR TI abuse OR AB abuse OR TI dependence OR AB dependence OR TI 
dependency OR AB dependency OR TI addiction OR AB addiction OR TI habituation OR AB 
habituation OR TI disorder* OR AB disorder* OR TI consumption OR AB consumption)
3 #1 AND #2 207,330
4 DE "Pregnancy" OR DE "Adolescent Pregnancy" OR DE "Pregnancy Outcomes" OR DE "Birth" 
OR DE "Induced Abortion" OR DE "Premature Birth" OR DE "Spontaneous Abortion" OR DE 
"Prenatal Care" OR DE "Childbirth Training" OR DE "Prenatal Development" OR DE "Prenatal 
Developmental Stages" OR DE "Prenatal Developmental Stages" OR DE "Embryo" OR DE 
"Fetus" OR DE "Prenatal Exposure" OR TI Pregnancy OR AB Pregnancy OR TI pregnant OR 
AB Pregnant OR DE "Postnatal Period" OR DE "Perinatal Period" OR DE "Prenatal Care" 
OR DE "Prenatal Development" OR DE "Prenatal Developmental Stages" OR DE "Prenatal 
Exposure" OR DE "Prenatal Care" OR DE "Childbirth Training" OR DE "Prenatal Development" 
OR DE "Prenatal Developmental Stages" OR DE "Prenatal Developmental Stages" OR DE 
"Prenatal Exposure" OR TI postpartum OR AB postpartum OR TI postnatal OR AB Postnatal 
OR TI perinatal OR AB perinatal OR TI postpartum OR AB postpartum OR "maternal 
exposure" OR TI lactat* OR AB lactat*
63,174
5 #3 AND #4 7,796
6 (((DE "Placebo") OR (DE "Clinical Trials")) OR (DE "Evidence Based Practice" OR DE 
"Treatment Effectiveness Evaluation")) OR (DE "Random Sampling") OR TX allocat* random* 
OR TX placebo* OR TX random* allocate* OR TX randomi* control* trial* OR TX ( (singl* n1 
blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* 
n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) OR TX clinic* 
n1 trial*
92,996
7 (MH "Meta Analysis") OR "meta analysis" OR (MH "Literature Review+") OR "literature 
review" OR (MH "Systematic Review") OR "meta analys*" OR metaanalys* OR (Systematic 
AND (review OR overview)) OR TI medlars OR AB medlars OR TI pubmed OR AB pubmed 
OR TI scisearch OR AB scisearch OR TI “british nursing index” OR AB “british nursing 
index” OR “Cochrane library” OR “Campbell library” OR “full text databases “ OR 
“electronic databases” OR handsearching OR systematic n3 literature OR systematic 
review* OR meta-analy* OR metaanaly* OR "research synthesis" OR embase OR medline 
OR psyclit OR pubmed OR scopus OR "sociological abstracts" OR "web of science" OR 
"systematic review" or "meta analysis"
66,904
8 #6 OR #7 152,807
9 #5 AND #8 512
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# Searches Results
1 "alcohol drinking" OR (MH "Drinking Behavior+") OR (MH "Alcohol Rehabilitation 
Programs+") OR (MH "Alcohol Withdrawal Syndrome+") OR (MH "Alcohol-Induced 
Disorders, Nervous System+") OR (MH "Alcohol-Related Disorders") OR (MH "Substance 
Abuse+") OR (MH "Alcohol Abuse Control (Saba CCC)") OR (MH "Alcohol Abuse (Saba 
CCC)") OR (MH "Alcohol Deterrents+") OR (MH "Alcoholism") OR (MH "Substance Use 
Treatment: Alcohol Withdrawal (Iowa NIC)") OR (MH "Alcoholics") OR (MH "Fetal Alcohol 
Syndrome") OR (MH "Substance Abuse Detection") OR TI "alcohol drinking" OR TI 
alcoholism OR TI alcohol OR AB "alcohol drinking" OR AB alcoholism OR AB alcohol
65,704
2 (MH "Addictions Nursing") OR (MH "Infant, Drug-Exposed") OR (MH "Substance Addiction 
Consequences (Iowa NOC)") OR (MH "Analgesics, Opioid+") OR (MH "Substance 
Dependence+") OR (MH "Street Drugs") OR "illicit drugs" OR (MH "Substance Abuse 
Detection") OR (MH "Substance Abusers") OR (MH "Drug Abuse (Saba CCC)") OR (MH 
"Drug Abuse Control (Saba CCC)") OR (MH "Designer Drugs") OR (MH "Cannabis") OR (MH 
"Cocaine+") OR "cocaine" OR (MH "Heroin") OR (MH "Amphetamine") OR (MH "Albuterol") 
OR 'addiction' OR 'substance-related disorders' OR 'substance-related disorder' OR 
'chemical dependence' OR 'addictive behavior' OR 'addictive behaviour' OR 'addictive 
behaviors' OR 'addictive behaviours' OR 'drug misuse'/exp OR 'drug misuse' OR 'street 
drug’ OR 'street drugs' OR 'recreational drugs' OR 'recreational drug' OR 'illicit drugs' 
OR 'illicit drug' OR cocaine OR 'cannabis' OR cannabis OR 'cannabis smoking' OR 
marijuana* OR hashish OR TI bhang OR ‘ C indica’ OR cannador* OR charas* OR ganja* 
OR ganjah* OR hemp* OR marihuana* OR heroin OR 'amphetamine' OR amphetamine 
OR ‘actedron’ OR ‘ actemin’ OR ‘ adderall’ OR ‘ adderall ir’ OR ‘ adderall xr’ OR ‘ adipan’ 
OR ‘ aktedrin’ OR ‘ aktedron’ OR ‘ alentol’ OR ‘ allodene’ OR ‘ alpha amphetamine’ OR ‘ 
alpha methylphenethylamine’ OR ‘ alpha methylphenylethylamine’ OR ‘ amfetamine’ OR 
‘ amphamed’ OR ‘ amphamine’ OR ‘ amphetaime’ OR ‘ amphetamin’ OR ‘ amphetamine 
base phosphate’ OR ‘ amphetamine base sulfate’ OR ‘ amphetamine detection’ OR 
‘ amphetamine hydrochloride’ OR ‘ amphetamine intoxication’ OR ‘ amphetamine 
metabolism’ OR ‘ amphetamine phosphate’ OR ‘ amphetamine resin complex’ OR ‘ 
amphetamine sulfate’ OR ‘ amphetamine toxicity’ OR ‘ amphetaminyl’ OR ‘ amphethamine’ 
OR ‘ amphezamin’ OR ‘ anara’ OR ‘ astedin’ OR ‘ badrin’ OR ‘ benzafinyl’ OR ‘ benzebar’ 
OR ‘ benzedrine’ OR ‘ benzolone’ OR ‘ benzpropamin’ OR ‘ benzpropamine’ OR ‘ beta 
aminopropylbenzene’ OR ‘ beta phenyl isopropylamine’ OR ‘ beta phenylisopropylamine’ 
OR ‘ betafen’ OR ‘ bluzedrin’ OR ‘ centramina’ OR ‘ centramine’ OR ‘ d l amphetamine’ OR ‘ 
delta amphetamine’ OR ‘ desoxynorephedrin’ OR ‘ dextro levo 2 methylphenethylamine’ OR 
‘ dextro levo 2 methylphenetylamine’ OR ‘ dextro levo alpha methylphenethylamine’ OR ‘ 
dextro levo amphetamine’ OR ‘ dextrolevo amphetamine’ OR ‘ diethamine’ OR ‘ diethanine’ 
OR ‘ dipan’ OR ‘ elastonin’ OR ‘ elastonon’ OR ‘ euphobine’ OR ‘ euphodine’ OR ‘ euphodyn’ 
OR ‘ fabedrine’ OR ‘ fenara’ OR ‘ fenedrin’ OR ‘ ibiozedrine’ OR ‘ isoamin’ OR ‘ isoamine’ 
OR ‘ isoamyn’ OR ‘ isoamyne’ OR ‘ isomyn’ OR ‘ l amphetamine’ OR ‘ levamfetamine’ OR ‘ 
levamphetamine’ OR ‘ levedrine’ OR ‘ levo amphetamine’ OR ‘ levo amphetamine sulphate’ 
OR ‘ levoamphetamine’ OR ‘ linampheta’ OR ‘ mecodrin’ OR ‘ mimetina’ OR ‘ monetamin’ 
OR ‘ monophos’ OR ‘ noclon’ OR ‘ norephedrane’ OR ‘ norphedrane’ OR ‘ novydrine’ 
OR ‘ obesin andromacro’ OR ‘ obetrol’ OR ‘ oktedrin’ OR ‘ oraldrina’ OR ‘ ortedrine’ OR ‘ 
percomon’ OR ‘ pharmamedrine’ OR ‘ pharmedrine’ OR ‘ phenamin’ OR ‘ phenedrine’ OR ‘ 
phenoprominum’ OR ‘ phenpromin’ OR ‘ phenyl isopropylamine’ OR ‘ phenylaminopropane’ 
OR ‘ profamina’ OR ‘ profetamine’ OR ‘ propisamine’ OR ‘ psychedrin’ OR ‘ psychedrine’ OR 
‘ psychoton’ OR ‘ racemic desoxy nor ephedrine’ OR ‘ racemic desoxy norephedrine’ OR ‘ 
racephen’ OR ‘ raphetamine’ OR ‘ rhinalator’ OR ‘ sedolin’ OR ‘ simpamina’ OR ‘ simpamine’ 
OR ‘ simpatedrin’ OR ‘ simpatedrine’ OR ‘ stimulan’ OR ‘ sympametin’ OR ‘ sympamine’ 
OR ‘ sympatedrine’ OR ‘ theptine’ OR ‘ vapedrine’ OR ‘ zedrin’ OR ‘ zedrine’ OR (TI Drugs 
OR AB Drugs OR benzodiazepine OR ‘opiate’ OR opioids OR 'tramadol' OR ‘adamon’ OR 
‘ amanda’ OR ‘ analab’ OR ‘ analdol’ OR ‘ andalpha’ OR ‘ bellatram’ OR ‘ biodalgic’ OR ‘ 
calmador’ OR ‘ calmol’ OR ‘ cg 315e’ OR ‘ cg315e’ OR ‘ contramal’ OR ‘ contramal lp’ OR ‘ 
dolana’ OR ‘ dolika’ OR ‘ dolmal’ OR ‘ dolotral’ OR ‘ dolzam’ OR ‘ dromadol’ OR ‘ e 381’ OR ‘ 
e 382’ OR ‘ e381’ OR ‘ e382’ OR ‘ eufindol’ OR ‘ exopen’ OR ‘ katrasic’ OR ‘ kontram xl’ OR ‘ 
kontram xl sr’ OR ‘ mabron’ OR ‘ melanate’ OR ‘ mosepan’ OR ‘ newdorphin’ OR ‘ nobligan’ 
OR ‘ nonalges’ OR ‘ o.p. pain’ OR ‘ omnidol’ OR ‘ pengesic’ OR ‘ penimadol’ OR ‘ prontofort’ 
OR ‘ radol’ OR ‘ rofy’ OR ‘ ryzolt’ OR ‘ sefmal’ OR ‘ sensitram’ OR ‘ takadol’ OR ‘ tamolan’ 
OR ‘ tandol’ OR ‘ tarol’ OR ‘ topalgic’ OR ‘ trabar’ OR ‘ trabilan’ OR ‘ trabilin’ OR ‘ tradol’ OR 
‘ tradol-puren’ OR ‘ tradolan’ OR ‘ tradonal’ OR ‘ tralic’ OR ‘ tramada’ OR ‘ tramadex’ OR ‘ 
tramadol hydrochloride’ OR ‘ tramadolium chloride’ OR ‘ tramagetic’ OR ‘ tramagit’ OR
105,036
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# Searches Results
 ‘ tramahexal’ OR ‘ tramake’ OR ‘ tramal’ OR ‘ tramal sr’ OR ‘ tramazac’ OR ‘ tramed’ OR ‘ 
tramol’ OR ‘ tramundin’ OR ‘ tramundin retard’ OR ‘ trasedal’ OR ‘ trasik’ OR ‘ trd-contin’ 
OR ‘ trexol’ OR ‘ tridol’ OR ‘ trodon’ OR ‘ trondon’ OR ‘ u 26225a’ OR ‘ u26225a’ OR ‘ ultram’ 
OR ‘ ultram er’ OR ‘ unitral’ OR ‘ urgendol’ OR ‘ zamadol’ OR ‘ zamudol’ OR ‘ zodol’ OR ‘ 
zumatran’ OR ‘ zydol’ OR ‘ zytram bd’ OR ‘ zytram xl sr’ OR 'oxycodone' OR ‘bionine’ OR 
‘ bionone’ OR ‘ bolodorm’ OR ‘ broncodal’ OR ‘ bucodal’ OR ‘ cafacodal’ OR ‘ cardanon’ 
OR ‘ codenon’ OR ‘ codix 5’ OR ‘ col 003’ OR ‘ col003’ OR ‘ dihydrohydroxycodeinone’ OR 
‘ dihydrohydroxydodeinone’ OR ‘ dihydrone’ OR ‘ dinarkon’ OR ‘ endone’ OR ‘ eubine’ 
OR ‘ eucodal’ OR ‘ eucodale’ OR ‘ eucodalum’ OR ‘ eudin’ OR ‘ eukdin’ OR ‘ eukodal’ OR ‘ 
eumorphal’ OR ‘ eurodamine’ OR ‘ eutagen’ OR ‘ hydrocodal’ OR ‘ hydroxycodeinoma’ OR 
‘ ludonal’ OR ‘ m-oxy’ OR ‘ medicodal’ OR ‘ narcobasina’ OR ‘ narcobasine’ OR ‘ narcosin’ 
OR ‘ nargenol’ OR ‘ narodal’ OR ‘ nsc 19043’ OR ‘ nucodan’ OR ‘ opton’ OR ‘ ossicodone’ 
OR ‘ oxanest’ OR ‘ oxecta’ OR ‘ oxicone’ OR ‘ oxicontin’ OR ‘ oxiconum’ OR ‘ oxikon’ OR ‘ 
oxy ir’ OR ‘ oxycod’ OR ‘ oxycodeinonhydrochloride’ OR ‘ oxycodone hydrochloride’ OR 
‘ oxycodonhydrochlorid’ OR ‘ oxycodyl’ OR ‘ oxycone’ OR ‘ oxycontin’ OR ‘ oxycontin cr’ 
OR ‘ oxycontin lp’ OR ‘ oxydose’ OR ‘ oxyfast’ OR ‘ oxygesic’ OR ‘ oxyir’ OR ‘ oxykon’ OR ‘ 
oxynorm’ OR ‘ pancodine’ OR ‘ pavinal’ OR ‘ percolone’ OR ‘ pronarcin’ OR ‘ remoxy’ OR ‘ 
roxicodone’ OR ‘ roxycodone’ OR ‘ sinthiodal’ OR ‘ stupenal’ OR ‘ supeudol’ OR ‘ tebodal’ 
OR ‘ tekodin’ OR ‘ thecodin’ OR ‘substance’:ti,ab) AND (TI misuse OR AB misuse OR TI 
use OR AB use OR TI abuse OR AB abuse OR TI dependence OR AB dependence OR TI 
dependency OR AB dependency OR TI addiction OR AB addiction OR TI habituation OR AB 
habituation OR TI disorder* OR AB disorder* OR TI consumption OR AB consumption)
3 #1 AND #2 105,036
4 (MH "Expectant Mothers") OR "pregnant women" OR "pregnant woman" OR (MH 
"Pregnancy+") OR (MH "Pregnancy in Adolescence+") OR (MH "Attitude to Pregnancy") 
OR (MH "Prenatal Exposure Delayed Effects") OR (MH "Pregnancy, Unwanted") OR (MH 
"Pregnancy, Unplanned") OR (MH "Pregnancy Trimesters") OR (MH "Pregnancy, Multiple") 
OR	(MH	"Breast	Feeding+")	OR	(MH	"Knowledge:	Breastfeeding	(Iowa	NOC)")	OR	(MH	
"Breastfeeding Impairment (Saba CCC)") OR (MH "Attitude to Breast Feeding") OR (MH 
"Breast Feeding Promotion") OR (MH "Perinatal Care") OR (MH "Postnatal Care+") OR 
(MH "Intrapartum Care+") OR (MH "Prenatal Care") OR (MH "Prepregnancy Care") OR 
(MH "Postpartum Care (Saba CCC)") OR (MH "Postpartum (Omaha)") OR (MH "Maternal 
Exposure") OR "maternal exposure" OR (MH "Maternal Behavior") OR (MH "Maternal 
Attitudes") OR (MH "Postexposure Follow-Up") OR (MH "Substance Abuse, Perinatal")
131,778
5 #3 AND #4 5,985
6 TX allocat* random* OR (MH "Quantitative Studies") OR (MH "Placebos") OR TX placebo* 
OR TX random* allocate* OR (MH "Random Assignment") OR TX randomi* control* trial* 
OR TX ( (singl* n1 blind*) or (singl* n1 mask*) )
or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) 
) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) OR TX clinic* n1 trial* OR PT Clinical trial 
OR (MH “Clinical trial+”)
70,555
7 (MH "Meta Analysis") OR "meta analysis" OR (MH "Literature Review+") OR "literature 
review" OR (MH "Systematic Review") OR "meta analys*" OR metaanalys* OR (Systematic 
AND (review OR overview)) OR TI medlars OR AB medlars OR TI pubmed OR AB pubmed 
OR TI scisearch OR AB scisearch OR TI psychlit OR AB psychlit OR TI psycINFO OR AB 
psycINFO OR TI “british nursing index” OR AB “british nursing index” OR “Cochrane 
library” OR “Campbell library” OR “full text databases “ OR “electronic databases” OR 
handsearching
211,972
8 #6 OR #7 211,972
9 #5 AND #8 754
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CENTRAL search strategy 
ID Search Hits
#1 MeSH descriptor: [Alcohol Drinking] explode all trees 2140
#2 MeSH descriptor: [Alcohol-Related Disorders] explode all trees 3234
#3 MeSH descriptor: [Alcoholism] this term only 2215
#4 MeSH descriptor: [Fetal Alcohol Syndrome] explode all trees 33
#5 alcohol:ti,ab 8351
#6 #1 or #2 or #3 or #4 or #5 9549
#7 MeSH descriptor: [Substance-Related Disorders] explode all trees 10670
#8 MeSH descriptor: [Prescription Drug Misuse] explode all trees 7
#9 MeSH descriptor: [Street Drugs] explode all trees 203
#10 MeSH descriptor: [Designer Drugs] explode all trees 5
#11 MeSH descriptor: [Cannabis] explode all trees 247
#12 MeSH descriptor: [Heroin] explode all trees 240
#13 MeSH descriptor: [Amphetamines] explode all trees 1039
#14 street drugs:ti,ab or "recreational drugs":ti,ab or "illicit drugs":ti,ab or cocaine:ti,ab or 
designer drugs:ti,ab or cannabis:ti,ab or marijuana*:ti,ab or hashish:ti,ab or bhang*:ti,ab 
or ganja*:ti,ab or hemp:ti,ab or heroin:ti,ab or amphetamine*:ti,ab (Word variations have 
been searched)
4251
#15 (drug or benzodiazepine or opioids or prescription or barbiturate or tramadol or 
oxycodone or substance):ti,ab next/6 (misuse or use or abuse or abuses or dependence or 
dependency or addiction or habituation or disorder or consumption):ab,ti (Word variations 
have been searched)
9715
#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 20886
#17 MeSH descriptor: [Pregnant Women] explode all trees 74
#18 MeSH descriptor: [Pregnancy] explode all trees 5318
#19 MeSH descriptor: [Breast Feeding] explode all trees 1154
#20 MeSH descriptor: [Postpartum Period] explode all trees 957
#21 MeSH descriptor: [Maternal Exposure] explode all trees 27
#22 pregnant:ti,ab or pregnancy:ti,ab or antenatal:ti,ab or ante-natal:ti,ab or prenatal:ti,ab 
or "breast feed*":ti,ab or breastfeed*:ti,ab or postnatal:ti,ab or post-natal:ti,ab or 
postpartum:ti,ab or lactat*:ti,ab or "maternal exposure*":ti,ab (Word variations have been 
searched)
22381
#23 #17 or #18 or #19 or #20 or #21 or #22 24867
#24 #6 and #16 and #23 in Trials 84
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ANNEX 4: COMPOSITION OF GUIDELINE GROUPS 
WHO Steering Group
Name WHO Department
Avni Amin Reproductive Health and Research
Lubna Bhatti Tobacco Free Initiative
Nicolas Clark Mental Health and Substance Abuse
Ahmet Metin Gulmezoglu Reproductive Health and Research
Rajat	Khosla Gender Equity and Human Rights
Mathews Mathai Maternal and Child Health
Mario Merialdi Reproductive Health and Research
Vladimir Poznyak Mental Health and Substance Abuse
Shekhar Saxena Mental Health and Substance Abuse
Edouard Tursan d’Espaignet Tobacco Free Initiative
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The harmful use of alcohol and 
illicit drugs is the third leading 
risk factor for premature deaths 
and disabilities in the world. It is 
estimated that 2.5 million people 
worldwide died of alcohol-
related causes in 2004, including 
320 000 young people between 
15 and 29 years of age.
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